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ABSTRACT
Introduction: The dietary inflammatory index (DII) assesses an individual’s
overall diet quality with regards to its inflammatory potential on a continuum from
maximally anti-inflammatory (lower or healthier DII scores) to maximally proinflammatory (higher or unhealthy DII scores). The DII measured at one point in time has
been associated with cancer risk in previous studies; however, data are lacking regarding
the change in DII over time and how these changes impact cancer risk. We assessed
changes in the DII, and evaluated associations between cumulative history, and changes
over time in dietary inflammatory potential, and risk of colorectal cancer (CRC) and
breast cancer (BRCA). Methods: Study participants were women aged 50-79 years
recruited from 1993-1998 into the Women’s Health Initiative (WHI) Observational Study
(OS) and Dietary Modification Trial (DMT), and followed through September 30, 2010.
The DII was calculated from repeated food frequency questionnaires (FFQ) data in the
OS (n=76,671) at baseline and Year 3, and in the DMT (n=48,482) at up to 11 time
points. Univariate generalized estimating equations were used to compare mean DII over
time, adjusting for multiple comparisons. We calculated ten cumulative averages of DII,
incrementally from baseline to Year 10, categorized each average into quintiles, and
estimated hazard ratios (HR) and 95% confidence intervals (95%CI) for CRC, colon,
rectal cancer and invasive BRCA incidence by DII quintiles in multivariable-adjusted

v

Cox regression models. We also derived patterns of changes in DII between baseline and
Year 3; and calculated HR for CRC, colon, rectal, and breast cancer incidence including
molecular and histologic BRCA subtypes, using multivariable-adjusted Cox regression
models. Results: In the OS, mean DII decreased from -1.14 (±2.58) at baseline to -1.50
(±2.60) at Year 3. In the DMT, DII decreased from -0.40 (±2.54) to its lowest point of 1.70 (±2.63) at Year 3 in the intervention arm and from -0.38 (±2.55) to its lowest point
of -1.04 (±2.60) at Year 3 in the control arm. These changes were influenced by BMI,
education, and race/ethnicity. During an average 11.7 years, 1,240 cases of CRC and
4,242 cases of BRCA were identified. HR for the association between high DII scores
and CRC were consistently significantly elevated in the first seven years of follow up, for
colon cancer with multivariable-adjusted HR ranging from 1.30 to 1.58 in quintile 3 vs. 1,
while no significant associations were observed for rectal cancer. Compared to
participants in the anti-inflammatory stable category, risk was increased in participants
with a pro-inflammatory stable diet, for CRC (HR, 1.18; 95%CI, 0.99, 1.41), and for
rectal cancer (HR, 1.53; 95%CI, 1.01, 2.32). HR revealed no significant association
between changes in DII and risk of invasive BRCA or its subtypes. Conclusion: In this
large prospective study of postmenopausal women, dietary inflammatory potential was
relatively stable in OS participants, but decreased significantly over time in women
enrolled in the DMT. DII changes were modified by BMI, education, and race/ethnicity.
Long-term pro-inflammatory diets increased the risk of colon cancer, while shorter-term
stable pro-inflammatory diets increased the risk of rectal cancer but not breast cancer or
its subtypes. Lowering the inflammatory potential of diet could be a means for colon
cancer, and potentially rectal cancer prevention in postmenopausal women.
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CHAPTER 1

INTRODUCTION
1.1

Statement of the Problem
Inflammation is a process central to carcinogenesis and other chronic diseases,

and there is consistent evidence that diet modulates inﬂammation.1-6 Evidence from both
observational and intervention studies show that chronic inflammation is associated with
the development of many cancers including colorectal and breast cancers.2,7-10 Studies
have shown an association between chronic inﬂammatory conditions and subsequent
malignant transformation in the inﬂammed tissue with some examples being
inflammatory bowel disease and subsequent development of colorectal cancer,11,12 or
Helicobacter pylori-related gastritis and gastric cancer.8 The etiology of inﬂammation
varies and can be infectious, such as viruses or bacteria, or it may be a noninfectious
irritant such as certain dietary factors.
Many dietary factors are known to affect inflammation, through pro-inflammatory
or anti-inflammatory mechanisms. A Western-style diet tends to be rich in proinflammatory foods that are high in sugar (especially desserts and soft drinks), refined
grains, red and processed meats, and fried foods that increase pro-inflammatory
biomarkers such as C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis
factor alpha (TNFα).1-3,7,9,13,14 By contrast, diets that are rich in fruits, vegetables, whole
1

grains, legumes, nuts, olive oil and fish (e.g., Mediterranean-type diet) tend to be
associated with reduced chronic inflammation.3,4,15-17 Likewise, East Asian populations,
whose diets contain many anti-inflammatory constituents and are absent many of the proinflammatory components in Western diets, have very low CRP levels.18,19 Specific
components of the diet also have been shown to be associated with lower levels of
inflammation; e.g., fruits and vegetables, omega-3 polyunsaturated fatty acids (PUFAs),
fiber, moderate alcohol intake, vitamin E, vitamin C, β-carotene, and magnesium.20
Dietary patterns are generally known to have a much wider safety margin with prudent
consumption than do pharmaceuticals.21,22 Conceptually, dietary indices or patterns
represent a broader picture of food and nutrient consumption, and may thus provide an
approach to examining the relationship between diet and the risk of chronic diseases that
may produce more intuitively appealing results that may be more predictive of disease
risk as compared to the examination of individual foods or nutrients separately.23-30
Despite the growing use of dietary pattern analysis, relatively few studies have
investigated the stability of dietary patterns over time,31-37 and to the best of our
knowledge, none has done so in relation to the inflammatory potential of diet. Dietary
behavior is subject to change over time,34,35 and dietary behaviors mainly influence
chronic disease outcomes when they persist for a longer period of time.31 Knowledge of
the stability of dietary patterns over time could aid researchers in planning follow-up
times right from study outset. The cost of maintaining large cohorts could be reduced if
diet is proven to be stable over time. For example, reduced frequency of diet data
collection may be warranted if there is not much variation in dietary habits over time.34
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Given the evidence that many dietary factors have either anti- or proinflammatory properties, and the idea that no nutrient is consumed alone but in
conjunction with other nutrients and non-nutrient components of food, the dietary
inflammatory index (DII) was developed38 and validated.39 The goal of the DII was to
assess an individual’s diet on a continuum from maximally anti-inflammatory to
maximally pro-inflammatory, thus providing a tool to measure the inflammatory potential
of whole diets and their associations with markers of inflammation, and with the
development of chronic diseases including cancer.

1.2

Purpose and Objectives
We proposed to utilize data from the Women’s Health Initiative (WHI) to

describe longitudinal changes in the inflammatory potential of diet and evaluate the
association of changes in the inflammatory potential of diet and risk of colorectal cancer
and breast cancer in postmenopausal women. The WHI began in 1992, and enrolled a
total of 161,808 women 50 to 79 years old, in 40 sites in the United States between 1993
and 1998.40 We hypothesized that the inflammatory potential of diet changes over time
and long-term pro-inflammatory diets or shorter-term changes towards pro-inflammatory
diets, increase risk of colorectal cancer and of breast cancer. Our study aims were the
following:
Aim I: To investigate the stability of the inflammatory potential of diet over time.
The WHI recruited a study population with a high racial and geographic diversity.
We proposed to calculate the DII at all the eleven time points at which food frequency
questionnaires were administered in the WHI, using data from the Observational Study
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(OS) (baseline and year 3) and Dietary Modification Trial (DMT) (baseline, year 1 to 10).
We expected that the inflammatory potential of diet would significantly change over time
and be influenced by social, demographic and clinical factors. The main study questions
for aim #1 included the following:
1. Are there changes in dietary inflammatory potential over time?
2. If there are any significant changes, how do demographic and lifestyle factors such as
body mass index (BMI), education, and race/ethnicity impact such changes?
3. What social, demographic and clinical factors predict change in DII?
4. How does the change in the inflammatory potential of diet in an intervention setting
differ from that in an observational setting?
Aim II: To evaluate the association between changes in the inflammatory potential
of diet over time and risk of colorectal cancer.
In specific aim #2, we evaluated the association between the inflammatory
potential of diet and risk of colorectal cancer with the hypothesis that a long-term proinflammatory diet increases colorectal cancer risk. The dietary inflammatory potential
assessed at baseline only has been linked to colorectal cancer risk (Tabung FK, Steck,
SE, Ma Y, et al, unpublished data, 2014), however, data is lacking on the impact of
longitudinal changes in dietary inflammatory potential on colorectal cancer development.
Utilizing the DII to evaluate the role of long term dietary inflammatory potential on the
risk of colorectal cancer is therefore warranted. The main questions for this aim included
the following:

4

1. How does long-term cumulative history of dietary inflammatory potential affect
colorectal cancer risk?
2. How do shorter-term changes in patterns of the inflammatory potential of diet over
time affect risk of colorectal cancer?
3. Do risk estimates differ by anatomic subsite (colon, rectum) both for cumulative
history and patterns of change in the dietary inflammatory potential?
Aim III: To investigate the association between changes in the inflammatory
potential of diet over time and risk of breast cancer in postmenopausal women.
In specific aim #3, we investigated the association between the inflammatory
potential of diet and breast cancer risk in postmenopausal women, with the hypothesis
that a long-term pro-inflammatory diet increases breast cancer risk. The association
between dietary patterns and breast cancer risk is inconsistent,41-45 with findings from
three large cohort studies not supporting an association between dietary patterns and
breast cancer risk.44,46,47 Given the central role of chronic inflammation in the
carcinogenesis process,48-50 and the modulation of inflammation by some dietary
patterns,3,4,14,16,17,48 an assessment of the dietary inflammatory potential at multiple time
points may be more predictive of breast cancer risk. The main questions for this aim
included the following:
1. How does long-term cumulative history of dietary inflammatory potential affect
breast cancer risk?
2. How do shorter-term changes in patterns of the inflammatory potential of diet over
time affect risk of breast cancer?
5

3. Do risk estimates differ by molecular or histologic subtype of breast cancer for
patterns of change in the dietary inflammatory potential?

1.3

Significance/relevance of the dissertation research
This dissertation addressed an important area of cancer research which includes

the role of total diet with respect to its inflammatory potential, in relation to risk of cancer
in a large, well-characterized cohort (the WHI) with adequate number of outcomes
providing ample power to detect significant associations. Given that the DII has been
shown to be associated with inflammatory biomarkers (Tabung FK, Steck SE, Zhang J,
Ma Y, et al., unpublished data, 2014) and with colorectal cancer incidence (Tabung FK,
Steck SE, Ma Y, et al., unpublished data, 2014) in this study population, the examination
of DII changes over time and cancer endpoints is a crucial next step in evaluating the DII
as a tool for cancer prevention.
1.3.1 High public health and clinical impact
This study is innovative in that this is the first time that repeated measures of the
DII are being used to evaluate the association between changes in the dietary
inflammatory potential over time and cancer endpoints. The study will likely have a large
public health impact by strengthening the evidence for a new tool assessing the long-term
overall quality of diet and providing support for its use in other studies of diet and cancer.
Patients at risk of inflammation-related conditions such as osteoporosis, obesity,
cardiovascular disease, and diabetes, may also be at risk of cancer.51,52 Therefore a
reduction in the inflammatory potential of the diet among patients with these conditions
may improve overall health and reduce their cancer risk. The diagnosis of most of these
chronic diseases may be also a teachable moment during which most patients undergo
6

lifestyle changes including diet changes to improve their survival experience.53,54 Health
professionals armed with the knowledge of the inflammatory potential of diets may be
able to impart sound nutritional guidance that improves the overall health of patients with
inflammation-related chronic diseases.
1.3.2 The role of the inflammatory potential of whole diets and dietary patterns on
cancer risk is largely unknown
Studies of individual foods and nutrients may be inadequate to elucidate the
overall role of long term diets and dietary patterns on the risk of degenerative diseases
including colorectal cancer and breast cancer. The role of diet in the risk of these cancers
is of great interest as a potentially modifiable risk factor given that most risk factors for
breast cancer are not generally modifiable. Many epidemiological studies of the
association between single dietary factors and colorectal and breast cancers have not
yielded consistent conclusive evidence except for overweight/obesity (increases risk of
postmenopausal breast cancer and colorectal cancer),55-62 regular alcohol
consumption,55,63,64 and red meat intake.65-70
In a dietary guidelines adherence study, Harnack and colleagues found evidence
to suggest that adherence to the cluster of dietary behaviors included in the Dietary
Guidelines for Americans is associated with a lower risk of cancers including colon and
breast cancers,71 while McCullough and colleagues found that following cancer
prevention guidelines, reduces risk of cancer, cardiovascular disease, and all-cause
mortality.72 This evidence supports the idea that studies of the oncogenic role of whole
diets and not individual nutrients may be more appropriate for population-based cancer
prevention efforts. As further evidence, the impact of total caloric intake, energy balance,
and weight gain on the risk of breast73,74 and colorectal cancer75,76 indicate a role for
7

overall diet and dietary patterns that may not be captured in studies of individual foods
and nutrients.62

1.4

Study Outline
Chapter 1 of this dissertation introduces the problem by first establishing the link

between dietary patterns and chronic inflammation, and the link between inflammation
and cancer, with the ultimate aim to elucidate the role of dietary inflammatory potential
in cancer development. Aims have been stated and their specific significance described,
in addition to the overall significance of the dissertation. Chapter 2 presents a detailed
background to the aims in an extensive review of the literature. It describes the relation
between diet and inflammation and inflammation and cancer, including possible
mechanisms of action. Selected theoretically-derived diet quality indices and their
relation to inflammation are described, including empirical methods of evaluating dietary
patterns and some statistical approaches to analyzing repeated dietary exposures with
dichotomous outcomes. Chapter 2 ends with a detailed review of possible risk factors for
colorectal cancer and breast cancer. In chapter 3, we describe the methods used to
achieve each of the three aims, including a detailed description of the DII. Results for
each of the three aims are presented separately in chapters 4, 5 and 6, as standalone
publishable manuscripts. Chapter 7 provides a detailed discussion of the results and a
conclusion.
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CHAPTER 2

BACKGROUND
2.1

Chronic inflammation and cancer

2.1.1 Overview
In the mid nineteen century, Virchow theorized that the lymphoreticular infiltrate
at sites of chronic inflammation may establish the setting in which cells grow
abnormally.7,77 A more contemporary version of Virchow’s hypothesis is that the
inflammatory processes induced by chronic injury contribute to the multistage
development of cancer and that the inflammation, rather than the specific cause of the
injury, account for subsequent carcinogenicity.78 Inflammation is a crucial function of the
innate immune system with acute inflammation being a self-limiting process that protects
against pathogens and initiates specific immunity, however, acute inflammation does not
always resolve.79 Many of the diseases of middle and old age may be driven, at least in
part, by chronic and often subclinical inflammation.79 Several lines of evidence, including
general or cell-specific gene inactivation and population-based studies, are consistent
with the view that inflammation plays an important role in cancer causation and/or
progression. As Balkwill et al. indicated,79 the links between chronic inflammation and
cancer are reinforced by several concepts including the following: i) many cancers arise
at sites of chronic inflammation and chronic inflammation increases cancer risk, ii) the
9

immune cells that mediate chronic inflammation are found in cancers and promote tumor
growth, iii) cancers produce chemical mediators that regulate inflammation, iv)
experimental cancers have been inhibited by the inhibition of inflammatory mediators, v)
susceptibility to, and severity of cancer is altered by the variation of inflammatory genes,
and vi) the long term use of non-steroidal inflammatory drugs reduces the risk of some
cancers.79
More recently, the role of inflammation in cancer development was highlighted
by Brucher and Jamall when they proposed a new paradigm for the epistemology of the
origin of cancer.80 They stressed that less than 10% of all cancers are hereditary, and
departed from the widely held concept that cancer originates from somatic mutations and
an inhibition of growth suppression, followed by cell proliferation and metastasis.80
According to their new paradigm, the origin of cancer follows a sequence of events
beginning with 1) a pathogenic stimulus which can be biologic or nonbiologic (including
diet), 2) followed by chronic inflammation, 3) from which fibrosis develops, with
associated changes in the cellular microenvironment if the inflammation does not resolve,
4) a pre-cancerous niche then develops which triggers 5) a chronic stress escape strategy
6) that transforms a normal cell to a cancer cell if the chronic stress does not resolve.80 If
this hypothesis is true, then intervening to prevent or reduce chronic inflammation that
may be triggered by potentially modifiable risk factors such as diet, may present an
excellent opportunity for the primary prevention of cancers.
2.1.2 Chronic inflammation and colorectal cancer
Several lines of evidence suggest that colorectal neoplasia may arise from colonic
areas with chronic low grade subclinical inflammation.81,82 Chronic inflammatory bowel
10

diseases, such as ulcerative colitis and Crohn’s disease have been associated with
increased risk of colon cancer.12 Moreover, several studies have shown a reduced risk of
colon cancer with use of aspirin or other anti-inflammatory agents.79,83,84 Patients with
long-standing ulcerative colitis and Crohn's disease have an increased risk of developing
colorectal cancer and patients with Crohn's disease in the small intestines are at increased
risk of small bowel adenocarcinoma.82,85 Inflammatory bowel disease-related colorectal
cancer is the result of a process which is believed to begin from no dysplasia, progressing
to indefinite dysplasia, low-grade dysplasia, high-grade dysplasia and finally to invasive
adenocarcinoma.86 This is also called the adenoma-carcinoma sequence, although
colorectal cancer can arise without proceeding through each of these steps.12,86,87
Several prospective studies have supported the hypothesis that inflammation is a
risk factor for the development of colon cancer.88-91 A study analyzing change in Creactive protein (CRP) and serum amyloid A (SAA) over time in relation to risk of
colorectal cancer using data from the WHI observational study, observed an increased
risk of colon cancer among women in the highest quintile of CRP change compared to
those in the lowest quintile (OR; 1.37, 95%CI; 0.95, 1.97), p-trend = 0.04) but no
association with SAA.89 Women with elevated concentrations of both CRP and SAA had
an increased risk of colon cancer (OR; 1.50, 95%CI; 1.12–2.00) compared to those with
low concentrations.89 The study observed no positive associations with rectal cancer and
weaker associations for colorectal cancer overall. Furthermore, temporal changes in
biomarkers more than 3 years did not predict risk.89 An examination of the association of
CRP levels with colorectal cancer incidence in a nested case-control study within the
Alpha Tocopherol, Beta-Carotene Cancer Prevention Study found an increased risk of
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colon cancer incidence for men with the highest concentration of CRP (OR, 2.9; 95%CI,
1.4, 6.0) compared to men with the lowest concentration, with the association being
stronger among lean individuals than in heavier individuals.91 Another nested casecontrol study found that the odds of developing colorectal cancer increased with higher
concentrations of CRP, such that persons in the highest quartile of CRP had a 2-fold
increased risk of colorectal cancer compared with persons in the lowest quartile (OR,
2.00; 95%CI, 1.16-3.46; Ptrend = 0.008), but the study did not conduct separate analysis
for rectal cancer.90
In summary, whether levels of inflammatory biomarkers are elevated before
biological onset of colorectal cancer, or indeed whether inflammatory biomarkers are risk
factors for the de novo development of colorectal cancer, are questions that relatively few
of the prospective studies have tried to address.92 The presence of malignant disease may
itself affect concentrations of circulating inflammatory biomarkers from retrospective
case-control studies or from cohort studies where case diagnosis close in time to blood
draw might reflect tumor marker status rather than true risk assessment. Whether
circulating concentration of inflammatory biomarkers truly reflects colonic inflammation
and/or translates into biological activity is unclear. This emphasizes the need for more
research to explore the association of inflammatory biomarkers with colonic
inflammation. As cancer is a relatively rare disease, small numbers of colorectal cancer
cases and lack of power pose problems in many prospective epidemiologic studies.
2.1.3 Inflammation and breast cancer
Studies focusing on the tumor microenvironment have demonstrated that
inflammation correlates with increased invasiveness and poor prognosis in many types of
12

cancer, including breast cancer.93 The cytokines interleukin-6 (IL-6), IL-1β and tumor
necrosis factor alpha (TNFα), have been found to be associated with breast cancer
progression.94-96 An analysis of data from the Health, Eating, Activity, and Lifestyle
Study on the relationship between circulating markers of inflammation (CRP and SAA)
and breast cancer survival found that SAA and CRP significantly predicted long-term
survival in breast cancer patients, independent of race, tumor stage, and BMI.93 In
contrast, a meta-analysis of prospective studies of the association between circulating
CRP and IL-6 and the development of specific cancers, found no association with an
increased breast cancer risk.97 In a Swedish study of 2,577,565 women to examine
possible associations between mastitis and subsequent risk of breast cancer, the
investigators found that breast cancer risk was slightly elevated in women with a history
of mastitis (incidence rate ratio: 1.23, 95%CI, 1.02-1.49).98 The absence of a correlation
between laterality of lesions (i.e., the breast with mastitis was not always the breast with
cancer), however, did not support a causal association between inflammation (mastitis)
and the development of breast cancer in the study.98
An assessment of the association for use of aspirin, other non-steroidal antiinflammatory drugs (NSAIDs), and acetaminophen with breast cancer risk among breast
cancer-free (at baseline) premenopausal women in the Nurse’s Health Study II, found
that regular use of aspirin (≥ 2 times/ week) was not significantly associated with breast
cancer risk (RR, 1.07; 95%CI, 0.89-1.29). Additionally, non-aspirin NSAIDs or
acetaminophen were not consistently associated with breast cancer risk in premenopausal
women, and results did not vary by frequency (days per week), dose (tablets per week),
duration of use or estrogen and progesterone receptor status of the tumor.99 In another
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study, the use of ibuprofen or acetaminophen was not associated with breast cancer
risk.100 In contrast, a case-control study to investigate the association of adult lifetime
aspirin intake with breast cancer risk, found evidence that aspirin use throughout a
woman's life may confer some benefit (adjusted OR 0.80, 95% CI: 0.68-0.94), comparing
aspirin users to non-users, and a large cohort study of postmenopausal women followed
for more than 6 years, found a trend of decreasing risk of incident breast cancer with
increasing frequency of aspirin use (Ptrend = 0.001).101 The multivariate-adjusted RR of
breast cancer was 0.71 (95% CI 0.58-0.87) for women who reported using aspirin six or
more times per week compared with women who reported no use. No association was
found between non-aspirin NSAID use and incident breast cancer.101
In summary, while most of the evidence is consistent that chronic inflammation
increases the risk of breast cancer recurrence or survival, the evidence has been less
consistent for the association between chronic inflammation and breast cancer incidence.
Most of the research on the association between chronic inflammation and breast cancer
incidence has been through the intermediacy of anti-inflammatory drugs such as aspirin
and non-aspirin NSAIDs and is inconsistent.
Many sites of chronic uncontrolled low grade inflammation many exist in the
body at the same time and most of the biomarkers of inflammation usually employed in
epidemiologic studies are non-specific. This may explain the weak associations or lack
thereof, between biomarkers of inflammation and the development of breast cancer or
colorectal cancer in some studies. Thus, biomarkers of inflammation are associated with
breast or colorectal cancer incidence and/or progression only to the extent that these
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markers correlate with breast or colorectal inflammation respectively. Moreover, CRP
(used in most of the studies) is a non-specific marker of inflammation.
2.1.4 Biologic plausibility and mechanisms for inflammation and cancer
The chronic inflammatory response represents a fine balance between active
inflammation, repair, and destruction that occurs in response to a persistent stimulus over
a prolonged period of time.9 Activation of leukocytes in response to such an ongoing
stimulus leads to the production of cytokines, and reactive oxygen species (ROS),
resulting in accumulated tissue destruction and subsequent attempts at healing via
remodeling, angiogenesis, and connective tissue replacement.9,102 A wide variety of
chronic inflammatory diseases are associated with cancer.78 Indeed, chronic inflammation
orchestrates a tumor-supporting microenvironment that is an indispensable participant in
the neoplastic process. Important components in this linkage are the cytokines produced
by activated innate immune cells that stimulate tumor growth and progression.103
Supporting evidence for the inflammation-cancer link comes from studies
showing that diverse infections and mechanistic agents trigger the inflammation
associated with human cancer. These links have been confirmed especially in terms of
colon cancer (colitis),8,12 gastric cancer and MALT1 lymphoma (Helicobacter pylori
infection),8,104,105 liver cancer (cholangitis and hepatitis virus B and C),106,107 and
Kaposi’s Sarcoma (Human Herpes Virus 8 infection).108 Chronic inflammation appears to
predispose to the development of colon cancer in the setting of inflammatory bowel
disease,79,109,110 following an “inflammation-dysplasia-carcinoma" model.111

1

mucosa-associated lymphoid tissue

15

A second line of evidence for the biologic plausibility of the association between
inflammation and cancer relates to the increased expression of inflammatory mediators
that occurs during tumor development. Balkwill and Mantovani demonstrated that acute
inflammation triggered by the exogenous administration of inflammatory biomarkers in
murine models promotes malignancy and metastasis under controlled conditions.7 The
link between inflammation and cancer is further supported by evidence from studies
showing a positive association between higher concentrations of inflammatory
biomarkers and increased risk of colon cancer.89,112,113
The third and complementary line of evidence is the fact that NSAIDs, which
inhibit COX-2 activity and tumor development in many experimental and clinical
settings, are inversely associated with certain cancers in epidemiological studies.78,114
Inflammatory cytokines induce the production of inflammatory enzymes such as the
cyclo-oxygenases (COX). The expression of COX-2 and lipid mediators of inflammation
increases during the multistage progression of neoplastic conditions.115 Observational
studies and human intervention trials have also indicated that the regular administration
of NSAIDs confers a 30–50% reduction in colorectal cancer risk or adenoma
recurrence.116,117 We previously found an association between the consumption of highly
pro-inflammatory diets and higher concentrations of inflammatory biomarkers including
IL-6, hs-CRP, TNFα-R2 and an overall inflammatory biomarker score derived from a
combination of these biomarkers (Tabung FK, Steck SE, Zhang J, et al, unpublished data,
2014). In another study to evaluate the association between the inflammatory potential of
diet and risk of colorectal cancer, we found an increased risk of colorectal cancer in
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participants consuming a highly pro-inflammatory diet (Tabung FK, Steck SE, Ma Y, et
al., unpublished data, 2014).

2.2

Dietary patterns and chronic inflammation

2.2.1 An overview of opportunities and challenges
The traditional approach to studying the relation between diet and disease has
been to focus on the effects of specific nutrients, foods or food groups but people
consume a wide variety of diets, not isolated nutrients or foods. Additionally, people eat
diets in specific patterns that are influenced by the environmental conditions of living,
religious opinions, personal preferences, food availability, economical status and many
other cultural factors. Dietary pattern research thus offers a more comprehensive
approach to the investigation of diet-disease associations. Nutritional epidemiologists cite
several reasons for preferring the dietary pattern approach over the traditional nutrientbased approach, including the following:25-27,118-121 1) nutrient-based research does not
consider the complex interactions among nutrients in metabolic reactions; nutrients may
interact with each other and inﬂuence their bioavailability and absorption; 2) increased
consumption of one food (i.e., red meat and related products) may be associated with
reduced consumption of other foods (i.e., fruit and vegetables) since the total energy
intake of individuals should remain stable; 3) many nutrients are highly correlated and
studying their separate effects is hampered by collinearity; 4) the effects of single
nutrients may be too small to detect while the synergistic and larger effect of nutrients
with similar effects may be more easily detected in dietary patterns; 5) analysis of
individual nutrients may be confounded by dietary patterns and 6) the success of “whole
diet” interventions including the Dietary Approaches to Stop Hypertension (DASH) trial
17

and the Lyon Diet Heart Study.122-124 The two main approaches for deriving dietary
patterns are the a priori or index-based approach and the a posteriori or data-driven
approach. These approaches are reviewed in more detail in sections 2.2.2 and 2.2.3.
The index-based approach is intuitively appealing, analytically simple to
compute, and easily reproducible and comparable across different studies. Scores that
dichotomize components do not account for the full range of foods consumed, while
scores that award points for a range of intakes consider variability in food intake but not
the amounts at the extremes of component intake distributions.25,28 Subjectivity may be
introduced during index construction in the selection of foods for inclusion. Also, the
addition of equally weighted components implies that each component is additively
related to health and equally important.25
Data-driven methods (e.g., factor analysis, cluster analysis) have shown some
level of reproducibility across populations.125,126 Patterns allow for biologic interactions
and can thus be the starting point for modeling different types of interactions among
foods.25 While factor analysis describes the variation in food intake in the population
based on correlations among dietary factors as a continuous variable, cluster analysis
separates subjects into mutually exclusive groups based on dietary intake as a categorical
variable.25 Generally, there is limited data on the reproducibility and validity of datadriven methods, though reproducibility in different populations can never be expected to
be exact due to the data-driven nature of the approach. Subjectivity is introduced at
various points including grouping of dietary items, treatment of input items (e.g., whether
to use grams, servings, percent energy or standardized intake items), the choice of
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analytical procedure (e.g., type of rotation to use), and deciding on the final dietary
pattern solution.25
Both index-based and data-driven approaches to dietary pattern analysis thus
characterize total diet and overcome most of the limitations of single-nutrient research,
and analysis results are more meaningful, interpretable and associated with health
outcomes.
Regarding the relation of dietary pattern and inflammation, Western-style eating
patterns are characterized by frequent intake of energy-dense food and beverage portions
delivering an excess of readily available carbohydrates and fats, and few other nutrients.
This eating pattern, combined with a sedentary lifestyle, results in weight gain, but it is
also associated with increased production of reactive oxygen species (ROS).127 As people
gain weight and become overweight and obese, CRP, along with other inflammatory
mediators, also increases.128,129 ROS, also known as free radicals, lead to an acute
oxidative imbalance, resulting in oxidative stress. Oxidative stress “turns on” genes that
control the production of cytokines and other proteins (biomarkers) involved in
inflammation.130,131 Since eating is not a one-time activity, but rather an activity that we
repeat meal after meal and day after day, the diet then becomes a central point of
negotiation for oxidative and inflammatory balance.
2.2.2 Comparison of selected diet quality indices and their association with
inflammation
This section reviews the strengths and limitations of three diet quality indices
[healthy eating index-2010 (HEI-2010)], dietary approaches to stop hypertension
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(DASH), and the Mediterranean dietary pattern), comparing each of them to the dietary
inflammatory index (DII) in terms of their ability to modulate inflammation. The
discussion is undertaken from both the perspective of the theoretical underpinnings of the
respective strategies for the development of each index, as well as the statistical
considerations /limitations of each index.
2.2.2.a Brief overview of the dietary inflammatory index (DII)
Details of the development38 and validation39 of the DII have been described
elsewhere. Briefly, an extensive literature search was performed to obtain peer-reviewed
journal articles that examined the association between six inflammatory biomarkers (IL1, IL-4, IL-6, IL-10, TNFα, and CRP) and 45 specific foods and nutrients (components
of the DII). Scores were derived and standardized to a representative global diet database
constructed based on 11 datasets from diverse populations in different parts of the world.
Overall DII scores for each individual represent the sum of each of the DII components in
relation to the comparison database.38 The DII score characterizes an individual’s diet on
a continuum from maximally anti-inflammatory to maximally pro-inflammatory, with a
higher DII score indicating a more pro-inflammatory diet and a lower DII score
indicating a more anti-inflammatory diet. A more detailed description of the DII can be
found in chapter 3, section 3.5.
2.2.2.b Healthy Eating Index (HEI)
The HEI was developed based on a 10-component system of five food groups
(grains, vegetables, fruits, milk and meat), four nutrients (percent energy from total fat,
percent energy from saturated fat, cholesterol intake, sodium intake), and a measure of
variety in food intake. Each of the 10 components has a score ranging from 0 to 10, so the
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total possible index score is 100. A score of 0 indicates non-compliance with
recommended amounts or ranges while a score of 10 indicates intakes closest to
recommended amounts or ranges.132
Though the HEI was developed to measure adherence to the Dietary Guidelines
for Americans (DGA) and the Food Guide Pyramid, some studies have investigated the
association of the HEI and inflammation with the main finding being that the HEI does
not significantly predict biomarkers of systemic inflammation such as CRP, SAA and IL6,133-135 and has equally performed poorly in predicting chronic disease risk.136 The HEI’s
low predictive ability (or lack thereof) for chronic systemic inflammation and chronic
disease may be due to its inability to distinguish between the form of carbohydrate,
saturated and unsaturated fats, or protein sources (e.g., processed meats versus fish).
These limitations were addressed in the development of an alternate HEI (aHEI). A study
comparing the disease predictive ability of the HEI and aHEI found that the aHEI
significantly predicted risk of cardiovascular disease (CVD) but both indices failed to
predict cancer risk.136,137 In a study to assess the association between several diet-quality
indices and plasma concentrations of biomarkers of inflammation and endothelial
dysfunction, higher aHEI scores were associated with lower concentrations of
inflammatory biomarkers.134
An updated version of the HEI (HEI-2010) was published in February 2013, to
reflect the 2010 updated DGA (DGA-2010).138 In accordance with the DGA-2010, the
HEI-2010 allows for flexibility in food choices. The advantage of this is that lack of any
one commodity does not prevent anyone from having a perfect HEI-2010 score.
Furthermore, the added component of seafood and plant proteins explicitly allows for
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vegan diets to be scored. Similar to the aHEI, the HEI-2010 now distinguishes quality
within food groups and acknowledges the health benefits of unsaturated fats. For
example, whole fruit and total fruit are now separate items, in order to operationalize the
recommendation to consume more whole fruit than fruit juices; and the maximum
standard for fatty acids is based on the ratio of monounstaturated fatty acids (MUFA)
plus polyunstaturated fatty acids (PUFA) to saturated fatty acids (SFA).138
The energy density approach adopted in the construction of the HEI-2010 adjusts
for energy intake. In contrast to the food-based adequacy components of the HEI-2010
where assigning the minimum score of zero was easily determined by no intake for the
specific component, arbitrary decisions had to be made for the moderation components
(sodium, refined grains and empty calories), for assigning the minimum score because
these components are reverse-scored and there is no scientific evidence on which to base
the minimum scores.138 For example, no scientific evidence specifies how high a sodium
intake would qualify for a score of zero. A value at approximately the 85th percentile of
the 2001-2002 population distribution of 1-day intakes was used to set the minimum
standards for these components.138
The validity of the HEI-2010 has not yet been determined for ethnic and cultural
groups, but the index would be expected to be valid for assessing the diets of
subpopulations for which the DGA are appropriate because the mixed dishes and sauces
that distinguish ethnic and cultural diets would be broken down into their ingredients and
assigned to food groups and nutrients, which are generally culturally neutral. Also, given
that the HEI-2010 has incorporated most of the limitations identified in the aHEI, its
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predictive ability for both chronic systemic inflammation and inflammation-related
chronic diseases will be expected to improve compared to the original HEI.
2.2.2.c Dietary Approaches to Stop Hypertension (DASH)
The DASH-style diet is typically high in fruits and vegetables, moderate in lowfat dairy products, and low in animal protein but with substantial amount of plant protein
from legumes and nuts.139 Evidence for the usefulness of the DASH diet plan in disease
prevention first came from two multicenter randomized controlled feeding trials.123,124
and has been incorporated in the DGA140 and the National Heart Lung and Blood
Institute’s DASH eating plan.141 These two trials demonstrated that a diet rich in fruit,
vegetables, and low-fat dairy products and low in saturated and total fat (DASH diet)
reduced blood pressure and that blood pressure is further reduced when the DASH diet is
followed in conjunction with significant reductions in sodium intake.123,124 The DASH
diet therefore includes food groups and sodium, with the food groups being grains,
vegetables, fruits, dairy, lean meat, nuts/seeds/legumes, fats/oils, and sweets.
The DASH diet has been shown to be associated with reduced systemic
inflammation142 and reduced risk of several inflammation-related chronic diseases such
as diabetes,143,144 cancer.145 and heart disease and stroke.139 Several diet indices have been
developed to capture the DASH diet plan and evaluate associations with health outcomes.
In a recent study, Miller et al compared four established DASH indices in regards to their
associations with colorectal cancer in the same population (the NIH-AARP cohort).28
They calculated separate indices defined by Dixon (7 food groups, saturated fat, and
alcohol), Mellen (9 nutrients), Fung (7 food groups and sodium), and Guenther (8 food
groups), and found that higher scores on all four indices were associated with reduced
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risk of colorectal cancer in both men and women.28 Miller et al concluded that “the
consistency in findings, particularly in men for both colon and rectal cancer, suggests
that all indices capture an underlying construct inherent in the DASH dietary pattern,
although the specific index used can affect results.”
There is no standardized methodology for calculating the DASH index and the
discrepancy in the predictive ability of the four indices, where the DASH-Dixon index
did not significantly predict colorectal cancer risk in women (in contrast to the other three
indices) demonstrates the idea that differences in the composition of the indices and
scoring algorithms can affect results.
2.2.2.d Mediterranean Diet Score (Med-diet)
A traditional Med-diet pattern typically has a high ratio of MUFA to SFA and
omega-3 to omega-6 PUFA. It equally has a rich supply of fruits, vegetables, nuts, seeds,
legumes, and grains. The Med diet has been widely studied with more than 20 different
indices developed based on the Med-diet and used to evaluate health outcomes. The
Med-diet has been shown to be associated with reduced chronic systemic
inflammation4,134,146-150 and reduced risk of several inflammation-related chronic diseases
such as diabetes,123 cancer139 and heart disease.140,151 A study to compare and evaluate the
reliability of 10 of these indices showed satisfactory performance in assessing adherence
to the Med-diet. However, in order to improve the reliability, and concordance between
the indices, the investigators suggested further research to standardize the number and
selection of components and the scoring criteria of the indices.146
The Med-diet score as described by Trichopoulou et al.,152 has been adapted and
used in many studies. Generally, the score is constructed by assigning a value of 1 to a
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high intake (≥median) of each desirable component, a value of 1 to a low intake
(<median) of each undesirable component, and a value of 0 to all other intakes. Desirable
components may include vegetables, fruits, nuts, seeds, whole grains, legumes, fish,
unsaturated fats, moderate alcohol, while undesirable components may include saturated
fat, red and processed meats, and dairy products. The higher the Med diet score, the
greater the adherence to the Med-diet pattern.152
2.2.3 Empirical methods to derive dietary patterns
Three statistical methods used to define dietary patterns include factor analysis,
cluster analysis, and reduced rank regression.23,125 These so-called a posteriori
approaches build on statistical exploratory methods driven by data.153 Despite the
differences in the goal of these methods, they are similar regarding their mathematical
foundation.154 There are many opportunities for subjectivity and decisions made by the
investigators may have an impact on the number and type of patterns derived, reported,
and analyzed. Specifically, the investigator must first decide whether or not to further
collapse the primary dietary data into a smaller number of items for entry into the
analysis. If the data are collapsed, a decision must be made on how to group the data.
Next, the investigator must decide how the input variables should be treated. After the
input variables have been entered into the procedure, a decision must be made on how
many patterns (the output variables) need to be retained in the final solution, which
patterns should be reported or analyzed, and how the patterns should be
named.23,25,120,155,156
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2.2.3.a Factor analysis
Factor analysis is a multivariate statistical technique, which uses information
reported in nutritional assessment methods (FFQs, 24HRs, or food records) to identify
common underlying dimensions (factors or patterns) of food consumption,23 by reducing
data into patterns based upon intercorrelations between dietary items.120 Factor analysis
includes both principal component analysis (PCA) and confirmatory factor analysis
(CFA). In nutritional epidemiology, the most commonly used method to derive dietary
pattern is PCA with varimax rotation, which enhances the difference between factor
loadings, and allow for easier interpretability.120 It is an appropriate modeling approach
for dietary patterns that are not necessarily independent of each other (that is, correlated
patterns).120 Factor analysis aggregates specific food items or food groups on the basis of
the degree to which food items in the dataset are correlated with one another. 23 A
summary score for each pattern is then derived and can be used in either correlation or
regression analysis to examine relationships between various eating patterns and
outcomes of interest.23 Verasso et al., (2012) compared dietary patterns derived through
PCA and CFA used as equivalent approaches in terms of stability and relevance and
found that CFA may be a useful alternative to PCA in epidemiologic studies, especially
when the sample size is small.154
2.2.3.b Cluster analysis
In contrast to factor analysis, cluster analysis aggregates individuals into
relatively homogeneous and mutually exclusive subgroups (clusters) with similar diets
and may use several different methods to do so (e.g., K-Means or Ward’s method).23,120
Individuals can be classified into distinct clusters or groups on the basis of the frequency
of food intake, the percentage of energy contributed by each food or food group, the
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average grams of food intakes, standardized nutrient intakes, or a combination of dietary
and biochemical measures.23 Compared to factors (continuous variables), clusters
(categorical variables) may be easier to handle in the analysis since they are mutually
exclusive and categorical. The idea that individuals have scores for all of the derived
factors makes the concept of factor scores less intuitive than an individual belonging to a
specific dietary pattern (or cluster).120
Cluster analysis may be preferable for use in planning dietary interventions
targeted to risk groups, as it allows the identification of subgroups and the association of
clearly defined eating patterns with outcome measures.119 Although conceptually
different, cluster analysis and factor analysis have shown similarities in grouping foods
into patterns. For example, several studies have identified a healthy cluster, with
important contributions from fruit, vegetables, breakfast cereals or whole grains, and lowfat dairy products, and with some including fish and nuts.119,120,157,158 One limitation of
the cluster analysis approach is lower power when comparing multiple subgroups with
health outcomes, relative to the linear variables generated by factor analysis (PCA). This
may be one reason why PCA has been more frequently adopted in nutritional
epidemiology. Nonetheless, when power is adequate, cluster analysis provides clear
descriptions of existing subgroup diets.119
2.2.3.c Reduced rank regression
Reduced rank regression (RRR) or maximum redundancy analysis determines
linear functions of predictors (foods) by maximizing the explained variation in responses
(disease-related nutrients). Key nutrients or biomarkers of disease (e.g., CRP, IL-6, HDLcholesterol) function as the response variables and linear combinations of foods are
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derived which maximize the explained variance in these responses.159 The classic PCA
method selects factors that explain as much predictor variation as possible. In contrast,
RRR extracts factors that explain as much response variation as possible.160 The results
from a limited number of investigations using RRR have shown stronger relations
between derived dietary patterns and cardiovascular disease than results from studies
using PCA.160,161 However, Tucker argued that because the dietary patterns are “forced”
to predict biological markers, the patterns are proxy variables for the biomarkers rather
than independent variables, and that the biomarkers are known to be good predictors of
the disease in question, therefore the dietary pattern derived is also predictive of the
disease in the same or very similar populations.119 While this may be a valid argument,
several other studies have applied RRR in different populations and settings153,162-165
though with mixed results that may not be necessarily related to issues of heterogeneity in
study populations.

2.3

Statistical approaches for analyzing repeated measures of diet

data
In longitudinal observational studies of the role of diet on health outcomes, diet
can be assessed several times during follow-up. Applying these repeated diet measures in
the evaluation of health outcomes is not always as straightforward as using diet data at
one point in time. Standard methods of analyzing these repeated measures require that the
number of measurements be constant over study participants and over time, e.g., the
proportional hazards assumption in Cox regression models,166 and thus most analyses
often ignore the repeated diet measures and use only baseline data to evaluate long term
disease outcomes. The following analytical approaches make use of repeated diet data:
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2.3.1 Patterns of change in diet intake over time
To create patterns of change over time in diet intake, the investigator needs to
decide how many time points of diet data to use, though it becomes increasingly difficult
to define patterns when using more than two time points. The data is categorized into
quantiles and patterns are defined as movements between quantiles across different points
in time.167 Quantiles must be chosen carefully to avoid too narrow or too wide definition
of patterns. For example, tertiles provide only three categories and the investigator needs
to decide whether change would be defined as movement of one tertile or two tertiles. A
categorical independent variable is then created with the patterns as categories, and used
to predict the outcome in an appropriate regression model (e.g., logistic regression model
or Cox proportional hazards regression model).
2.3.2 Absolute/relative changes in diet over time
This approach would typically consider one interval of time at a time. The use of
absolute change may be misleading because the absolute difference between two high
diet intake values or two low diet intake values across two points in time may be
numerically identical and when the difference is entered in a regression model, these two
participants with different diet intake levels will be classified in the same group.
The usefulness of percent change or relative change in classifying participants
based on their diet intake may depend on the range of values for the specific dietary
factor. For a composite factor that may include both positive and negative values within a
narrow range, for example, the dietary inflammatory index, percent change may not
properly classify participants. Movement from a score of -1 to -2 (1 unit change in the
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anti-inflammatory direction) has a 100% change, whereas movement from 9 to 8 (another
1 unit change in the anti-inflammatory direction) only has an 11% change, even though
the absolute value of the change and the direction are the same.
2.3.3 Pooled repeated observations (PRO) of diet
This approach is a generalized person-year technique which incorporates all
repeated diet measurements made at equally spaced intervals of time.168 This is the
method used in the Framingham Study Cohort.168,169 The method as originally proposed
by Wu and Ware treats each time interval as a mini-follow-up study and pools
observations across all intervals to examine the short-term development of disease.166 The
outcome for this method is assumed to occur once (that is, event/no event), in contrast to
other sampling designs in which the outcome is also measured repeatedly over time.166
In analyses using only baseline diet data, repeated observations are ignored. These
observations are time dependent and since individuals change over time, this data which
could influence the outcome is lost. The PRO method uses all of this data and updates the
risk factors or diet data and persons at risk at the beginning of each observation
interval.168 For example, if 500 persons were enrolled in a study and at the end of the first
interval, 30 were diagnosed with the disease of interest, while 20 were lost to follow-up
or died of other causes, these 50 persons are removed from the population at risk and the
remaining 450 become at risk for the next interval and so on till the last interval. The data
obtained from all intervals is then pooled to yield a sample from which interval
predictions for disease can be examined as opposed to one long term prediction as would
be the case if only baseline diet data were used.168
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Three main assumptions underlie the PRO method, which include the following:
1) the time at which data is recorded is not relevant to the occurrence of an event; for
example, the probability of developing disease among persons with the same risk profile
in the first interval is the same as in the ninth interval, 2) the relation between risk factors
(e.g., diet) and outcome is independent of time, that is, there are no secular trends, and 3)
the current risk profile is all that is needed to predict risk in the next interval, meaning
that a person’s past history is not important in this prediction.168
Wu and Ware proposed a general logistic regression model to incorporate
repeated measurements in predicting a dichotomous outcome.166 When the three
assumptions listed above are applied to this model, it reduces to the PRO method.168 The
PRO method can also be implemented using the complementary log transformation [(-log
(1-p)] for the conditional probability of survival in an interval, proposed by Prentice and
Gloeckler.170 These two regression models produce similar results when the intervals are
short and the outcome is rare compared to number of persons at risk for the outcome.171
2.3.4 Cumulative average diet
The incidence of the outcome in an interval going forward can be related to the
cumulative average of diet intake calculated from the preceding intervals. For example,
the incidence of the outcome from year 3 going forward can be related to the cumulative
average of diet data from baseline, years 1 to 3, while the incidence of the outcome from
year 5 going forward can be related to the cumulative average of baseline, years 1-5 diet
data. The averages can be calculated unweighted or weighted. For example, if previous
diet history is hypothesized to influence the outcome more than current diet, more weight
can be given to diet data from older intervals compared to more recent intervals. Hu and
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colleagues related incidence of cardiovascular disease in two-year intervals, to
cumulative average fat intake from all preceding intervals, in a study comparing
approaches for modeling repeated dietary measurements.172 To avoid the possibility of
change of diet due to subclinical disease, outcomes that developed during the period for
which diet is being averaged can be excluded from analyses. Exclusion of previously
diagnosed cases also ensures that only participants at risk of developing the outcome
going forward are included in the models

2.4

Risk factors for colorectal cancer
Colorectal cancer (colon and rectum cancers combined) is the third (after lung and

breast cancer) most commonly diagnosed cancer and the second leading cause of cancerrelated deaths in the US.173 The American Institute for Cancer Research (AICR)
estimates that half of colorectal cancers can be prevented by healthy lifestyle habits. In
total, close to 400,000 cases of colorectal cancer in the United States can be prevented
each year by eating a healthy diet, undertaking regular physical activity, maintaining a
healthy weight and limiting alcohol consumption.174 This suggests that colorectal cancer
is one of the most preventable types of cancer. An analysis of colon cancer risk factors in
women found reduced risk for current postmenopausal hormone use, being physically
active, taking aspirin, and being screened. Women who smoked, had a consistently high
relative weight, had a low physical activity level, consumed red or processed meat daily,
were never screened, and consumed low daily amounts of folate, had almost a 4-fold
higher cumulative risk of colon cancer by age 70 years. The study also found that for
women with a high risk factor profile, adopting a healthier lifestyle could dramatically
reduce colon cancer risk.175
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2.4.1 Dietary patterns
The 2011 Continuous Update Project report of the WCRF/AICR, on colorectal
cancer found that consuming foods containing fiber and being physically active reduces
colorectal cancer risk, while having excess body fat, alcohol, and intake of red and
processed meats increase risk.174 The WCRF/AICR “Second Expert Report” indicated
that there is convincing evidence linking specific dietary factors to colorectal cancer risk,
but suggested the examination of broad patterns of diet as a way of understanding the
causal relationship between diet and cancer development.11 The field of dietary patterns
research has been growing rapidly, with five systematic reviews/meta-analyses
examining the association between dietary patterns and colorectal cancer risk, published
between 2010 and 2013.176-180 However, none of the studies included in these reviews
examined associations between changes in dietary patterns and colorectal cancer risk.
Despite some differences in design, methods and population characteristics of the
individual studies included in the different reviews, all five reviews produced remarkably
consistent results on the associations between the dietary patterns identified and risk of
colorectal cancer. Results from a posteriori patterns generally showed a reduced risk of
colorectal cancer from consuming a plant-based pattern characterized by a high intake of
fruits and vegetables, legumes, and some dairy, while an animal-based pattern
characterized by high intake of red/processed meat, refined gains, and added sugars was
associated with increased risk.28,30,41,42,176,177,180-182
The consistency of results despite differences in the number, type and quantity of
foods in the identified patterns between different populations could mean that specific
differences in foods are not as important as consuming an overall plant-based or animal33

based dietary pattern to have a beneficial or detrimental effect respectively, on colorectal
cancer risk.180 The reviews also included results from a priori diet quality indices such as
DASH, HEI, aHEI and Med Diet. Higher scores on the dietary indices showed a
protective association with colorectal cancer risk. These indices share similar features
such as the emphasis on whole grains, fruits and vegetables intakes and the penalization
of excessive intake of animal products.177,180 These features broadly align a priori dietary
patterns with the patterns that have been identified using a posteriori methods.
However, these findings are heterogeneous by gender and anatomic subsite of
colorectal cancer. There has been more consistency in findings for colon cancer than for
rectal cancer. In the review by Megalhaes et al., there were significant and similar
findings for proximal and distal colon tumors but no significant association with rectal
cancer.179 Miller et al., found more consistent results for a priori patterns and colorectal
cancer in men,177,183 while findings from a posteriori patterns were less clear, with four of
eight studies and five of nine studies observing significant associations in men and
women, respectively.177
Current data do not place emphasis on the analysis of changes over time in dietary
patterns in relation to colorectal cancer risk, despite the idea that dietary behavior is not
stable over time and dietary changes may impact colorectal cancer risk estimates
differently than diet assessed at only one point in time. Findings of the association
between dietary patterns and colorectal cancer risk have been consistent despite
differences in the composition of a posteriori and a priori dietary patterns. The majority
of studies have been conducted in North America or European populations including
mostly Europeans or European Americans. Studies conducted in diverse and disparate
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populations will be needed to determine the impact of sociodemographic factors
(including gender) on the association between dietary patterns and risk of colorectal
cancer.
2.4.2 Smoking and alcohol intake
Carcinogens from tobacco reach the colorectal mucosa through either the gut or
the circulatory system and could damage or alter the expression of important cancerrelated genes.184 Tobacco smoking has consistently been associated with colorectal
adenomas (precursors of colorectal cancer)185 but not with colorectal cancer until
recently. It has been suggested that the reason for this discrepancy may be a 35- to 40year lag time between exposure and disease, which would not be captured by earlier
studies and studies with shorter follow-up.186 Recent investigations, with more thorough
measurement of smoking exposure and longer exposure periods, have reported a positive
association between cigarette smoking and the risk of colorectal cancer.184,187,188 Paskett
et al., investigated the associations between cigarette smoking and colorectal cancer in
the Women’s Health Initiative, and found that active exposure to cigarette smoking
appears to be a risk factor for rectal cancer but not colon cancer.189 Several systematic
reviews and meta-analyses have been conducted with the consistent conclusion that
cigarette smoking significantly increases colorectal cancer risk.184,190 There are however,
inconsistencies relative to colorectal cancer subsite, with some studies showing positive
results only for the rectum.189,191
With the considerable evidence linking smoking to higher risk of colorectal
cancer, it is also important to consider the impact of quitting smoking on risk attenuation.
In a pooled analysis of eight studies to evaluate the association between cigarette
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smoking history and colorectal cancer risk, researchers found that colorectal cancer risk
remained increased for about 25 years after quitting smoking, and the pattern of decline
in risk varied by colorectal cancer subsite.192 A study that examined lifetime smoking
history and incidence of colorectal cancer in a large cohort of men followed for more
than 12 years, also found that past and current smoking are associated with an increase in
risk.193
The International Agency for Research on Cancer (IARC) concluded that the
burden of alcohol-associated cancer (including colorectal cancer) is substantial and
needs to be considered when making public health recommendations on alcohol
consumption,194 though unresolved issues relative to anatomical site (colon/rectum)
remain. A meta-analysis of 27 cohort and 34 case-control studies found strong evidence
(with dose-response) for an association between alcohol drinking of >1 drink/day and
colorectal cancer risk.195 Several other meta-analyses have supported a positive
association between alcohol intake and colorectal cancer risk.196-199 Acetaldehyde may be
predominantly responsible for alcohol-associated carcinogenesis. Acetaldehyde is
carcinogenic and mutagenic, binds to DNA and proteins, destroys folate and results in
secondary hyperproliferation.200 Acetaldehyde is produced by tissue alcohol
hydrogenases, cytochrome P 4502E1 and through bacterial oxidative metabolism in the
upper and lower gastrointestinal tract.200
2.4.3 Overweight/obesity and physical activity
In 2001, the IARC convened a panel of international experts to discuss the role of
overweight, obesity and lack of physical activity in cancer prevention and control. The
panel judged that there was sufficient evidence (causal) that excess body weight increases
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the risk of cancers of the colon, breast (in postmenopausal women), endometrium,
kidney, and adenocarcinoma of the esophagus.201 Regarding physical activity, the IARC
panel judged also that there was sufficient evidence from human studies for a cancerpreventive effect of physical activity against cancers of the colon and breast.201 The
WCRF/AICR 2010 CUP panel on colorectal cancer reviewed the most recent evidence on
physical activity and colorectal cancer and concluded that there was convincing evidence
that higher levels of physical activity, within the range studied, protect against colon
cancer, with evidence of dose-response. The report further indicated that the effect is
stronger for colon cancer; but with no evidence of an effect for rectal cancer. The effect
was strong and consistent in men, but less so in women and there was plausible evidence
for mechanisms of action in humans.174 Evidence from the European Prospective
Investigation into Cancer and Nutrition (EPIC) on the association between adherence to
the WCRF/AICR recommendations on weight management and physical activity, showed
that risk reduction in participants in the fourth and fifth categories of the adherence score
compared with those within the first category was 27% for colorectal and 16% for breast
cancer.202
One major class of mechanisms that may form a physiological and causal link
between excess body weight, physical inactivity and cancer risk are alterations in the
metabolism of endogenous hormones, including insulin, bioavailable sex steroids,
insulin-like growth factor (IGF-I), IGF-binding proteins (IGFBPs)174,201,203 and chronic
low-grade inflammation.204 Obesity increases insulin resistance and associated changes in
blood values (high glucose, free fatty acids, insulin, and IGF-1). These circulating factors
increase proliferation and decrease apoptosis of cancer cells, thus promoting tumor
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growth.174,205 Sustained moderate physical activity raises the metabolic rate and increases
maximal oxygen uptake. In the long term, regular periods of such activity increase the
body’s metabolic efficiency and capacity, and so have a beneficial effect on body fatness.
In addition, physical activity may protect against colon cancer by decreasing
inflammation.174
2.4.4 Regular use of Non-steroidal anti-inflammatory drug (NSAID)
Several studies have suggested a protective effect of aspirin and non-aspirin
NSAIDs on colorectal cancer79,83,84 but some studies have failed to show a beneficial
effect. The effect of aspirin on the risk of cancer among healthy women has been
examined in the Women Health Study, a randomized controlled trial with an average
follow-up time of 10.1 years. A dose of 100mg of aspirin was administered in the
intervention group every other day against a placebo in the control group. The outcome
was confirmed cancer of any site. This trial concluded without enough evidence that
alternate day use of low-dose aspirin for an average 10 years of treatment lowers the risk
of total cancer, breast, colorectal, or other site-specific cancers.206 Another randomized
controlled trial examined the association between regular use of low-dose aspirin and
incidence of invasive and noninvasive colorectal tumors. The aspirin arm was terminated
after a mean follow-up of 5 years. The relative risk of developing colorectal cancer for
aspirin compared with placebo was 1.15 (95%CI 0.80–1.65), with no significant trend for
decreasing risk by year of follow-up.207
In contrast, two large meta-analyses have demonstrated a beneficial effect of
aspirin and non-aspirin NSAIDs on colorectal cancer development. In 2007, the US
Preventive Services Task Force (USPSTF) commissioned the two meta-analyses:83,84 the
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one examined the benefits and harms of non-aspirin NSAIDs and cyclooxygenase (COX2) inhibitors for the prevention of colorectal cancer and adenoma. Colorectal cancer
incidence was lower with non-aspirin NSAIDs in cohort studies (RR; 0.61, 95%CI; 0.48,
0.77) and case-control studies (RR; 0.70, 95%CI; 0.63, 0.78).84 Risk of colorectal
adenoma was also reduced with non-aspirin NSAIDs use in cohort studies (RR; 0.64,
95%CI, 0.48, 0.85) and case-control studies (RR; 0.54, 95%CI, 0.40, 0.74]) and by COX2 inhibitors in randomized, controlled trials (RR; 0.72, 95%CI, 0.68 to 0.77).84 The other
meta-analysis examined the benefits and harms of employing aspirin for the
chemoprevention of colorectal cancer. In this study, regular use of aspirin reduced the
incidence of colonic adenomas in randomized clinical trials (RR; 0.82, 95%CI, 0.70 to
0.95), case-control studies (RR; 0.87, 95%CI, 0.77 to 0.98), and cohort studies (RR; 0.72,
95%CI, 0.61 to 0.85).83 In cohort studies, regular use of aspirin was associated with
reduced risk of 22% for colorectal cancer.83
Despite this evidence showing that aspirin and non-aspirin NSAIDs appear to be
effective at reducing the incidence of colonic adenoma and colorectal cancer, especially
if used in high doses for a prolonged period of time, the USPSTF currently recommends
against the use of aspirin and non-aspirin NSAIDs for the prevention of colorectal cancer
in individuals at average risk for the disease (D recommendation). This is likely due to
adverse side effects such as cardiovascular events and gastrointestinal harms.84 This
recommendation may likely change as more evidence accumulates.

2.5

Risk factors for breast cancer
Breast cancer is the most commonly diagnosed cancer in women, and is the

second leading cause of cancer-related deaths in American women after lung cancer.173
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Breast cancer in women accounts for about a third of all cancer cases and about 15% of
all cancer deaths among women in the United States. Risk factors include diet, physical
activity, body size, reproductive and hormonal factors, among many other factors. The
role of diet in breast cancer risk is of great interest as a potentially modifiable risk factor.
2.5.1 Dietary patterns
Most of the established risk factors for breast cancer such as family history,
lactation, and reproductive history are generally not modifiable. Epidemiological studies
have shown that the risk of breast cancer varies with diet - a potentially modifiable factor
– though the evidence is inconsistent.41-47,181,182,208-211 Dietary patterns contain a complex
mix of foods, nutrients and other compounds that could influence breast cancer risk in
ways not detected by studies of individual foods and nutrients. Evidence shows a positive
association between the Western-style dietary pattern (rich in added sugar, refined grains,
red and processed meats, and fried foods) and increased risk.41,43,212-214 Studies have also
observed a decreased risk with the prudent-type dietary pattern (rich in fruits, vegetables,
whole-grains, legumes, nuts, olive oil and fish),43,181,182,212-217 but other studies have not
found significant associations with any of these dietary patterns identified by a posteriori
methods except in subgroup analyses in some studies.46,180,181,212,218,219 In the Black
Women’s Health Study, the prudent pattern was weakly associated with lower risk
overall, but was significantly associated with lower risk in normal weight women and in
women with estrogen receptor negative breast cancer.220 A meta-analysis of 15
prospective studies found that high intake of fruits, and fruits and vegetables combined, is
associated with a weak reduction in risk of breast cancer with no dose-response.221
Similarly, in a pooled analysis of 8 large prospective studies, only weak and non40

significant associations were observed with increasing consumption of fruit and
vegetables.219 Other dietary patterns investigated are the vegetarian diet. One study found
no significant association between a vegetarian versus non-vegetarian diet and breast
cancer risk,222 while there was a non-significant inverse association between
vegetarianism and risk of pre- or postmenopausal breast cancer in the EPIC-Oxford
cohort, United Kingdom.223
Regarding a priori dietary patterns, an index derived from 23 recommended food
items was not associated with breast cancer risk in one study.224 Similarly, in the Nurse’s
Health Study, an investigation of the association of several dietary indices and
postmenopausal breast cancer found no significant association with any of the indices,
except when stratifying by hormone receptor status of the cancer. Women who scored
high in some of the indices had a lower risk of estrogen receptor negative breast
cancer.225
Studies of the association between dietary patterns and breast cancer risk have
been conducted in populations other than North Americans and Europeans. Some reports
indicate that dietary patterns rich in vegetables and seafood are associated with a
decreased breast cancer risk in Korean women,226,227 and Chinese women.228 Findings
from one study suggest that a diet characterized by low intake of meat/starches and high
intake of legumes is associated with a reduced risk of breast cancer in Asian Americans,
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while another study found evidence of an inverse association between a healthy

dietary pattern and breast cancer risk among Iranian women.212 A Japanese study found
that the prudent dietary pattern is negatively associated with breast cancer risk, while the
high fat and Japanese patterns may increase breast cancer risk among obese Japanese
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women.214 It is also important to note that none of the published studies examined the
association of changes in dietary patterns and risk of breast cancer, though changes in
dietary patterns may impact risk differently than dietary patterns assessed at only one
point in time.
2.5.2 Overweight/obesity and physical activity
Obesity is a state of chronic systemic low-grade inflammation.229 Adipose tissue
is now known to secrete a growing number of inflammatory mediators (adipokines)
including CRP. The secretion of these inflammatory mediators is increased in obesity,230
and they regulate physiological and pathological processes, including immunity and
inflammation.229 There is increasing epidemiologic evidence of an association between
BMI and energy expenditure and the risk of breast cancer. Women who are overweight or
obese, especially women who gain weight throughout adulthood, are at an increased risk
for developing breast cancer after menopause.231-233 Conversely, overweight women are
at reduced risk for developing breast cancer in the premenopausal years.234 A pooled
analysis of cohort studies showed that BMI has significant inverse and positive
associations with breast cancer among pre- and postmenopausal women, respectively.
Compared with premenopausal women with a BMI of less than 21 kg/m2, women with a
BMI exceeding 31 kg/m2 had a relative risk of 0.54 (95%CI; 0.34, 0.85). In
postmenopausal women, the relative risk for these women was 1.26 (95%CI; 1.09,
1.46).235 A meta-analysis to assess the strength of associations between BMI and different
sites of cancer estimated that each 5 kg/m2 increase in BMI was associated with a 12%
increased risk of postmenopausal breast cancer (RR; 1.12; 95%CI, 1.08, 1.16).236 In
postmenopausal women, the association has been shown to be modified by hormone
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replacement therapy; users are at higher risk compared to non-users, and by estrogen
receptor/progesterone receptor (ER/PR) status; with women having ER+/PR+ tumors
being at higher risk compared to ER-/PR- tumors.231,233,237 A meta-analysis of 9 cohorts
and 22 case-control studies, further confirmed that the association between BMI and
breast cancer risk is dependent on menopausal status and ER/PR status.237
Studies have shown that physical activity increases concentrations of a number of
cytokines with anti-inflammatory effects such as IL-1ra (interleukin-1 receptor
antagonist) and IL-10 and inhibits the production of the pro-inflammatory cytokine
TNFα.238 Physical activity also has been shown to be associated with reduce
concentrations of some pro-inflammatory cytokines such as CRP and other biomarkers of
inflammation.239-242 These results consistently show that physical activity reduces chronic
inflammation – a crucial process in cancer development.
Physical activity has been shown to reduce breast cancer risk. A study
investigating the relation between recreational physical activity (RPA) and breast cancer
risk, found that RPA at any intensity level during the reproductive and postmenopausal
years was associated with reduced breast cancer risk and that substantial postmenopausal
weight gain may eliminate the benefits of RPA.243 Physical activity also was found to be
associated with reduced breast cancer risk in the WHI, with longer duration providing the
most benefit.244 The association between physical activity and postmenopausal breast
cancer risk has been confirmed consistently enough that the US Department of Health
and Human Services Physical Activity Guidelines Advisory Committee concluded in
2008 that “strong evidence demonstrates that, compared with less active persons, more
active women have lower rates of breast cancer.”245
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2.5.3 Hormone replacement therapy and oral contraceptive use
Evidence shows that oral contraceptive use increases a young woman's risk of
breast cancer. A multisite case-control study analyzed data on women younger than 45
years of age (to maximize opportunities for extended exposure) who used oral
contraceptives throughout their entire reproductive years. In this population of younger
women, use of oral contraceptives for 6 months or longer was associated with an
increased risk for breast cancer of 30% (OR,1.3; 95%CI, 1.1, 1.5).246 There was also a
significant dose-response relationship. To investigate the possibility that chance or bias,
including selective screening of contraceptive users, contributed to the putative
association, an evaluation of screening histories and methods of diagnosis failed to
support the speculation that associations could be due to selective screening.246 Among
women 45 years of age and older, no associations of risk with use of oral contraceptives
were noted.246
Increased risk of breast cancer with combined use of estrogen and progesterone
has been reported in some studies.247,248 In the study by Schaier et al., the risk was greater
for lean women, but there was no evidence of increased risk in heavier women,248 which
is similar to the finding in the collaborative reanalysis.249 This effect modification by
BMI is contrary to the study results that endogenous estrogen increases risk of breast
cancer, given that overweight and obese women have relatively higher endogenous
estrogen levels than lean women due to non-ovarian synthesis of estrone as a result of the
peripheral conversion of androgens.248 Another study reported that obese postmenopausal
women had a greater increase in circulating free estradiol in response to oral estrogen
compared with normal weight women.250
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The association between exogenous estrogen use and breast cancer risk lacked
clinical trial support until 1993 when the WHI began two randomized placebo-controlled
trials that separately evaluated estrogen plus progestin (in women with an intact uterus)
as well as estrogen alone (in women with a previous hysterectomy)251 (NB: In the
absence of a uterus, estrogen treatment is the only way to relieve a women of hot flashes
or other menopausal symptoms, and in the estrogen-alone trial, there would be
confounding by endogenous estrogen if the uterus is present). After a mean follow-up of
5.3 years there was a slightly increased risk of breast cancer, HR, 1.26; 95%CI, 1.00,
1.59.251 However, women reporting prior use of estrogen plus progesterone experienced
higher risk for breast cancer associated with estrogen plus progesterone use than those
who never used postmenopausal hormones. Longer duration of prior use of estrogen plus
progesterone appeared to have a cumulative effect of estrogen plus progestin on risk of
incident breast cancer and these effects were not found to be modified by age,
race/ethnicity, family history, parity, age at first birth or BMI.251
In contrast to the substantial evidence linking exogenous hormone use (combined
estrogen plus progestin) with increased breast cancer risk, the parallel WHI estrogenalone trial showed an unanticipated potential reduction in breast cancer risk (HR, 0.77;
95%CI, 0.59, 1.01) in the estrogen-alone group compared to the placebo group after 7.1
years of follow-up.252 Differences in breast cancer screening between the intervention and
placebo groups did not explain the observed effects.40 The suggestion of a reduced risk
for breast cancer motivated Stefanick et al to conduct a detailed analysis of the WHI
estrogen-alone trial data focusing only on breast cancer outcome. Their main analysis
results provided no evidence that the use of estrogen-alone increased risk of breast
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cancer (HR, 0.80; 95%CI, 0.62, 1.04).253 However, in adherence-adjusted analyses that
censored follow-up 6 months after a woman became nonadherent, a larger and significant
reduction in the incidence of invasive breast cancer was observed in the estrogen-alone
group compared with the placebo group (HR, 0.67; 95%CI, 0.47-0.97) and the risk did
not differ by estrogen or progesterone receptor status of the cancer.253
No significant interaction of exposure to exogenous hormone and BMI on breast
cancer risk was observed in either the estrogen-alone trial or in the combined estrogen
plus progestin trial.251-253 The differences in the results of the two WHI trials strongly
suggest a role for progestin in increasing breast cancer risk. The biological mechanisms
underlying an effect of exogenous hormones on the breast are complex. One hypothesis is
that progesterone does not down-regulate estrogen and progesterone receptors in the
breast may contribute to its adverse effects.254 It is paradoxical however, that the addition
of exogenous estrogen by use of conjugated equine estrogen in the WHI trial253 and the
reduction of endogenous estrogen by use of aromatase inhibitors (exemestane) in the
MAP.3 trial255 both reduced risk of breast cancer incidence. The conceptual model that
breast cancer growth may be stimulated or inhibited solely by the respective addition or
withdrawal of estrogen thus falls apart.
In summary, the long-term effect of estrogen use on the risk of breast cancer is
still an open question. Women exposed to exogenous hormones (especially combined
estrogen and progestin) are at increased risk for breast cancer. The risk increases with
duration of use, but also reduces after cessation of use of exogenous hormones and has
largely, if not wholly disappeared after 2 to 5 years post-cessation. The increase in risk
among older women exposed to exogenous hormones suggests that the trade-offs
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between risks and benefits should be carefully assessed. In this assessment, it is important
to consider the type of hormone as well as individual characteristics of the woman, such
as BMI.
2.5.4 Demographic factors
Many demographic factors influence the incidence and survival rates from breast
cancer. The disease is more common in older women, among women in upper rather than
lower social classes, among women who never have been married, among women living
in urban areas, and among European Americans than African Americans, at least among
those over age 50.256
The strongest risk factor for breast cancer is age. A woman’s risk of developing
the disease increases as she gets older. That is because with more years of life, there are
more opportunities for genetic damage (mutations) in the body, and as we age, our bodies
are less capable of repairing genetic damage. According to Surveillance, Epidemiology,
and End Results (SEER) program statistics from 2005-2009, the median age at diagnosis
for cancer of the breast was 61 years of age. Approximately 0% were diagnosed under
age 20; 2% between 20 and 34; 10% between 35 and 44; 22% between 45 and 54; 25%
between 55 and 64; 20% between 65 and 74; 15% between 75 and 84; and 6% 85+ years
of age.257
European American women are slightly more likely to develop breast cancer
(age-adjusted incidence rate: 127.3 per 100,000 women) than African American (121.2
per 100,000 women), Hispanic, and Asian women. But African American women are
more likely to develop more aggressive, more advanced-stage breast cancer that is
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diagnosed at younger ages. African American women are also more likely to die from
breast cancer. Based on the SEER data for patients who died in 2005-2009 in the US, the
breast cancer mortality rate for African American women is 31.6 per 100,000 women
compared with 22.4 per 100,000 women for European American women.257 Some of
these differences in outcomes may be due to tumor biology (e.g., higher prevalence of
triple negative tumors in African Americans).258 Compared to European American
women, women of African ancestry tend to have more aggressive breast cancers that
present more frequently as estrogen receptor-negative (ER-) tumors.258-260 Triple negative
comprise approximately 15% of breast cancers and have been associated with high-grade
histology, aggressive clinical behavior, and poor survival.261 Other possible explanations
for racial disparities in aggressiveness of disease include less access to mammography
screening and lower quality medical care,262,263 as well as various lifestyle patterns
(eating habits and weight issues for example) that are more common in some ethnic
groups than in others. In a study to evaluate differences in the stage and biology of breast
cancer between African American and European American women who had a screening
mammogram, Grabler et al., found that African American women in the regularly
screened population were less likely than irregularly screened African American women
to have ER- breast cancers (26% vs. 36%, p<0.05), PR- breast cancers (35% vs. 46%,
p<0.05), and poorly differentiated breast cancers (39% vs.53%, p<0.05).264 European
American women in the irregularly screened population also had worse prognostic
factors than European American women in the regularly screened population, though
these were not statistically significant.264 Regular screening for breast cancer may thus
contribute to the narrowing of racial disparities in breast cancer risk.
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CHAPTER 3

METHODS
3.1

Statement of research aims and hypotheses
The overall aim of this study was to characterize longitudinal trends in the

inflammatory potential of the diet and then evaluate the association of longitudinal
changes in the inflammatory potential of diet and risk of colorectal cancer and breast
cancer in the WHI. Our overall hypothesis is that long term changes in dietary behavior
towards increased consumption of pro-inflammatory diets increases the risk of cancer
over time.
In specific aim #1, we investigated the stability of the inflammatory potential of
diet over time using the dietary inflammatory index (DII). In this aim we hypothesized
that the inflammatory potential of diet significantly changes over time and is influenced
by social, demographic and clinical factors. In specific aim #2, we examined the
association between the inflammatory potential of diet and risk of colorectal cancer with
the hypothesis that a sustained high level of dietary inflammatory potential over time,
increases risk of colorectal cancer. In specific aim #3, we examined the association
between the inflammatory potential of diet and breast cancer in postmenopausal women,

49

with the hypothesis that a sustained high level of dietary inflammatory potential over
time, increases risk of breast cancer in postmenopausal women. Specific research
questions have been restated in section 3.6, before the description of the statistical
methods for each of the three aims.

3.2

Description of the study population
The WHI study is a large and complex clinical investigation of strategies for the

prevention and control of some of the most common causes of morbidity and mortality
among postmenopausal women. The design of the WHI has been described in detail
elsewhere.40 Briefly, The WHI began in 1992, spanning across 40 sites in the United
States, and enrolled a total of 161,808 women between 1993 and 1998 and included fullscale randomized controlled trials, with an average of 11.3 years of follow-up until
September 30, 2010. The WHI enrolled 93,676 women into the OS and 68,132
participants into clinical trials (CT).265 The WHI CT included: the DMT component,
n=48,835, the Hormone Therapy component (HT, estrogen-alone or estrogen plus
progestin, n=27,347). Participants enrolled in at least one of the clinical trial components
were screened for eligibility and invited to join the calcium and vitamin D component
(CaD, n=36,282) at their first or second annual clinic visits. For the DMT, women were
randomly assigned to a usual-diet comparison group (n = 29,294) or an intervention
group with a 20% low-fat dietary pattern with increased vegetables, fruits, and grains (n =
19,541). At baseline, the mean age was 63 years and about 18% of the women were from
ethnic minority groups including: 9.1% African-Americans (n=14,618), 4% Hispanics
(n=6,484), and 2.6% Asians (n=4,190). Women who proved to be ineligible for, or who
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were unwilling to enroll in the CT components were invited to be part of the prospective
cohort of women in the OS.40
Exclusion criteria for both the OS and CT included any medical condition
associated with a predicted survival of less than three years, alcoholism, other drug
dependency, mental illness (e.g., major depressive disorder), dementia, active
participation in another intervention trial and not likely to live in the area for at least 3
years. Demographic information and dietary data were obtained by self-report using
standardized questionnaires. Certified staff performed physical measurements, including
blood pressure, height and weight, and blood samples at the baseline clinic visit. Women
were further excluded from the DM if their diets were assessed to have <32% energy
from fat.266 The WHI protocol was approved by the institutional review boards at the
Clinical Coordinating Center at the Fred Hutchinson Cancer Research Center (Seattle,
WA) and at each of the 40 Clinical Centers.14

3.3

Diet assessment
During baseline screening for the WHI, all participants completed a standardized

food frequency questionnaire (FFQ) developed for the WHI to estimate average daily
nutrient intake over the previous three-month period. At follow-up, the FFQ was
completed at year 3 for all the observational study participants and for all participants in
the DMT at year 1, and a random third of DMT participants from year 2 onwards. The
three sections of the WHI FFQ included 19 adjustment questions related to type of fat
intake, 122 composite and single food line items asking about frequency of consumption
and portion size, and four summary questions that asked about the usual intake of fruits
and vegetables and added fats for comparison to information gathered from the line
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items. The nutrient database, linked to the University of Minnesota Nutrient Data System
for research (NDSR), is based on the US Department of Agriculture Standard Reference
Releases and manufacturer information. This FFQ has demonstrated good comparability
to 24-hour dietary recall interviews and food records in the WHI.266 For all three study
aims, we used all the FFQs in the OS and DMT and calculated the DII at eleven different
time points.

3.4

Outcomes assessment
For aim #1, changes in the DII over time, calculated at 11 time points constituted

our outcome of interest. A detailed description of the DII is provided in section 3.5. In
aims #2 and #3, where colorectal cancer and breast cancer were the outcomes of interest,
the DII was the main exposure of interest.
The WHI outcomes ascertainment and adjudication methods have been previously
described.267 Briefly, physicians in the Clinical Centers, the Clinical Coordinating Center,
and the National Institutes of Health (NIH) classified WHI outcomes. In the first stage,
the local Clinical Center physician adjudicator reviewed the documents and assigned a
diagnosis. All locally adjudicated primary and safety endpoint events of each trial
component were then centrally reviewed. A fraction of locally adjudicated secondary
endpoints were also referred for central adjudication for quality control purposes. The
primary results for each clinical trial component were based on data derived from central
adjudication. To minimize potential bias in the ascertainment and classification of
outcomes, WHI required that local and central physician adjudicators not be exposed to
any information that could result in potential unblinding, including participant contact or
other aspects of the research record.
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Invasive breast and colorectal cancers were documented and coded according to
primary site, anatomic subsite, diagnosis date, extent of disease (stage, tumor size, and
laterality), tumor morphology (behavior, grade, histology) her2neu status and estrogen
and progesterone receptors status (breast cancer only). We have chosen to focus on breast
and colorectal cancers in this dissertation because these cancers have been associated
with diet and inflammation in previous studies and because these were primary or
secondary endpoints in WHI allowing for adequate numbers of cases for analyses.
Incident invasive and in situ (ductal and lobular carcinoma in situ) breast cancers,
including second primaries, were ascertained and adjudicated. Incident invasive and in
situ colon and rectal cancers were determined. Recurrent cancers were not included. All
cancer related hospitalizations, surgeries, procedures, diagnostics or treatments for each
first self-report of a malignant tumor were investigated. For the full coding of the cancer,
pathology reports from diagnostic aspirations, biopsies, and surgeries, plus the discharge
summary, were used.
Since the diagnosis of some early cancers and cancer precursors is dependent on
whether or not screening has occurred, there was potential for over-reporting of
diagnoses in some arms of the study, particularly the unblinded intervention arm of the
DMT component. For this reason and for safety purposes in the HT component, all
clinical trial participants had regular screening mammograms as part of study protocol.
Screening for colorectal cancer was not done in WHI. At each follow-up contact (semiannually in the clinical trial, and annually in the observational study), however,
information on screening procedures for colorectal cancer was collected, including: fecal
occult blood testing, flexible sigmoidoscopy, and colonoscopy.
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3.5

Description of the dietary inflammatory index (DII)
The development38 and validation39 of the DII has been described elsewhere. The

goal in developing the DII was to create a score for specific foods and dietary
constituents thought to positively or negatively affect levels of inflammation. All
research articles through the year 2010 that were identified as assessing the role of one or
more of 45 different foods and dietary constituents on specific inflammatory markers
were used to create the scores. Due to the large number of articles on inflammation, the
literature search was limited to six well-established inflammatory markers: CRP, IL-1β,
IL-4, IL-6, IL-10, and TNFα out of which CRP, IL-1β, IL-6 and TNF-α are considered
pro-inflammatory biomarkers and IL-4 and IL-10 are considered anti-inflammatory
cytokines. A total of 1,943 research articles were reviewed and scored in the creation of
the DII.
One of three possible values was assigned to each article based on the effect of
the food parameter on inflammation: “+1” was assigned if the effects were proinflammatory (significantly increased IL-1B, IL-6, TNFα, or CRP or decreased IL-4 or
IL-10); “-1” if the effects were anti-inflammatory (significantly decreased IL-1B, IL-6,
TNFα, or CRP or increased IL-4 or IL-10) and “0” if the food parameter was not
significantly associated with the inflammatory marker. Full details of the scoring
algorithm are described in this reference.38
Articles were first weighted by study design, with clinical trials in humans
receiving the greatest weight (i.e., 10 of possible 10) to cell culture experimental studies
receiving the lowest weight (i.e., 3 of possible 10). Using these weighted values, the proand anti-inflammatory fractions for each food parameter were calculated. The food
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parameter-specific overall inflammatory effect score was then calculated by: 1) dividing
the weighted pro- and anti-inflammatory articles by total weighted number of articles and
2) subtracting the anti-inflammatory fraction from the pro-inflammatory fraction (Figure
3.1). A cut point of 236, the median of the total weighted number of articles across all
the food parameters, was chosen to indicate an optimally robust pool of literature. All
food parameters with a weighted number of articles ≥236 were assigned the full value of
the score. Foods and constituents with a weighted number of articles <236 were adjusted
as follows: 1) number of weighted articles was divided by 236; 2) the fraction was then
multiplied by the food parameter-specific raw inflammatory effect score, which resulted
in the food parameter-specific overall inflammatory effect score.
To avoid the arbitrariness resulting from simply using raw intake amounts
(resulting in different units of measurement for various nutrients having large influences
on the overall score), the DII was standardized to a representative range of dietary intake
based on actual human consumption. This was accomplished by constructing a composite
database representing a wide range of diets across diverse populations living in a variety
of countries in different regions of the world. Authors of articles reporting on data from
nutrition surveys were contacted to request access to complete datasets. A total of 11
such datasets were identified and used in developing the composite database.38
Calculation of the DII in a given study is based on dietary intake data that are then
linked to the global mean intake database derived from the 11 datasets. An individual’s
diet is then expressed relative to the standard global mean as a z-score. This is achieved
by subtracting the standard global mean from the amount reported by the individual and
dividing this value by its standard deviation. To minimize the effect of “right skewing,”
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this value is converted to a percentile score. To achieve a symmetrical distribution with
values centered on 0 (null) and bounded between -1 (maximally anti-inflammatory) and 1
(maximally pro-inflammatory) each percentile score is doubled and then 1 is subtracted.
The centered-percentile value for each food parameter is then multiplied by its respective
food parameter-specific inflammatory effect score to obtain a food parameter-specific DII
score. Finally, all of the food parameter-specific DII scores are summed to create the
overall DII score for an individual. More positive scores represent a more proinflammatory diet, whereas more negative scores represent a more anti-inflammatory
diet.

3.6

Statistical analysis

3.6.1 Statistical methods applicable to all three aims
Confounding in all the Cox proportional hazards (PH) regression models was
assessed using the following three questions as suggested by Szklo and Nieto:268 1) is the
confounder related to both exposure (DII) and outcome (colorectal cancer or breast
cancer)? 2) Does the exposure-outcome association seen in the age-adjusted crude model
have the same magnitude and similar direction as the associations observed within strata
of the potential confounder? 3) Does the exposure-outcome association seen in the crude
model have the same magnitude and similar direction as that observed association in the
model adjusted for the potential confounder? Confounding was not assessed in aim #1 as
there was no specific exposure of interest in the prediction model for DII change.
Effect modification took precedence over confounding; that is, if a variable was
assessed to be both a confounder and effect modifier, it was treated as an effect modifier.
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We inserted “interaction terms" of main exposure and effect modifier in the models and
considered significant effect modification at P ≤ 0.05.
Statistical modeling consisted of variable selection and model selection. For the
DII prediction model in aim #1, the automated stepwise approach was used to identify
significant predictors of DII change. In the Cox PH models in aims #2 and #3, all
variables assessed to be confounders or significant effect modifiers were retained in the
models. Model selection was considered in specific situations to either include or exclude
a covariate from the model and improve the model’s overall precision. The log-likelihood
ratio test was used for model selection.
Participant characteristics were summarized using frequencies (percentage) for
categorical variables and means (standard deviation) for continuous variables. All pvalues were 2-sided, and P <0.05 for aim #1 and 95% confidence intervals not including
1 for aims #2 and #3, were considered to indicate statistical significance. All statistical
analyses were conducted using Statistical Analysis Systems software, version 9.3 (SAS,
Inc., Cary, NC).
3.6.2 Statistical methods for specific aims #1
The statistical methods for this aim were designed to answer the following four
research questions: 1) Are there changes in dietary inflammatory potential over time? 2)
If there are significant changes, how do demographic and lifestyle factors impact these
changes? 3) What social, demographic and clinical factors significantly predict changes
in DII in an observational setting? and 4) How does the change in the inflammatory
potential of diet in an intervention setting differs from that in an observational setting?
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We computed mean DII scores at baseline and Year 3 in the OS and at 11
different time points between baseline and Year 10 inclusive in the DMT; and used these
to describe changes over time in the OS, or plotted DII scores on graphs for a visual
appraisal of the longitudinal trend, separately for the intervention and control arms of the
DMT. Analyses were stratified by BMI, race/ethnicity and educational level. To
determine significant differences between mean DII scores calculated at different time
points, we constructed marginal linear regression models using generalized estimating
equations (GEE) that adjusted for the within-subject correlation in the DII measurements,
to calculate and compare all pair-wise contrast estimates between mean DII scores. The
GEE model was a univariate model with time from baseline as the only independent
variable and changes in the DII over time as the dependent variable, adjusted for multiple
comparisons using the Bonferroni approach, and stratified in the DMT by intervention
arm.
Next, we utilized stepwise linear regression to construct the most parsimonious
predictive multivariable model for change in DII from baseline to Year 3 in the OS. A
previous WHI study investigated predictors of dietary change and maintenance in the
DMT and included intrapersonal, interpersonal, intervention characteristics and clinical
center characteristics as predictors.269 The DMT intervention moved participants toward
an anti-inflammatory diet; therefore, predictors of dietary change investigated by Tinker
et al are likely to predict DII change in the DMT. We therefore focused mainly on the
potential predictors of DII change in the OS. We included the following baseline
variables in the stepwise regression model: baseline DII, age group, BMI (kg/m2),
race/ethnicity, education, smoking status, physical activity, history of diabetes,
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hypertension, arthritis, cancer, use and duration of estrogen-alone and of combined
estrogen and progesterone, use of statins, anti-depressants, and non-steroidal antiinflammatory drugs (NSAID) (see section 4.3 for the categories of these variables). The
entry criterion into the stepwise linear regression model was P <0.1, while the exit
criterion was P >0.1. The stepwise model identified variables that were included in a
multivariable linear regression model to calculate beta (β) coefficients, corresponding pvalues and the R2 for the overall predictive model. Participants with implausible reported
energy (<600kcal/d or >5000kcal/d), extreme BMI values (<15kg/m2 or >50kg/m2),
single FFQs or missing FFQs, as well as those with missing data in the predictors in the
final model were excluded from this analysis.
3.6.3 Statistical methods for specific aims #2 and #3
Statistical methods for these two aims were similar and designed to provide
answers to the following three main questions: 1) How does long-term cumulative history
of dietary inflammatory potential impact risk of colorectal cancer and risk of breast
cancer? 2) How do shorter-term changes in patterns of the inflammatory potential of diet
over time impact risk of colorectal cancer and risk of breast cancer? 3) Do risk estimates
differ by anatomic subsite (colon, rectum) of colorectal cancer and by molecular or
histologic subtype of breast cancer?
We used data from 142,511 women participating in the WHI OS and DMT.
Women with colorectal cancer or breast cancer at baseline or missing colorectal cancer or
breast status at baseline, or those who reported breast removal at baseline were excluded,
as well as women with implausible reported total energy intake values (≤600 kcal/day or
≥5000 kcal/day) or extreme BMI values (<15kg/m2 or > 50kg/m2).
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To determine how cumulative history of dietary inflammatory potential affects
risk of colorectal cancer and breast cancer, we calculated ten cumulative averages of DII
incrementally starting from the average between baseline and year one DII.172
The cumulative average was then categorized into quintiles, and used to estimate hazards
ratios for colorectal cancer or breast cancer in multivariable-adjusted Cox proportional
hazards (PH) regression models, while excluding from the models colorectal cancer cases
or breast cancer cases diagnosed prior to year one. This approach was repeated for the
average DII of baseline, year one, and year two with cancer cases diagnosed prior to year
two excluded to avoid the possibility of change in diet due to subclinical disease, and to
include only participants at risk of developing cancer going forward. This approach was
repeated until DII estimates at all time points were used.172
For each time segment, Cox proportional hazards regression models were used to
estimate hazards ratios (HR) and 95% confidence intervals (95%CI) for colorectal, colon,
rectal cancer, and invasive breast cancer incidence, by quintiles of cumulative average
DII, with adjustment for multiple covariates.
To determine how changes in patterns of the inflammatory potential of diet over
time affect risk of colorectal cancer or breast cancer, we calculated the DII from baseline
and year 3 food frequency questionnaires (FFQ) in the OS and DMT in participants with
at least two FFQs at these two time points. Since diet data was assessed in the OS at
baseline and Year 3 only, we selected these two time points to maximize the number of
participants with at least two FFQs. We categorized the DII at both time points into
quintiles (Q) and further categorized changes in the inflammatory potential of diet based
on quintile differences between baseline and year 3, as follows: 1) anti-inflammatory
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stable: Q1 or Q2 at both time points or change from Q3 to Q2; 2) anti-inflammatory
change: changes ≤ -2Q; 3) neutral inflammation stable: changes from Q2 to Q3, Q4 to Q3
or stable at Q3 at both time points; 4) pro-inflammatory change: changes ≥ 2Q; 5) proinflammatory stable: Q4 or Q5 at both time points or change from Q3 to Q4. Cox
proportional hazards regression models were used to estimate hazard ratios (HR) and
95% confidence intervals (95%CI) for colorectal, colon (proximal and distal), and rectal
cancer incidence, by patterns of changes in DII, with adjustment for multiple covariates.
Similar models were constructed for invasive breast cancer. We used AIC to determine
the model with the best precision. Each covariate in the final model was tested for the
proportional hazards assumption using cumulative sums of Martingale-based residuals.
All multivariable-adjusted models included the following covariates: age,
race/ethnicity, educational level, smoking status, diabetes, hypertension, arthritis,
NSAIDs use, category and duration of estrogen use, category and duration of estrogen &
progesterone use, DMT arm , BMI, and physical activity (minutes/week) as potential
confounders. Effect modification in models for both the cumulative average DII and
changes in the DII and cancer incidence was investigated by included 2-way cross
product terms in the models. Potential effect modifiers included age group, BMI,
educational level, race/ethnicity, combined use of estrogen and progesterone. We
conducted a power analyses to determine ranges of estimated HR to be obtained in the
analytic models given the incidence proportions (event rate) for colorectal and breast
cancers in this study, using the PASS software program (NCSS, LLC, Kaysville, Utah)
(Table 3.1).
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3.7

Tables and figures
5) -World composite database for
45 food parameters based on
data from 11 countries
-Calculate world mean and
standard deviation for each of the
45 food parameters

1) 1943 articles on 45 food parameters
identified and scored

2) Weight articles by study design and
calculate pro- and anti-inflammation
fractions

Dietary intake
made available
to the scoring
algorithm

6) Based on available dietary intake
data calculate z-scores and
centered percentiles for each of the
food parameters for each individual
in the study, based on the world
average and standard deviation.

3) Adjust scores if total weighted
articles is <236

4) Inflammatory effect score calculated
from 2) and 3)

7) Multiply centered percentile by the inflammatory effect
score to obtain “component-sp

-Calculate world mean and standard deviation for each
of the 45 food parameters
ci8) Sum all of the “component specific DII score
ic. DII score.”
to create the “overall DII score” for an indi
idual.
Figure 3.1: Sequence
of steps in creating the DII. (adapted from Shivappa, N.,
Steck SE, Hurley TG, Hussey JR, Hebert JR, Designing and Developing a
.
Literature-derived, Population-based Dietary Inflammatory Index. Public
Health Nutr, 2013: p. 1-8.)
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Table 3.1. Estimated ranges of hazard ratios for colorectal and breast cancers based
on the available incidence proportions for the two cancer sites
Estimated range of
Cancer incidence
Cancer Site
hazard ratios (HR) based
proportion (event rate)
on available cancer cases
Models for cumulative average DII (baseline to Year 2)
Colorectal
1.06 – 1.19
0.0132
Colon
1.06 – 1.21
0.0107
Rectal
1.13 – 1.47
0.0026
Invasive breast cancer
1.03 – 1.10
0.0455
Models for Patterns of change in DII quintiles between baseline and Year 3
Colorectal
1.04 – 1.12
0.0135
Colon
1.04 – 1.14
0.0113
Rectal
1.07 – 1.32
0.0024
Invasive breast cancer
1.02 – 1.06
0.0518
Triple negative BRCA
1.08 – 1.26
0.0038
HER2+/ER- subtype
1.12 – 1.43
0.0016
Luminal A BRCA
1.03 – 1.09
0.0270
Luminal B BRCA
1.07 – 1.25
0.0042
Ductal carcinoma
1.02 – 1.08
0.0338
Lobular carcinoma
1.06 – 1.21
0.0054
Mixed ductal/lobular
1.05 – 1.18
0.0074
carcinoma
NB: power=80%, tests=2-sided, alpha=0.05, standard deviation of DII =2.30, R2 varied from 0.1 to 0.9 by
0.1, and the event rate was the incidence proportion of each cancer type. (BRCA=breast cancer)
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4.1

Abstract
Introduction: The dietary inflammatory index (DII) measured at one point in

time has been associated with cancer risk in previous studies and repeat measures have
been analyzed in relation to inflammatory biomarkers. However, data are lacking
regarding the change in DII over longer periods of time. We assessed changes in the DII
among women in the Women’s Health Initiative (WHI). Methods: The DII was
calculated using data from repeated food frequency questionnaires in the WHI
Observational Study (OS; n=76,671) at baseline and Year 3, and in the Dietary
Modification Trial (DMT; n=48,482) at 11 time points. Univariate generalized estimating
equations were used to compare mean DII changes over time, adjusting for multiple
comparisons. Multivariable linear regression models were used to determine predictors of
DII change. Results: In the OS, mean DII decreased from -1.14 at baseline to -1.50 at
Year 3. In the DMT, DII decreased from -0.40 to -1.70 in the intervention arm and from
-0.38to -1.04 in the control arm from baseline to Year 3. These changes were influenced
by BMI, education, and race/ethnicity. A prediction model explained ≈22% of the
variance in the change in DII scores in the OS. Conclusion: In this population of
postmenopausal women, dietary inflammatory potential was relatively stable in OS
participants, but decreased significantly over time in women enrolled in the DMT. DII
changes were modified by BMI, education, and race/ethnicity. Future research is
warranted to examine whether reductions in DII over time are associated with decreased
chronic disease risk.
Key words: dietary inflammatory index, Women’s Health Initiative, prediction,
longitudinal trends
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4.2

Introduction
Dietary index or pattern analysis can produce more intuitively appealing results

that may improve prediction of disease risk as compared to examining individual foods or
nutrients separately.4,23,24,26 Despite the growing use of dietary index or pattern
analysis,28-30 relatively few studies have investigated the stability of dietary indices or
patterns over time,31-37 or the factors influencing such stability.269-271 To the best of our
knowledge, this evaluation has not been conducted in relation to the inflammatory
potential of diet.
Dietary behaviors are subject to change over time,34,35 and mainly influence
chronic disease outcomes when they persist over time.31 Knowledge of the longitudinal
stability of dietary patterns could aid researchers in planning follow-up measurements or,
as Weismayer et al. indicated,34 the cost of maintaining such cohorts could be reduced if
diet is proven to be stable over time (e.g., by reducing the necessity for frequent data
collection).
The dietary inflammatory index (DII) was developed38 and validated39 based on
the evidence that many dietary factors have anti- or pro-inflammatory properties and the
idea that no nutrient or food is consumed alone but in conjunction with other nutrients. In
the current study, we calculated the DII based on the food frequency questionnaires
(FFQ) used in the Women’s Health Initiative (WHI) Observational Study (OS) and
Dietary Modification Trial (DMT). Our goal was to examine the stability of the
inflammatory potential of diet, and the predictors of change in dietary inflammatory
potential over time. We compared dietary behaviour change in an observational cohort of
participants as well as in the DMT (i.e., intervention) population.
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4.3

Methods

4.3.1 Participants
The design of the WHI has been described in detail elsewhere.40 The WHI began
in 1992, spanning across 40 sites in the United States, and enrolled a total of 161808
women between 1993 and 1998 and included full-scale randomized controlled trials, with
ongoing follow-up. We used data up to September 30, 2010 for this investigation. The
women were enrolled into the OS (n=93676) or Clinical Trials (CT, n=68132), with one
of the CTs being the DMT (n=48835). Other components of the CT included hormone
therapy and calcium and vitamin D.265 The three CT components were overlapping, with
some participants simultaneously recruited into more than one trial.40
Exclusion criteria included any medical condition associated with a predicted
survival of <3 years, alcoholism, other drug dependency, mental illness (e.g., major
depressive disorder), dementia, not likely to live in the area for ≥3 years, and active
participation in another intervention trial. Women were further excluded from the DMT if
their diets were assessed to have <32% energy from fat.266 Demographic information and
dietary data were obtained by self-report using standardized questionnaires, and certified
staff performed physical measurements. The WHI protocol was approved by the
institutional review boards at the Clinical Coordinating Center at the Fred Hutchinson
Cancer Research Center (Seattle, WA) and at each of the 40 Clinical Centers.14
4.3.2 Dietary Assessment
Figure 4.1 describes the administration of FFQs in the WHI OS and DMT. During
screening for the WHI, all participants completed a baseline FFQ. Follow-up measures
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included: an FFQ completed by all DMT participants in Year 1; an FFQ completed
annually from Year 2 until study end (approximately ten years) in a random third of
DMT participants; and an FFQ completed at Year 3 for ≈90% of OS participants. There
was an average of two FFQs per participant in the OS and three FFQs per participant in
the DMT. The 122-item WHI FFQ line item nutrient data was obtained from the
University of Minnesota’s Nutrient Data system for research (NDSR) version 4.03_31
software,272 which is based on the US Department of Agriculture Standard Reference
Releases and manufacturer information. The WHI FFQ has shown comparable results
with 24-hour dietary recall interviews and food records in the WHI.266
4.3.3 Description of the DII (outcome of interest)
The main outcome of interest is longitudinal change in the DII. Details of the
development38 and validation39 of the DII have been described elsewhere. Briefly, an
extensive literature search was performed to obtain peer-reviewed journal articles that
examined the association between six inflammatory biomarkers (IL-1, IL-4, IL-6, IL-10,
TNFα, and CRP) and 45 specific foods and nutrients (components of the DII). Scores
were derived and standardized to a representative global diet database constructed based
on 11 datasets from diverse populations in different parts of the world. Overall DII scores
for each individual represent the sum of each of the DII components in relation to the
comparison database.38 The DII score characterizes individuals’ diets on a continuum
from maximally anti-inflammatory to maximally pro-inflammatory, with higher DII
scores indicating more pro-inflammatory diets, while lower scores indicate more antiinflammatory diets. In the WHI FFQ, 32 of the 45 original DII components were
available for inclusion in the overall DII score. Components such as ginger, turmeric,
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garlic, oregano, pepper, rosemary, eugenol, saffron, flavan-3-ol, flavones, flavonols,
flavonones, anthocyanidins that are included in the original DII calculation38 were not
included in the current study because they were not assessed in the WHI FFQ.
4.3.4 Statistical analysis
Participants with reported total energy intake judged to be implausible
(<600kcal/d or >5000kcal/d) (n=1,796), or with extreme body mass index (BMI)
(<15kg/m2 or >50kg/m2) (n=2,051) as well as those with only one FFQ (n=1,5479) or
missing FFQ (n=32), were excluded from the current study, leaving 76,671 in the OS and
46,482 in the DMT for the final analyses (Figure 1). Frequencies and percentages were
calculated to describe baseline characteristics of participants. We computed mean DII
scores at baseline and Year 3 in the OS and at 11 different time points between baseline
and Year 10 inclusive in the DMT; and used these to describe changes over time in the
OS, or plotted DII scores on graphs for a visual appraisal of the longitudinal trend,
separately for the intervention and control arms of the DMT. Analyses were stratified by
BMI, education, and race/ethnicity. To determine significant differences between mean
DII scores calculated at different time points, we constructed marginal linear regression
models using generalized estimating equations (GEE) that adjusted for within-subject
correlation in the DII measurements, in order to calculate and compare all pair-wise
contrast estimates between mean DII scores. The GEE model was a univariate model
with time from baseline as the only independent variable and changes in the DII over
time as the dependent variable, adjusted for multiple comparisons using the Bonferroni
approach, and stratified in the DMT by intervention arm.

69

Next, we utilized stepwise linear regression to construct the most parsimonious
predictive multivariable model for change in DII from baseline to Year 3 in the OS. A
previous WHI study (Tinker et al.,2007) investigated predictors of dietary change and
maintenance in the DMT and included intrapersonal, interpersonal, intervention
characteristics and clinical center characteristics as predictors 269. The DMT intervention
moved participants toward an anti-inflammatory diet; therefore, predictors of dietary
change investigated by Tinker et al are likely to predict DII change in the DMT. We
therefore focused mainly on the potential predictors of DII change in the OS. We
included the following baseline variables in the stepwise regression model: baseline DII,
age group, BMI, race/ethnicity, educational level, physical activity, history of diabetes,
hypertension, arthritis, cancer, use of non-steroidal anti-inflammatory drugs (NSAIDs),
statins, anti-depressants, unopposed estrogen use, combined estrogen and progesterone
use (Table 4.1 presents categories of potential predictors). The entry criterion into the
stepwise linear regression model was P <0.10, while the exit criterion was P >0.10. The
stepwise model identified variables that were included in a multivariable linear regression
model to calculate beta (β) coefficients, corresponding p-values, and the R2 for the overall
predictive model. Participants with missing data in the predictors (n=3,438) were further
excluded, leaving a final sample of 73,233 OS participants for the prediction model.
Analyses were conducted using SAS® version 9.3 (SAS Institute). All tests were
2-sided and p<0.05 was used to assess statistical significance of parameter estimates.

4.4

Results
Participant characteristics were similar between OS and DMT for many covariates

including race/ethnicity, educational level, smoking status, arthritis, unopposed estrogen
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use, and combined estrogen and progesterone use (Table 4.1). More OS (23.8%) than
DMT (16.7%) participants were ≥70 years; a higher proportion of participants in the
DMT (38.4%) than OS (25.4%) were obese; and the proportion of individuals with a
previous cancer diagnosis reported at baseline, was about three times higher in the OS
(12.8%) than in the DMT (4.4%), likely due to cancer survivors joining the WHI but
being excluded from the DMT (Table 4.1).
In the OS, the mean (±SD) overall DII decreased from -1.14 (±2.58) at baseline to
-1.50 (±2.60) at Year 3. Corresponding averages for the DMT intervention arm were 0.40 (±2.54) and -1.70 (±2.63); and for the control arm, -0.38 (±2.55) and -1.04 (±2.60)
(Figure 4.2) (all p-values for between-group differences across time were <0.0001). Mean
DII scores at baseline were significantly different than at all other time points in both the
intervention and control arms, as shown in the Bonferroni-adjusted p-values for all pairwise comparisons in Table 4.2.
There was evidence for interaction between DII change and BMI, education, and
race/ethnicity; so, analyses were further stratified by these variables in the OS and DMT.
In the OS, normal-weight women experienced the largest decrease in DII between
baseline and Year 3 [-1.39 (±2.55) to -1.81 (±2.54)] compared to obese women [-0.78
(±2.61) to -1.04 (±2.67)]; while women with at least some college education showed the
greatest change in DII [-1.39 (±2.51) to -1.77 (±2.52)] compared to women with less than
a high school education, whose DII scores were more pro-inflammatory [0.26 (±2.71) to
0.06 (±2.71)]. In terms of race/ethnicity, Asians/Pacific Islanders (A/PI) experienced the
largest change in DII [-1.76 (±2.53) to -2.04 (±2.51)], followed by European Americans

71

(EA) [-1.25 (±2.52) to -1.63 (±2.53)]. African Americans (AA) and Hispanics (HP) had
more pro-inflammatory DII scores.
Figures 4.3, 4.4 and 4.5 present the corresponding longitudinal trends in the DMT
intervention and control arms, which parallel those in the OS upon stratification by BMI,
education, and race/ethnicity; though DII changes in the intervention arm were greater
than in the control arm. Normal-weight women consistently experienced the largest DII
decrease over time, followed by overweight women, while obese women showed the
smallest decrease in DII over time (Figure 4.3). Highly educated women experienced the
most anti-inflammatory changes over time (Figure 4.4). A/PI showed the largest DII
decreases over time, while AA and HP showed the smallest changes over time (Figure
4.5).
The final predictive model presented in Table 4.3 explained 22% of the variance
in DII changes between baseline and Year 3 in the OS. Decreases in DII over time were
predicted by baseline DII (having a higher baseline DII predicted a larger decrease in
DII), being A/PI or EA, having BMI<25kg/m2, being more educated, being a nonsmoker,
and meeting public health recommendations for physical activity.

4.5

Discussion
Using data from both the WHI OS and DMT, we described changes over time in

the inflammatory potential of diet using the DII. The DII score in the OS remained
relatively stable from baseline to Year 3, with an average change of -0.36 ± 2.35,
representing about 2% of the full range of change in DII scores (-9.52 to 10.71). We
demonstrated that the DII decreased substantially from baseline to Year 1 in the DMT
intervention arm, achieving the lowest mean score in Year 3, and then increasing
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gradually until study end. The longitudinal trend of DII changes was similar in both arms
of the DMT; however, changes in the intervention arm were almost double those
observed in the control arm during the first five years of follow-up. In both the OS and
DMT, participants who experienced the largest DII decrease had a normal BMI, a high
educational level, and were A/PI or EA. Those who experienced the smallest decrease
were obese, had less than high school education, and were HP or AA.
OS participants may have started the study consuming foods with lower mean
inflammatory potential compared to DMT participants, likely due to DMT eligibility that
required women to consume diets with ≥32% energy from fat.40,266 This requirement had
the effect of producing higher DII scores (i.e., more pro-inflammatory) at baseline for
DMT participants because fat is a strongly pro-inflammatory component of the DII 38. It
also could help explain reductions in the DII among DMT participants, who needed to
meet a dietary fat entry criterion.273
Highly educated women could be more heavily exposed to information about
healthier food choices and have better financial access to a wider variety of healthier food
choices than women with lower educational levels. In a study on the longitudinal trends
in diet over a 20-year period, diet quality improved with higher educational attainment.274
Chaix et al. observed that poorly educated participants shopping in specific supermarket
brands and in supermarkets whose catchment areas included more poorly educated
residents had higher BMIs or waist circumferences.275 Additionally, Drewnowski et al.
found lower levels of education and incomes, among other factors, to be consistently
associated with higher obesity risk.276 These findings could partially explain our result
showing that obese and less-educated participants experienced the smallest decreases in
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DII. The low DII scores in A/PI and EA compared to other race/ethnic groups may be
due to different dietary patterns inherent in the cultures of the racial/ethnic groups. For
example, diets of most Asian populations contain numerous anti-inflammatory
constituents and lack many of the pro-inflammatory substances in Western diets.277,278 In
the WHI, EA women are relatively better educated279 and may be more willing to change
their diets in keeping with recommendations.276
While the slight decrease in the dietary inflammatory potential from baseline to
Year 3 in participants in the OS, provided insights into changes in dietary behavior over
time, the follow-up period was insufficient to draw conclusions regarding long-term
changes in dietary behavior in an observational setting. Participants in the control arm of
the DMT were not asked to make dietary changes and were observed throughout the 10year follow-up period; however, the trend in dietary behavior change over time in this
group was similar, though smaller, to that observed in the intervention arm. Participants
randomized to the control arm may have been motivated to change their diets prior to
joining the study, and thus made personal efforts to improve their diets over time.
Some studies have examined the stability of dietary patterns over time;31-37
however, to the best of our knowledge, this is the first to study the stability of a dietary
index describing the inflammatory potential over time. Previous studies reported
inconsistent results on the stability of dietary behaviors over time, with some indicating
stable behaviors after a short follow-up period of about 2 to 4 years,33,37 and others
reporting significant changes only after a moderately long follow up (e.g., ≥7 years).34,36
Changes in diet over time may be due, in part, to the response to frequent updates to
dietary guidelines, changes over time in the availability of different foods in some
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communities, and disease diagnosis that may alter dietary intake (e.g., diabetes or
hypertension). Methodologic differences between studies would include differences in
duration of follow-up, frequency and method of diet assessment, and sample composition
and size.
This study has several strengths including the relatively large population-based
sample in the OS and DMT, good regional and racial/ethnic representation, and inclusion
of large number of potential predictors of DII change. The DMT had a relatively long
follow-up duration with diet assessed annually on random subsamples of the study
population. Our study also had some limitations: FFQ data were not available in the OS
after Year 3; thus we were not able to compare dietary behavior change between the OS
and DMT beyond the first three years of follow up. The decrease in dietary inflammatory
potential in the first three years may have been due to survey learning effects, in part
attributed to social desirability bias, rather than a real improvement in diet quality. This
limitation might have been mitigated had social desirability, an established source of bias
of dietary self-report data, been measured in the WHI.280,281 In our DMT sample, not
every participant had FFQ data at all 11 time points, which could have reduced the effect
of survey learning as participants did not complete the FFQ every year. Sample sizes
from Year 8 to 10 were very small and may not be representative of the entire DMT
population. Although WHI enrolled only postmenopausal women, average DII scores in
the WHI were comparable to other US populations that have been examined.39,282
After including a comprehensive list of demographic, lifestyle and health-related
factors, our final prediction model explained 22% of the variation in DII change in the
OS. This represents reasonable explanatory ability when one considers that a change
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score is accompanied by large overall variance owing to the fact that the variance of a
difference is the sum of the variance of the individual components283 (while the absolute
difference can often be quite small). Other potential predictors of DII change that are
outside the scope of the current study may include behavioural factors, such as those
investigated by Tinker et al. in the prediction of dietary change and maintenance in the
DMT.269

4.6

Conclusion
In this population of postmenopausal women, the average DII was relatively

stable in the OS from baseline to Year 3, but decreased significantly over time in a
manner consistent with improved anti-inflammatory potential, achieving its lowest mean
value at Year 3 in DMT intervention participants and, to a smaller extent, among control
arm participants. In all three study groups, the extent of decrease was influenced by BMI,
education, and race/ethnicity. Baseline DII and several demographic, lifestyle and clinical
factors significantly predicted changes in the inflammatory potential of diet in the first
three years of follow up in an observational setting. Future research is warranted to
examine whether reductions in DII over time are associated with decreased chronic
disease risk.
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4.7

Tables and figures

142511 participants recruited into the WHI OS and DMT
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93,676 participants in the OS

48,835 participants in the DMT

76,671 included in analyses
(after excluding 1,785 due to
implausible total energy
values, 23 missing FFQs,
1,340 due to extreme BMI
values and 13,857 due to
single FFQ,)

46,482 included in analyses (after excluding 11 due to implausible total
energy values, 9 missing FFQs, 711 due to extreme BMI values and 1,622
due to single FFQ,)

76,671
FFQs at
baseline

76,671
FFQs at
Year 3

43,132
FFQs at
Year 1
46,311
FFQs at
baseline

7,848
FFQs at
Year 3

14,389
FFQs at
Year 2

14,230
FFQs at
Year 5
12,396
FFQs at
Year 4

11,322
FFQs at
Year 7
17,175
FFQs at
Year 6

3,741
FFQs at
Year 9

6,822
FFQs at
Year 8

991
FFQs at
Year 10

Figure 4.1. Participant flow in the administration of food frequency questionnaires in the Women’s Health Initiative (WHI)
Observational Study (OS) and Dietary Modification Trial (DMT), 1993-2010

Table 4.1.Baseline characteristics of study participants, frequency (%), Women's Health
Initiative, 1993-1998

Characteristic

Observational
Study
(n=76,671)

Age groups (years)
<50-59
24144 (31.5)
60-69
34293 (44.7)
70-79
18234 (23.8)
2
Body mass index (kg/m )
Normal ( <25)
30577 (39.9)
Overweight (25.0 - <30)
26605 (34.7)
Obese (≥30)
19489 (25.4)
Race/ethnicity
Asian or Pacific Islander
2102 (2.7)
African American
4697 (6.1)
Hispanic/Latino
2253 (3.0)
European American
66331 (86.8)
Other
1078 (1.4)
Educational level
Less than high school
814 (1.1)
Some high school/GED
21209 (27.9)
Some years of
54067 (71.0)
college/graduate
Smoking status
Never
38661 (50.1)
Former
32813 (43.3)
Current
4242 (5.6)
Physical activity (PA), minutes/week
Not meeting PA
39636 (52.2)
recommendations
Meeting PA
36254 (47.8)
recommendations
Diabetes
66796 (87.1)
No
9875 (12.9)
Yes
Hypertension
51266 (68.0)
No
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Dietary
Modification
Trial
intervention
arm (n=18,604)

Dietary
Modification
Trial control
arm (n=27,878)

6832 (36.7)
8681 (46.7)
3091 (16.6)

10203 (36.6)
13033 (46.7)
4642 (16.7)

5230 (28.1)
6534 (35.1)
6840 (36.8)

6820 (24.5)
9940 (35.7)
11118 (39.9)

421 (2.3)
1932 (10.4)
661 (3.6)
15263 (82.2)
286 (1.5)

645 (2.3)
2836 (10.2)
999 (3.6)
22916 (82.3)
430 (1.6)

186 (1.0)
5703 (30.8)

332 (1.2)
8609 (31.1)

12604 (68.2)

18761 (67.7)

9502 (51.7)
7715 (50.0)
1169 (6.3)

14386 (52.1)
11370 (41.2)
1842 (6.7)

10860 (65.2)

16421 (65.7)

5797 (34.8)

8567 (34.3)

15450 (83.1)
3154 (16.9)

22952 (82.3)
4926 (17.7)

10811 (65.5)

15974 (64.5)

24147 (32.0)
5704 (34.5)
Yes
Arthritis
39324 (51.6)
10042 (54.5)
No
36845 (48.4)
8371 (45.5)
Yes
Cancer
66375 (87.2)
17613 (95.6
No
9757 (12.8)
809 (4.4)
Yes
Duration of estrogen use by category
47756 (62.3)
11648 (62.6)
None
9785 (12.7)
2573 (13.8)
<5 Years
5808 (7.6)
1368 (7.4)
5 to <10 Years
4609 (6.0)
1102 (5.9)
10 to <15 Years
8711 (11.4)
1911 (10.3)
15+ Years
Duration of estrogen & progesterone use by category
53804 (70.2)
13431 (72.2)
None
10943 (14.3)
2671 (14.4)
<5 Years
6392
(8.3)
1388 (7.4)
5 to <10 Years
37228 (4.9)
749 (4.0)
10 to <15 Years
1808 (2.3)
362 (2.0)
15+ Years
Statin use
No
64049 (83.5)
13937 (74.9)
Yes
12622 (16.5)
4667 (25.1)
Antidepressant use
No
67557 (88.1)
15502 (83.3)
Yes
9114 (11.9)
3102 (16.7)
NSAIDs use
No
36819 (48.0)
6687 (35.9)
Yes
39852 (52.0)
11917 (64.1)
NSAIDs=Non-steroidal Anti-inflammatory Drugs
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8794 (35.5)
14989 (54.3)
12596 (45.7)
26382 (95.6)
1210 (4.4)
17496 (62.8)
3748 (13.4)
2086 (7.5)
1685 (6.0)
2863 (10.3)
20195 (72.4)
3934 (14.1)
2162 (7.8)
1103 (4.0)
484 (1.7)
20601 (73.9)
7277 (26.1)
23144 (83.0)
4734 (17.0)
9732 (34.9)
18146 (65.1)

0

1

2

3

4

5

6

7

8

9

10

0.0
-0.2
Mean DII score

-0.4
-0.6
-0.8

-0.38
-0.40
-0.65

-1.0

-0.68
-0.93

-1.2
-1.4
-1.6
-1.8

-1.04

-0.94

-1.00

-0.93

-1.32
-1.55

-1.70

-1.62

-1.61

-1.47

-1.00

-1.43

-0.84
-1.02
-1.35

-1.27

-1.48

Time from Baseline (years)
Intervention

Control

Figure 4.2. Average dietary inflammatory index (DII)1 scores across years of follow-up in
the Dietary Modification Trial, by study arm; Women's Health Initiative, 1993-20102
1

(P-value for the difference in DII scores between intervention and control was 0.62 at
baseline, and <0.0001 for each year from year 1 onwards)
2
Numbers of participants (Intervention: 19470, 18061, 6081, 3255, 5071, 5835, 7160,
4641, 2734, 1578, and 417; Control: 29216, 26753, 8882, 4922, 7902, 9028, 10860,
7252, 4451, 2344 and 632; for Years 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, respectively)
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Table 4.2. Bonferroni-adjusted p-values of all pair-wise comparisons of the mean dietary inflammatory index scores across years of
follow-up in the Dietary Modification Trial; Women's Health Initiative, 1993-2010
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Time point
(Sample
size)
0 (277916)
1 (25749)
2 (8524)
3 (4717)
4 (7553)
5 (10375)
6 (8634)
7 (6918)
8 (4240)
9 (2244)
10 (600)

0
(18520)

1
(17383)

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.0004

<0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
<0.0001 <0.0001 <0.0001 <0.0001 <0.0001
0.01
0.0004
0.99
0.99
<0.0001
0.11
0.99
0.99
0.99
0.99
0.99
0.99
0.99
<0.0001
0.23
0.99
0.99
0.01
0.001
0.99
0.004
0.61
<0.0001
0.68
0.99
0.99
0.22
0.01
0.99
0.04
0.99
<0.0001 0.0003
0.99
0.99
0.52
0.03
0.99
0.05
0.99
<0.0001
0.01
0.99
0.99
0.99
0.99
0.99
0.99
0.99
<0.0001 0.0002
0.99
0.99
0.99
0.99
0.99
0.99
0.99
<0.0001 <0.0001
0.09
0.003
0.33
0.04
0.99
0.99
0.99
<0.0001
0.99
0.99
0.99
0.99
0.99
0.99
0.14
0.99
0.99
0.99
0.99
0.99
0.99
0.99
0.99
0.24
0.99

Blue=control arm, Green=intervention arm

2
(5865)

3
(3131)

4
(4843)

5
(5596)

6
(6800)

7
(4404)

8
(2582)

9
(1497)

10
(391)

Intervention arm
1

2

3

4

5

6

7

8

9

10

0

0.0

0.0

-0.5

-0.5

Mean DII score

Mean DII score

0

Control arm

-1.0
-1.5
-2.0

1

2

3

4

5

6

7

8

9

10

-1.0
-1.5

-2.0
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-2.5

-2.5
Time from baseline (years)
Normal weight

Overweight

Time from baseline (years)
Obese

Normal weight

Overweight

Obese

Figure 4.3. Average dietary inflammatory index over time by body mass index category and Dietary Modification Trial arm; Women's
Health Initiative, 1993-2010

Control arm

1.5

1.5

1

1

0.5

0.5

0

0

-0.5

0

1

2

3

4

5

6

7

8

-1
-1.5
-2

Time from baseline (years)
<High school

83

Some college/graduate

High school/GED

9

10

Mean DII score

Mean DII score

Intervention arm

-0.5

0

1

2

3

4

5

6

7

8

9

10

-1
-1.5
-2

Time from baseline (years)
<High school

High school/GED

Some college/graduate

Figure 4.4. Average dietary inflammatory index (DII) over time by educational level and Dietary Modification Trial arm; Women's
Health Initiative, 1993-2010
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1
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0
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-1
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Mean DII scores

Mean DII scores
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0
1

2

3
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-1
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A/PI
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Time from baseline (years)
Other

A/PI

AA

HP

EA

Other

Figure 4.5. Average dietary inflammatory index (DII) over time by race/ethnicity and Dietary Modification Trial arm; Women's
Health Initiative, 1993-20101

Table 4.3. Multivariable predictive model of change in dietary inflammatory index over
time in the Observational Study; Women's Health Initiative, 1993-2010
Predictors
Baseline DII
Body mass index (kg/m2)
Normal weight (>25)
Overweight(25 - <30)
Obese(>30)
Race/ethnicity
European American
African American
Asian or Pacific Islander
Hispanic
Other
Educational level
Some college/graduate
Some high school/GED
Less than high school
Use of NSAIDs
Yes
No
Age group (years)
50-59
60-69
70-79
Physical activity (minutes/week)
Meeting PA recommendation
Not meeting PA
recommendation
Smoking status
Never
Former
Current
Hypertension status
No
Yes
Diabetes
No
Yes

β (SE)

P-value (β)

-0.44 (0.00)

<0.0001

referent
0.25 (0.02)
0.10 (0.02)

<0.0001
<0.0001

referent
0.48 (0.03)
-0.17 (0.05)
0.68 (0.05)
0.07 (0.06)

<0.0001
<0.0001
<0.0001
0.28

referent
0.31 (0.02)
0.47 (0.10)

<0.0001
<0.0001

referent
0.08 (0.01)

<0.0001

referent
-0.04 (0.01)
0.02 (0.01)

<0.0001
0.18

referent
0.26 (0.02)

<0.0001

referent
-0.07 (0.02)
0.24 (0.03)

<0.0001
<0.0001

referent
0.06 (0.01)

<0.0001

referent
0.10 (0.02)

<0.0001
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Use of estrogen & progesterone
None
< 5y
5 to <10y
10 to <15y
≥15y

referent
0.00 (0.02)
-0.10 (0.02)
-0.09 (0.02)
0.10 (0.04)
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0.91
0.0001
0.0002
0.02
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5.1

Abstract
Introduction: To evaluate changes in the inflammatory potential of diet and

subsequent risk of colorectal cancer (CRC), we used the dietary inflammatory index
(DII), to predict newly incident CRC in the Women’s Health Initiative (WHI). Methods:
Data were obtained from 110,665 postmenopausal women recruited from 1993-1998 into
the WHI and followed through September 30, 2010. Food frequency questionnaires data
were used to compute cumulative average DII scores that were then used in Cox
proportional hazards (PH) models to estimate hazard ratios (HR) and 95% confidence
intervals (95%CI) for newly incident CRC. Patterns in DII change from baseline to Year
3 were computed in a subset of 79,484 women, from which HR were calculated using
Cox PH models. Results: HR for the association between high DII scores and CRC were
consistently significantly elevated in the first seven years of follow up, for colon cancer
with multivariable-adjusted HR ranging from 1.30 in Year 2 to 1.58 in Year 7, comparing
the highest with the lowest quintile. No significant associations were observed between
cumulative average DII and rectal cancer. Compared to participants in the antiinflammatory stable category, risk was increased in participants with a pro-inflammatory
stable diet, for CRC (HR, 1.18; 95%CI, 0.99, 1.41), and for rectal cancer (HR, 1.53;
95%CI, 1.01, 2.32). Conclusion: A history of long-term pro-inflammatory diets increases
the risk of colon cancer while shorter-term stable pro-inflammatory diets, increase the
risk of rectal cancer. Lowering the inflammatory potential of diet could be a means for
colon cancer, and potentially rectal cancer prevention.
Key words: changes in dietary inflammatory potential, colorectal cancer, dietary
patterns, Women’s Health Initiative
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5.2

Introduction
Colorectal cancer is the third most commonly diagnosed cancer in American

women after lung and breast cancers.173 The etiology of colorectal cancer involves a
complex interaction of cellular and molecular processes with environmental factors. Of
these factors, dietary patterns that modulate inflammation48-50 may be important, given
the central role of inflammation in the carcinogenesis process.79 The American Institute
for Cancer Research estimates that half of colorectal cancers can be prevented by
adopting healthy lifestyle behaviors including healthy dietary patterns.174 Dietary
patterns, or dietary indices that take into account multiple dietary factors, can provide a
more comprehensive assessment of diet and may be more predictive of disease processes
and outcomes than single nutrients or foods.23,26
Most dietary patterns derived through data-driven approaches or index-based
methods have been shown to be associated with colorectal cancer risk.28,30,176,177,180
However, these findings are often heterogeneous by anatomic subsite of colorectal
cancer. We previously reported that a more pro-inflammatory diet as measured by the
dietary inflammatory index (DII)38,39 was associated with increased risk of colorectal
cancer using baseline food frequency questionnaire data in the Women’s Health Initiative
(WHI), and that the association was more pronounced for colon cancer than for rectal
cancer (Tabung FK, Steck SE, Ma Y, et al., unpublished data, 2014).
Despite the growing interest in the role of dietary patterns in colorectal cancer
risk,28,30,176,177,180 most studies have examined dietary patterns at one point in time only.
However, dietary behaviors mainly influence chronic disease outcomes when they persist
for a longer period of time.31 We have shown that DII scores decreased significantly in

89

women enrolled in the WHI Dietary Modification Trial. The longitudinal trend in DII
scores was similar to that of percent fat reduction over time (Tabung FK, Steck SE,
Zhang J, et al., unpublished data, 2014). Risk of colorectal cancer is believed to
accumulate over time, thus, dietary changes over time may have a greater impact on
colorectal cancer risk compared with diet assessed at only one point in time. In the
current study, our objective is to evaluate the role of both the cumulative history, and the
changes in the inflammatory potential of diet over time, on colorectal cancer risk.

5.3

Methods

5.3.1 Study population
The WHI study is a large and complex clinical investigation of strategies for the
prevention and control of some of the most common causes of morbidity and mortality
among postmenopausal women. The design of the WHI has been described in detail
elsewhere.40 Briefly, the WHI began in 1992, implemented in 40 sites across the United
States, and enrolled a total of 161,808 women between 1993 and 1998. The WHI enrolled
93,676 women into an Observational Study (OS) and 68,132 participants into Clinical
Trials (CT), with an average of 11.3 years of follow-up until September 30, 2010.265 The
CTs included three components: Hormone Therapy, Calcium and Vitamin D, and the
Dietary Modification Trial (DMT). For the DMT, women were randomly assigned to a
usual-diet comparison group (n=29,294) or an intervention group (n=19,541) with a 20%
low-fat dietary pattern with increased vegetables, fruits, and whole grains. Women who
proved to be ineligible for, or who were unwilling to enroll in the CT components were
invited to be part of the prospective cohort of women in the OS.40
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Exclusion criteria for both the OS and CT included any medical condition
associated with a predicted survival of less than three years, alcoholism, other drug
dependency, mental illness (e.g., major depressive disorder), dementia, active
participation in another intervention trial and not likely to live in the area for at least 3
years. Demographic information and dietary data were obtained by self-report using
standardized questionnaires. Certified staff performed physical measurements, including
blood pressure, height and weight, and blood samples at the baseline clinic visit. Women
were further excluded from the DMT if their diets were assessed to have <32% energy
from fat.266 The WHI protocol was approved by the institutional review boards at the
Clinical Coordinating Center (CCC) at the Fred Hutchinson Cancer Research Center
(Seattle, WA) and at each of the 40 Clinical Centers.14
5.3.2 Diet assessment
Figure 5.1 describes the administration of food frequency questionnaires (FFQ) in
the WHI. During screening for the WHI, all participants completed a baseline FFQ. At
follow-up, the FFQ was completed at Year 3 for ≈90% of OS participants. About 92% of
DMT participants completed an FFQ in Year 1, and a random third of participants were
invited to complete an FFQ annually from Year 2 until study end (approximately ten
years) (Figure 5.1). There was an average of two FFQs per participant in the OS and three
FFQs per participant in the DMT. The 122-item WHI FFQ line-item nutrient data was
obtained from the University of Minnesota’s Nutrient Data system for research (NDSR)
version 4.03_31 software,272 which is based on the US Department of Agriculture
Standard Reference Releases and manufacturer information. The WHI FFQ has shown
comparable results with 24-hour dietary recall interviews and food records in the WHI.266
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5.3.3 The dietary inflammatory index (DII)
Details of the development38 and validation39 of the DII have been described
elsewhere. Briefly, an extensive literature search was performed to obtain peer-reviewed
journal articles that examined the association between six well known inflammatory
biomarkers (IL-1β, IL-4, IL-6, IL-10, TNFα, and CRP) and 45 specific foods and
nutrients (components of the DII). Scores were derived and standardized to a
representative global diet database constructed based on 11 datasets from diverse
populations in different parts of the world. Overall DII scores for each individual
participant represent the sum of each of the DII components in relation to the comparison
global diet database.38 The DII score characterizes an individual’s diet on a continuum
from maximally anti-inflammatory to maximally pro-inflammatory, with a higher DII
score indicating a more pro-inflammatory diet and a lower (i.e., more negative) DII score
indicating a more anti-inflammatory diet. In the WHI FFQ, 32 of the 45 original DII
components were available for inclusion in the overall DII score (see38 for list of 45 DII
components). Components such as ginger, turmeric, garlic, oregano, pepper, rosemary,
eugenol, saffron, flavan-3-ol, flavones, flavonols, flavonones, anthocyanidins that are
included in the original DII calculation38 were not included in the current study because
they were not available from the WHI FFQ.
5.3.4 Outcomes assessment
The WHI outcomes ascertainment and adjudication methods have been previously
described.267 Briefly, participants (or next-of-kin) self-reported cancer diagnoses reported
on questionnaires annually in the OS or semiannually in the CT through 2005 and
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annually in all thereafter. Colorectal cancer events reported were verified by centrally
trained physician adjudicators after review of medical records and pathology reports.
The outcome for these analyses was colorectal cancer, including cancers of the
colon and rectum (including rectum and rectosigmoid). Proximal colon cancers were
defined as cancers of the cecum, ascending colon, right colon, hepatic flexure of colon,
and transverse colon (ICD=C18.0, C18.2-18.4), and distal colon cancers were defined as
cancers of the splenic flexure of colon, descending colon, left colon and sigmoid colon
(ICD=C18.5-18.7). Survival time was defined as days from enrollment or randomization
until colorectal cancer diagnosis while censoring time was defined as days from
enrollment or randomization until death or last contact occurring on or before September
30, 2010, in participants without colorectal cancer.
5.3.5 Statistical analysis
We utilized data from 142,511 women participating in the WHI OS and DMT.
Exclusion criteria included: women with colorectal cancer at baseline or missing
colorectal cancer status at baseline (n=2,272), women with reported total energy intake
values judged to be implausible (≤600 kcal/day or ≥5000 kcal/day) (n=1,796) or extreme
BMI values (<15kg/m2 or > 50kg/m2) (n=2,014), as well as women with single FFQs
(n=15,122) or missing FFQs (n=32) (Figure 5.1). Additionally, we excluded participants
with missing data in the covariates (n=10,610), leaving a total of 110,665 participants for
these analyses (72,261 in OS and 38,404 in DMT). Frequencies and percentages were
computed to describe the distribution of covariates across quintiles of cumulative average
DII for the DII assessed from baseline to Year 3.
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To determine the role of cumulative history of the inflammatory potential of diet
in colorectal cancer risk over time, we calculated ten cumulative averages of DII
incrementally starting from the average between baseline and year one DII.172 The
cumulative average was then categorized into quintiles, and used to estimate hazard ratios
(HR) for newly incident overall colorectal, colon, and rectal cancers, using multivariableadjusted Cox regression models Colorectal cancers diagnosed prior to year one were
excluded from the models. This approach was repeated for the average DII of baseline,
year one, and year two, with colorectal cancer cases diagnosed prior to year two excluded
to avoid the possibility of change in diet due to subclinical disease and to ensure that only
participants at risk of developing colorectal cancer going forward, were included in the
models. This approach was repeated until DII estimates at all ten time points were
used.172 We categorized the cumulative average DII into quintiles, used these to calculate
HRs and then plotted the HRs on graphs for a visual appraisal of the longitudinal trend in
risk, separately for colon and rectal cancers in the DMT.
To determine the role of changes in patterns of the inflammatory potential of diet
over time in colorectal cancer risk, we calculated the DII from baseline and year 3 FFQs
administered to 79,484 women in the OS and DMT. We categorized the DII at both time
points into quintiles (Q) and further categorized changes in the inflammatory potential of
diet based on quintile differences between baseline and year 3, as follows:
1. Anti-inflammatory stable: Q1 or Q2 at both time points or change from Q3 to Q2;
2. Anti-inflammatory change: changes ≤ -2Q;
3. Neutral inflammation stable: changes from Q2 to Q3, Q4 to Q3 or stable at Q3 at
both time points;
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4. Pro-inflammatory change: changes ≥ 2Q;
5. Pro-inflammatory stable: Q4 or Q5 at both time points, or change from Q3 to Q4.
The names given to these categories of DII changes were meant to be qualitative
only. Next, Cox proportional hazards regression models were used to estimate HR and
associated 95%CI for colorectal, colon (proximal/distal), and rectal cancer incidence, by
patterns of DII changes, with adjustment for multiple covariates. The anti-inflammatory
stable category, considered to be the healthiest category, was the referent for all models.
Potential confounders that changed HRs by >10% were retained in the final model
and included: age group (years) (50-59, 60-69, 70-79); race/ethnicity, European
American (EA), African American (AA), Hispanic (HP), Asian or Pacific Islander
(A/PI), and other race groups (other); educational levels (less than high school, some high
school /GED, at least some college/graduate education); smoking status (current, past,
never); body mass index [BMI= weight(kg)/height(m)2] (normal weight (<25kg/m2),
overweight (25-<30 kg/m2), and obese (≥30kg/m2)); physical activity (PA) was
categorized based on public health recommendations,284 as meeting or not meeting PA
recommendations (≥150 minutes/week of moderate intensity PA or ≥75 minutes/week of
vigorous intensity PA versus<150 minutes/week of moderate intensity PA or <75
minutes/week of vigorous intensity PA, respectively); history of diabetes (yes/no),
hypertension (yes/no), arthritis (yes/no); non-steroidal anti-inflammatory drug (NSAID)
use (yes/no); category and duration of estrogen use and category and duration of
combined estrogen and progesterone use both categorized into five groups (none, <5y, 5
to <10y, 10 to <15y, and ≥15y). Data on potential confounders were collected by selfadministered questionnaires on demographics, medical history, and lifestyle factors.40
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Each covariate in the final models for both cumulative average DII and patterns of
changes in DII was tested for proportional hazards using cumulative sums of Martingalebased residuals. Age group, and smoking status violated the PH assumption and models
were therefore stratified by these two covariates. We investigated effect modification of
the association between cumulative average DII, and changes in the DII and colorectal
cancer incidence by age, race/ethnicity, education, BMI and NSAID use, by including
two-way cross-product terms for these covariates in the models, and assessed significant
effect modification at p <0.05. None of the cross-product terms were significant and
therefore no subgroup analyses were conducted. Statistical significance was determined
by evaluating 95%CI. Statistical analyses were conducted using SAS® version 9.3 (SAS
Institute, Cary, NC), and all tests were two-sided.

5.4

Results
Table 5.1 shows the distribution of participants’ characteristics in quintiles of

cumulative average DII from baseline to year 3. Proportions of most covariates differed
between the quintiles. For example, there was a higher proportion of AA (15%),
participants with < high school education (2%), current smokers (9%), and obese
participants (37%), in the highest compared to the lowest quintile (Table 5.1). During an
average 11.7 years of follow-up, 1,240 incident colorectal cancer cases (1,036 colon and
219 rectal) were identified.
Table 5.2 presents hazard ratios of the association between cumulative average
DII and colorectal cancer. Comparing participants in the highest with the lowest quintile
of DII, in Year 3 where OS participants had the only other diet assessment, the
cumulative average DII was significantly associated with an increased risk of colorectal
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cancer overall (HR, 1.33; 95%CI, 1.10, 1.61) and in subgroup analyses of OS participants
(HR, 1.34; 95%CI, 1.05, 1.70) but not DMT participants (HR, 1.28; 95%CI, 0.95, 1.73).
In all other years of follow-up, HR were indicative of a positive association in DMT
participants but did not attain statistical significance.
Figures 5.1 and 5.2 present HR and 95%CIs for colon and rectal cancers,
respectively, at the various time points of cumulative diet assessment comparing DMT
participants in the highest to the lowest cumulative average DII quintile. For colon
cancer, risk was not significantly increased in Year 1, but from Year 2 to Year 7, risk was
consistently significantly increased, and became attenuated from Year 7 to study end in
Year 10 (Figure 5.1). We found no significant results for cumulative DII and rectal
cancer (Figure 5.2).
In the first 3 years of follow-up, 29.3% of participants were classified as having
an anti-inflammatory stable pattern, 11.7% experienced anti-inflammatory change, 23.6%
were in the neutral inflammation stable category, 12.1% experienced pro-inflammatory
changes, while 23.3% were in the pro-inflammatory stable category. Table 5.3 presents
the results of the associations between changes in the inflammatory potential of diet and
colorectal cancer risk. Using participants in the anti-inflammatory stable category as the
referent, rectal cancer risk was significantly increased in participants with a proinflammatory stable diet (HR, 1.53; 95%CI, 1.01, 2.32). HR for colon cancer (HR, 1.11;
95%CI, 0.91, 1.35) and overall colorectal cancer (HR, 1.18; 95%CI, 0.99, 1.41) were
positive but not statistically significant (Table 5.3).
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5.5

Discussion
In this large prospective study, we demonstrated that: 1) a higher cumulative

average score of the DII is associated with an increased risk of colorectal cancer
especially colon cancer, while 2) a stable pro-inflammatory diet from baseline to year 3
increased the risk of rectal cancer. To the best of our knowledge, this is the first study to
characterize the association between the cumulative history, and changes over time in the
inflammatory potential of diet, and risk of colorectal cancer. Given that FFQs were
administered to OS participants at baseline and Year 3; a cumulative average DII could
only be calculated for OS participants at Year 3, whereas analyses at all other time points
included DMT participants. We selected these two time points for the analyses of
changes in the DII over time, to include the maximum number of participants with FFQs
(Figure 5.1). There was no statistically significant association between cumulative
average DII and rectal cancer in the DMT, though a power calculation indicated that we
could observe significant HR ranging from 1.13 to 1.47. There was however, a
significantly higher risk of rectal cancer in models for changes in DII between baseline
and Year 3 where analyses included subjects from both the OS and DMT.
Our results are generally similar to previous findings from studies of diet quality
and colorectal cancer risk,28,145,202,285 in terms of poorer diet quality (here characterized
by higher, more pro-inflammatory DII scores) being associated with increased colorectal
cancer risk. These other studies assessed diet quality at only one point in time. However,
in a previous study we demonstrated that diet quality with respect to its inflammatory
potential improves significantly over time in an interventional setting, though it is
relatively stable in an observational setting (Tabung FK, Steck SE, Zhang J et al.,
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unpublished data, 2014). Risk of colorectal cancer is believed to accumulate over time;
thus, dietary changes over time may have a greater impact on colorectal cancer risk
compared with diet assessed at only one point in time.
However, the relative stability of the dietary inflammatory potential in an
observational setting could mean that diet assessment at any point in time during the
study could be equally important in determining disease risk estimates. In the current
study, we obtained a HR of 1.18 (95%CI, 0.99, 1.41) for the association between changes
from baseline to Year 3 in the inflammatory potential of diet and colorectal cancer risk,
comparing a stable pro-inflammatory change to an anti-inflammatory stable change, and
a HR of 1.34 (95%CI, 1.05, 1.70) for the association between cumulative average DII and
colorectal cancer risk from baseline to Year 3, comparing the highest and lowest quintiles
of cumulative average DII in the OS. These risk estimates are similar to the HR of 1.22
(95%CI, 1.05, 1.43) we obtained in a previous study, for the association between the
dietary inflammatory potential at baseline only, and colorectal cancer risk (Tabung FK,
Steck SE, Ma Y, et al., unpublished data, 2014).
The link between inflammation and colorectal cancer is supported by findings
from several studies showing either a reduced risk of colorectal cancer with regular use of
NSAIDs,83,84 or a positive association between higher concentrations of inflammatory
biomarkers and increased colorectal cancer risk.89,113 Other potential mechanisms through
which a pro-inflammatory diet may increase risk of colorectal cancer include components
of the metabolic syndrome, especially insulin resistance or glucose intolerance,286-288 and
the microbiota. A high and sustained pro-inflammatory potential of the diet may
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compromise the host-microbiota mutualism favoring the proliferation of toxic bacteria
that have been suggested to promote colorectal carcinogenesis.289
Strengths of the current study include accounting for changes in the inflammatory
potential of diet over time in a large, well-characterized population of more than 110,000
women, a long follow-up period, the inclusion of women of diverse race/ethnic groups,
and the central adjudication of colorectal cancer diagnosis. The use of a novel dietary
index to score diet quality based on inflammatory potential supports the evidence linking
inflammation and colorectal cancer. Limitations include known measurement error in
using an FFQ for the assessment of diet and its inflammatory potential over time,
potential residual or unmeasured confounding, though we adjusted for many potential
confounders in the models. We assumed that the random 30% of DMT participants
sampled from year 2 until study end was representative of the entire DMT study
population, a plausible assumption since these random subsamples were used for
intervention monitoring in the DMT, though the sample size reduced in the last two years
of follow-up.

5.6

Conclusion
A history of long-term pro-inflammatory diets increases the risk of colon cancer,

while shorter-term stable pro-inflammatory diets increase the risk of rectal cancer. Our
findings suggest lowering the inflammatory potential of diet as a means for colon cancer,
and potentially rectal cancer prevention.
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5.7

Tables and figures

142,511 participants recruited into the WHI OS and DMT
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93,676 participants in the OS

48,835 participants in the DMT

75,321 included in final analyses (after
excluding 1,785 due to implausible total
energy values, 23 missing FFQs, 838 due
to colorectal cancer at baseline, 872
missing colorectal cancer status at
baseline, 1,313 due to extreme BMI
values, and 13,524 due to single FFQ)

45,954 included in final analyses (after excluding 11 due to implausible
total energy values, 9 missing FFQs, 16 due to colorectal cancer at
baseline, 546 missing colorectal cancer status at baseline, 701 due to
extreme BMI values and 1,598 due to single FFQ)

75,321
FFQs at
baseline

75,321
FFQs at
Year 3

42,660
FFQs at
Year 1
45,786
FFQs at
baseline

14,241
FFQs at
Year 2

7,757
FFQs at
Year 3

14,127
FFQs in
Year 5

12,297
FFQs at
Year 4

11,188
FFQs at
Year 7

16,957
FFQs at
Year 6

3,655
FFQs at
Year 9

6,714
FFQs at
Year 8

960
FFQs at
Year 10

Figure 5.1. Participant flow in the administration of food frequency questionnaires in the Women’s Health Initiative (WHI)
Observational Study (OS) and Dietary Modification Trial (DMT), 1993-2010

Table 5.1. Frequencies (%) of participant's characteristics across quintiles of cumulative average DII (Years 0-3); Women's Health
Initiative, 1993-2010

Characteristic
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Age groups (years)
<50-59
60-69
70-79
Race/ethnicity
Asian or Pacific Islander
African American
Hispanic/Latino
European American
Other
Educational level
< High school
Some high school/GED
Some years of
college/graduate
Smoking status
Never
Former
Current
Body mass index (kg/m2)

Q1 (-6.586, < 3.184)
(Healthiest)

Q2 (-3.184, < 2.103)

Q3 (-2.103, <
-0.734)

Q4 (< 0.734, 1.041)

Q5 (1.041,
5.315) (Least
healthy)

6980 (30.8)
10739 (47.4)
4934 (21.8)

6779 (30.3)
10527 (47.1)
5064 (22.6)

7191 (32.5)
10177 (46.0)
4777 (21.5)

7596 (34.7)
9784 (44.7)
4502 (20.6)

8040 (37.2)
9532 (44.1)
4043 (18.7)

988 (4.4)
713 (3.1)
319 (1.4)
20339 (89.8)
294 (1.3)

537 (2.4)
1021 (4.6)
433 (1.9)
20092 (89.8)
287 (1.3)

569 (2.6)
1428 (6.4)
643 (2.9)
19189 (86.7)
316 (1.4)

517 (2.3)
1906 (8.7)
827 (3.8)
18287 (83.6)
345 (1.6)

394 (1.8)
3104 (14.4)
1166 (5.4)
16596 (76.8)
355 (1.6)

87 (0.4)
4315 (19.1)

146 (0.6)
5810 (26.0)

194 (0.9)
6407 (28.9)

252 (1.1)
7024 (32.1)

413 (1.9)
8339 (35.6)

18251 (80.6)

16414 (73.4)

15544 (70.2)

14606 (66.8)

12863 (59.5)

11335 (50.0)
10572 (46.7)
746 (3.3)

11625 (52.0)
9698 (43.3)
1047 (4.7)

11554 (52.2)
9365 (42.3)
1226 (5.5)

11383 (52.0)
9073 (41.5)
1426 (6.5)

12248 (50.9)
9276 (38.6)
2247 (9.3)
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Normal weight ( <25)
9722 (42.9)
Overweight (25.0 - <30)
7728 (34.1)
Obese (≥30)
5203 (23.0)
Physical activity (PA), minutes/week
Not meeting PA
8016 (42.2)
recommendations
Meeting PA recommendations
13090 (5.8)
Diabetes
20000 (88.3)
No
2653 (11.7)
Yes
Hypertension
15986 (70.6)
No
76667 (29.4)
Yes
Arthritis
11669 (51.5)
No
10984 (48.5)
Yes
NSAIDs use
No
9504 (42.0)
Yes
13149 (58.0)
Duration of estrogen use by category
14000 (61.8)
None
2788 (12.3)
<5 Years
1789 (7.9)
5 to <10 Years
1503 (6.6)
10 to <15 Years
2573 (11.4)
15+ Years
Duration of estrogen & progesterone use by category
14746 (65.1)
None

8285 (37.0)
7858 (35.1)
6227 (27.9)

7631 (34.5)
7864 (35.5)
6650 (30.0)

7009 (32.0)
7750 (35.4)
7123 (32.6)

6202 (28.7)
7397 (34.2)
8016 (37.1)

11810 (52.8)

12667 (57.2)

13521 (61.8)

15096 (69.8)

10560 (47.2)

9478 (42.8)

8361 (38.2)

6519 (30.2)

19499 (87.2)
2871 (12.8)

18915 (85.4)
3230 (14.6)

18482 (84.5)
3400 (15.5)

17870 (82.7)
3745 (17.2)

15238 (68.1)
7132 (31.9)

14777 (66.7)
7368 (33.3)

1445 (66.0)
7432 (34.0)

13799 (63.8)
7816 (36.2)

11425 (51.1)
10945 (48.9)

11628 (52.5)
10517 (47.5)

11661 (53.3)
10221 (46.7)

11950 (55.3)
9665 (44.7)

9064 (40.5)
13306 (59.5)

9387 (42.4)
12758 (57.6)

9881 (45.2)
12001 (54.8)

10479 (48.5)
11136 (51.5)

13559 (60.6)
2823 (12.6)
1773 (7.9)
1464 (6.6)
2751 (12.3)

13684 (61.8)
2855 (12.9)
1752 (7.9)
1353 (6.1)
2501 (11.3)

13729 (62.7)
2900 (13.3)
1578 (7.2)
1279 (5.8)
2396 (11.0)

14198 (65.7)
2808 (13.0)
1470 (6.8)
1129 (5.2)
2010 (9.3)

15220 (68.0)

15649 (70.7)

15918 (72.7)

16585 (76.7)

<5 Years
5 to <10 Years
10 to <15 Years
15+ Years

3672 (16.2)
2293 (10.1)
1357 (6.0)
585 (2.6)

3316 (14.8)
2008 (9.0)
1226 (5.5)
600 (2.7)

3174 (14.3)
1823 (8.2)
1003 (4.5)
496 (2.3)

3033 (13.9)
1618 (7.4)
914 (4.2)
399 (1.8)

2661 (12.3)
1365 (6.3)
670 (3.1)
334 (1.6)
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Table 5.2. Risk of colorectal cancer by quintiles of cumulative average dietary inflammatory index over a ten-year period of time;
Women's Health Initiative, 1993-2010

Years of diet data
assessment
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Quintile 1
(Healthiest)

Quintile 2

Quintile 3

Quintile 4

Quintile 5 (Least
healthy)

Referent

OR (95%CI)

OR (95%CI)

OR (95%CI)

OR (95%CI)

Ptrend

104/7436
1.06 (0.82, 1.36)

89/7287
0.87 (0.67, 1.14)

117/7251
1.25 (0.98, 1.60)

119/7116
1.30 (1.02, 1.66)*

0.008

0.97 (0.74, 1.27)

0.85 (0.64, 1.13)

1.11 (0.85, 1.46)

1.16 (0.88, 1.53)

0.13

98/7614
1.03 (0.79, 1.34)

83/7509
0.85 (0.65, 1.12)

101/7414
1.15 (0.86, 1.48)

119/7304
1.39 (1.08, 1.79)*

0.003

0.99 (0.75, 1.31)

0.85 (0.63, 1.13)

1.05 (0.79, 1.39)

1.27 (0.95, 1.68)

0.05

257/22113

243/21902

223/21659

291/21324

1.20 (1.01, 1.42)

1.14 (0.96, 1.36)

1.11 (0.93, 1.33)

1.50 (1.26, 1.77)*

<0.000
1

1.13 (0.94, 1.35)

1.08 (0.90, 1.30)

1.00 (0.83, 1.21)

1.33 (1.10, 1.61)*

0.02

163/14370
1.20 (0.96, 1.49)
1.16 (0.92, 1.46)

159/14322
1.18 (0.95, 1.48)
1.13 (0.89, 1.43)

132/14247
1.02 (0.81, 1.29)
0.94 (0.73, 1.20)

187/14120
1.50 (1.21, 1.86)*
1.34 (1.05, 1.70)*

0.003
0.11

Baseline, year 1, DMT
n(cases/non cases)
108/7549
Age adjusted
1.00
Multivariable1.00
adjusted
Baseline, years 1,2, DMT
n(cases/non cases)
100/7734
Age adjusted
1.00
Multivariable1.00
adjusted
Baseline, years 1-3, OS & DMT
n(cases/non cases)
226/22427
Age adjusted

1.00

Multivariable1.00
adjusted
Baseline, years 1-3: OS
n(cases/non cases)
137/14424
Age adjusted
1.00
Multivariable1.00
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adjusted
Baseline, years 1-3: DMT
n(cases/non cases)
90/7808
Age adjusted
1.00
Multivariable1.00
adjusted
Baseline, years 1-4, DMT
n(cases/non cases)
77/7910
Age adjusted
1.00
Multivariable1.00
adjusted
Baseline, years 1-5, DMT
n(cases/non cases)
70/8001
Age adjusted
1.00
Multivariable1.00
adjusted
Baseline, years 1-6, DMT
n(cases/non cases)
61/8091
Age adjusted
1.00
Multivariable1.00
adjusted
Baseline, years 1-7, DMT
n(cases/non cases)
46/8105
Age adjusted
1.00
Multivariable1.00
adjusted
Baseline, years 1-8, DMT
n(cases/non cases)
42/8108

93/7704
1.05 (0.80, 1.38)

77/7576
0.87 (0.66, 1.18)

96/7484
1.20 (0.92, 1.57)

106/7370
1.37 (1.06, 1.79)*

0.005

1.05 (0.79, 1.41)

0.88 (0.65, 1.20)

1.12 (0.84, 1.51)

1.28 (0.95, 1.73)

0.07

83/7832
1.09 (0.81, 1.46)

82/7695
1.07 (0.80, 1.44)

90/7537
1.30 (0.98, 1.72)

86/7489
1.28 (0.96, 1.70)

0.04

1.09 (0.80, 1.49)

1.09 (0.79, 1.49)

1.24 (0.91, 1.70)

1.22 (0.88, 1.70)

0.16

77/7943
1.13 (0.83, 1.53)

71/7794
1.07 (0.79, 1.46)

76/7638
1.17 (0.86, 1.59)

75/7558
1.25 (0.93, 1.70)

0.15

1.11 (0.80, 1.54)

1.04 (0.75, 1.46)

1.15 (0.83, 1.51)

1.20 (0.85, 1.71)

0.31

65/8006
1.08 (0.78, 1.50)

73/7866
1.16 (0.84, 1.59)

64/7711
1.05 (0.75, 1.45)

67/7626
1.26 (0.92, 1.74)

0.22

1.08 (0.76, 1.53)

1.23 (0.87, 1.74)

1.11 (0.77, 1.60)

1.24 (0.85, 1.80)

0.30

61/8004
1.36 (0.93, 1.93)

57/7912
1.25 (0.87, 1.79)

55/7728
1.20 (0.83, 1.73)

56/7662
1.39 (0.97, 2.00)

0.21

1.33 (0.90, 1.95)

1.24 (0.83, 1.84)

1.24 (0.83, 1.86)

1.30 (0.85, 1.98)

0.32

53/8012

47/7918

44/7719

43/7700

Age adjusted
1.00
Multivariable1.00
adjusted
Baseline, years 1-9, DMT
n(cases/non cases)
30/8111
Age adjusted
1.00
Multivariable1.00
adjusted
Baseline, years 1-10, DMT
n(cases/non cases)
19/8118
Age adjusted
1.00
Multivariable1.00
adjusted

1.32 (0.90, 1.92)

1.17 (0.79, 1.73)

1.09 (0.73, 1.62)

1.26 (0.85, 1.87)

0.56

1.28 (0.85, 1.92)

1.14 (0.75, 1.74)

1.11 (0.72, 1.73)

1.15 (0.72, 1.82)

0.85

47/8010
1.57 (1.02, 2.42)*

36/7906
1.23 (0.78, 1.93)

36/7741
1.28 (0.82, 2.02)

37/7710
1.53 (0.98, 2.38)

0.23

1.57 (0.99, 2.50)

1.21 (0.74, 1.99)

1.25 (0.76, 2.07)

1.35 (0.80, 2.28)

0.64

37/8005
1.83 (1.10, 3.05)*

27/7877
1.44 (0.84, 2.45)

25/7762
1.33 (0.78, 2.30)

27/7716
1.59 (0.94, 2.72)

0.41

1.91 (1.09, 3.34)*

1.39 (0.77, 2.53)

1.31 (0.71, 2.41)

1.45 (0.77, 2.74)

0.84
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*Statistically significant; aHazard ratios and 95% confidence interval; bAll multivariable models were adjusted for age, race/ethnicity, educational level,
smoking status, diabetes, hypertension, arthritis, NSAID use, category and duration of estrogen use, category and duration of estrogen & progesterone
use, body mass index, physical activity and total energy intake

HR (95%CI) for colon cancer risk
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Figure 5.2. Multivariable-adjusted hazard ratios for the association between cumulative
average DII (highest vs. lowest quintile) and colon cancer risk; Women's Health Initiative
Dietary Modification Trial, 1993-2010

HR (95%CI) for rectal cancer risk
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Figure 5.3. Multivariable-adjusted hazard ratios for the association between cumulative
average DII (highest vs. lowest quintile) and rectal cancer risk; Women's Health Initiative
Dietary Modification Trial, 1993-2010
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Table 5.3. Risk of colorectal cancer across patterns of change in the dietary inflammatory index (DII) between baseline and year 3;
Women's Health Initiative, 1993-2010

Patterns of DII changes
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All participants
Colorectal cancer,
n(cases/non cases)
Age adjusted
Multivariable-adjustedb
Risk by colorectal cancer
subsite
Colon cancer n(cases/non
cases)
Age adjusted
Multivariable-adjusted
Proximalc colon n(cases/non
cases)
Age adjusted
Multivariable-adjusted
Distalc colon n(cases/non
cases)
Age adjusted
Multivariable-adjusted
Rectald cancer n(cases/non

Antiinflammat
ory stable

Antiinflammatory
change

Neutral
inflammation
stable

Proinflammatory
change

Proinflammatory
stable

Referent

HR (95%CI)a

HR (95%CI)

HR (95%CI)

HR (95%CI)

290/23169

131/9168

251/18575

122/9476

277/18025

1.00
1.00

1.22 (1.00, 1.49)
1.13 (0.92, 1.39)

1.12 (0.95, 1.32)
1.04 (0.88, 1.24)

1.12 (0.92, 1.38)
1.04 (0.84, 1.29)

1.29 (1.10, 1.52)
1.18 (0.99, 1.41)*

249/23210

107/9192

215/18611

103/9495

226/18076

1.00
1.00

1.15 (0.92, 1.45)
1.06 (0.86, 1.36)

1.10 (0.92, 1.32)
1.04 (0.86, 1.25)

1.09 (0.86, 1.37)
1.01 (0.80, 1.28)

1.27 (1.06, 1.52)
1.11 (0.91, 1.35)

142/23209

63/9192

131/18611

69/9495

142/18076

1.00
1.00

1.19 (0.87, 1.61)
1.12 (0.83, 1.51)

1.18 (0.93, 1.49)
1.11 (0.87, 1.42)

1.28 (0.96, 1.70)
1.20 (0.90, 1.62)

1.40 (1.11, 1.77)
1.23 (0.96, 1.59)

60/23210

22/9191

55/18611

22/9495

48/18075

1.00
1.00
46/23413

0.98 (0.60, 1.59)
0.93 (0.65, 1.52)
24/9275

1.16 (0.80, 1.67)
1.10 (0.76, 1.60)
43/18783

0.95 (0.58, 1.54)
0.89 (0.54, 1.47)
20/9578

1.10 (0.75, 1.61)
0.99 (0.66, 1.49)
57/18245

cases)
Age adjusted
Multivariable-adjusted

1.00
1.00

1.37 (0.84, 2.25)
1.24 (0.75, 2.04)

1.19 (0.79, 1.80)
1.12 (0.73, 1.72)

1.13 (0.67, 1.90)
1.10 (0.64, 1.88)

1.70 (1.15, 2.51)
1.53 (1.01, 2.32)*

*Statistically significant in multivariable models; aHazard ratio and 95% confidence interval; bAll multivariable models were adjusted for age,
race/ethnicity, educational level, smoking status, diabetes, hypertension, arthritis, NSAID use, category and duration of estrogen use, category and
duration of estrogen & progesterone use, dietary modification trial arm , body mass index, physical activity; cICD-O-2 codes used to define location
of colon cancer include C18.0 (cecum), C18.2 (ascending colon, right colon), C18.3 (hepatic flexure of colon), C18.4 (transverse colon), C18.5
(splenic flexure of colon), C18.6 (descending colon, left colon) and C18.7 (sigmoid colon); dRectal cancer included all rectum and rectosigmoid
cases.
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6.1

Abstract
Introduction: We utilized the dietary inflammatory index (DII) to evaluate

associations between cumulative history, and changes over time in dietary inflammatory
potential, and risk of breast cancer in the Women’s Health Initiative (WHI). Methods:
We included 106,644 postmenopausal women aged 50-79 years recruited from 19931998 into the WHI Observational Study and Dietary Modification Trial, and followed
through September 30, 2010. We utilized data from food frequency questionnaires
(FFQs) to calculate ten cumulative averages of DII, incrementally from baseline to Year
10, categorized each average into quintiles, and used to estimate hazards ratios (HR) and
95% confidence intervals (95% CI) for invasive breast cancer incidence in multiple Cox
proportional hazards regression models. We also derived patterns of changes in DII in a
subset of 76,329 women between baseline and Year 3, and used multiple Cox regression
models to estimate hazard ratios (HR) and 95% CI for incidence of invasive breast cancer
and its subtypes. Results: During an average 11.7 years, 4,242 cases of invasive breast
cancer were identified. There was no substantial association between any of the ten
averages of cumulative DII calculated between baseline and Year 10, and risk of invasive
breast cancer. Also, HR revealed no substantial association between changes in DII
between baseline and Year 3, and risk of invasive breast cancer or any of its subtypes.
Conclusion: We did not observe a significant association between a history of long-term
pro-inflammatory diets as well as shorter-term changes in the inflammatory potential of
diets, and breast cancer risk in postmenopausal women. Findings imply that lowering the
inflammatory potential of diet may not be a major means for breast cancer prevention.
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6.2

Introduction
Breast cancer is the most commonly diagnosed cancer in American women173 and

most of the risk factors, including reproductive factors,290 and family history of breast
cancer,291 are generally non-modifiable. Diet, a potentially modifiable factor has been
implicated in breast carcinogenesis, with specific dietary factors such as alcohol55 and
red/processed meat66,67 shown to be associated with increased risk. The fact that people
eat meals consisting of a wide variety of individual foods with potentially complex
interactions among the foods and nutrients has led to a growing interest in the
examination of broader dietary patterns in relation to breast cancer risk.
Results of previous studies examining the association between dietary patterns
and breast cancer risk are inconsistent.41-47,181,182,208-211 Some studies have found an
increased risk of breast cancer with the Western (or unhealthy) diet pattern41,42 or a
reduced risk with the prudent (or healthy) pattern,181,182 while others failed to observe a
significant association.43-45 Indeed, some studies have found results contrary to
hypothesized associations; that is, higher consumption of the prudent pattern associated
with increased risk42 and higher consumption of the Western pattern associated with
reduced risk208 of breast cancer. Additionally, findings from three large cohort studies did
not support an association between the Western or prudent patterns and breast cancer
risk.44,46,47
Given the central role of chronic inflammation in the carcinogenesis
process110,292,293 dietary patterns that modulate inflammation may be more predictive of
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breast cancer risk. Additionally, dietary behaviors mainly influence chronic disease
outcomes, including breast cancer, when they persist for a longer period of time,31
therefore changes in diet over time or the cumulative history of diet over time may be
more predictive of breast cancer risk, compared to diet assessed at one point in time. We
have shown that the inflammatory potential of diet decreased significantly over time
among women enrolled in the Women’s Health Initiative Dietary Modification Trial
(WHI DMT) (Tabung FK, Steck SE, Zhang J, Ma Y, Liese AD, Tylavsky FA, et al.,
unpublished data, 2014). In the current study, we utilized the dietary inflammatory index
(DII)38,39 to investigate the role of cumulative history, as well as changes in the
inflammatory potential of diet, on breast cancer risk in postmenopausal women.

6.3

Methods

6.3.1 Study population
The WHI study is a large and complex clinical investigation of strategies for the
prevention and control of some of the most common causes of morbidity and mortality
among postmenopausal women. The design of the WHI has been described in detail
elsewhere.40 Briefly, The WHI began in 1992, implemented in 40 sites across the United
States, and enrolled a total of 161,808 women between 1993 and 1998. The WHI enrolled
93,676 women into an Observational Study (OS) and 68,132 participants into Clinical
Trials (CT), and followed them until September 30, 2010.265 The CTs included three
components: Hormone Therapy, calcium and vitamin D, and the DMT. For the DMT,
women were randomly assigned to a usual-diet comparison group (n=29,294) or an
intervention group (n=19,541) with a 20% low-fat dietary pattern with increased
vegetables, fruits, and whole grains. Women who proved to be ineligible for, or who were
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unwilling to enroll in the CT components were invited to be part of the prospective
cohort of women in the OS.40
Exclusion criteria for both the OS and CT included any medical condition
associated with a predicted survival of less than three years, alcoholism, other drug
dependency, mental illness (e.g., major depressive disorder), dementia, active
participation in another intervention trial and not likely to live in the area for at least 3
years. Demographic information and dietary data were obtained by self-report using
standardized questionnaires. Certified staff performed physical measurements, including
blood pressure, height and weight, and blood samples at the baseline clinic visit. Women
were further excluded from the DMT if their diets were assessed to have <32% energy
from fat.266 The WHI protocol was approved by the institutional review boards at the
Clinical Coordinating Center (CCC) at the Fred Hutchinson Cancer Research Center
(Seattle, WA) and at each of the 40 Clinical Centers.14
6.3.2 Diet assessment
Figure 6.1 describes the administration of food frequency questionnaires (FFQ) in
the WHI. During screening for the WHI, all participants completed a baseline FFQ. At
follow-up, the FFQ was completed at Year 3 for ~90% of OS participants. About 92% of
DMT participants completed an FFQ in Year 1, and a random third of participants were
invited to complete an FFQ annually from Year 2 until study end (approximately ten
years later) (Figure 6.1). There was an average of two FFQs per participant in the OS and
three FFQs per participant in the DMT. The 122-item WHI FFQ line item nutrient data
was obtained from the University of Minnesota’s Nutrient Data system for research
(NDSR) version 4.03_31 software,272 which is based on the US Department of
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Agriculture Standard Reference Releases and manufacturer information. The WHI FFQ
has shown comparable results with 24-hour dietary recall interviews and food records.266
6.3.3 The dietary inflammatory index (DII)
Details of the development38 and construct validation39 of the DII have been
described elsewhere. Briefly, an extensive literature search was performed to obtain peerreviewed journal articles that examined the association between six well known
inflammatory biomarkers (Interleukin (IL)-1β, IL-4, IL-6, IL-10, tumor necrosis factor
alpha, and C-reactive protein) and 45 specific foods and nutrients (components of the
DII). Scores were derived and standardized to a representative global diet database
constructed based on 11 datasets from diverse populations in different parts of the world.
Overall DII scores for each individual participant represent the sum of each of the DII
components in relation to the comparison global diet database.38 The DII score
characterizes an individual’s diet on a continuum from maximally anti-inflammatory to
maximally pro-inflammatory, with a higher DII score indicating a more proinflammatory diet and a lower (i.e., more negative) DII score indicating a more antiinflammatory diet. In the WHI FFQ, 32 of the 45 original DII components were
available for inclusion in the overall DII score (see38 for list of 45 DII components).
Components such as ginger, turmeric, garlic, oregano, pepper, rosemary, eugenol,
saffron, flavan-3-ol, flavones, flavonols, flavonones, anthocyanidins that are included in
the original DII calculation38 were not included in the current study because they were
not available from the WHI FFQ.
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6.3.4 Outcomes assessment
The WHI outcomes ascertainment and adjudication process has been previously
described.267 Briefly, participants (or next-of-kin) self-reported cancer diagnoses reported
on questionnaires annually in the OS or semiannually in the CT through 2005 and
annually in all thereafter. Invasive breast cancer was documented and coded according to
primary site, diagnosis date, extent of disease (stage, tumor size, and laterality), tumor
morphology (behavior, grade, histology) her2neu status and estrogen and progesterone
receptors (ER, PR) status. Incident invasive breast cancer, including second primaries,
were ascertained and adjudicated, but recurrent cancers were not included. For the full
coding of the cancer, pathology reports from diagnostic aspirations, biopsies, and
surgeries, plus the discharge summary, were used.
Breast cancer outcomes for the current study included invasive breast cancer, and
molecular and histologic subtypes of breast cancer. Molecular subtypes were defined
based on previous work by Carey et al., as follows: triple negative (HER2−, ER−, PR−),
(HER2+, ER−, PR−) subtype, luminal A (ER+ and/or PR+, HER2−), and luminal B
(ER+ and/or PR+, HER2+).294 The histological subtypes were defined based on SEER
morphology codes. These included ductal carcinoma (including intraductal carcinoma,
8500/2, and infiltrating ductal carcinoma, 8500/3), lobular carcinoma (including lobular
carcinoma, 8520/3, and lobular carcinoma in situ, 8520/2), and a combination of ductal
and lobular carcinomas (8522/3 and 8520/2). Survival time was defined as days from
enrollment or randomization until breast cancer diagnosis while censoring time was
defined as days from enrollment or randomization until death or last contact occurring on
or before September 30, 2010, in participants without breast cancer.
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6.3.5 Statistical analysis
We utilized data from 142,511 women participating in the WHI OS (93,676) and
DMT (48,835). Exclusion criteria included women with a history of breast cancer at
baseline or missing breast cancer status at baseline (n=5,078), those who reported breast
removal at baseline (n=277), or those with single FFQs or missing FFQs (n=14,655), as
well as women with implausible reported total energy intake values (≤600 kcal/day or
≥5000 kcal/day) (n=1,796) or extreme BMI values (<15kg/m2 or > 50kg/m2) (n=1,991)
(Figure 6.1). Additionally, participants with missing data in the covariates listed below
(n=10,797) were excluded, leaving a total of 106,644 participants for these analyses
(68,319 in OS and 38,325 in DMT). Frequencies and percentages were computed to
describe the distribution of covariates across quintiles of cumulative average DII for the
DII assessed from baseline to Year 3.
To determine how cumulative history of the inflammatory potential of diet,
affects breast cancer risk over time, we calculated cumulative averages of DII
incrementally starting from the average between baseline and year one DII 172.
The cumulative average was then categorized into quintiles, and used in multiple Cox
proportional hazards (PH) models to estimate hazard ratios (HR) for the incidence of
invasive breast cancer, while excluding breast cancer cases diagnosed prior to year one.
This approach was repeated for the average DII of baseline, year one, and year two with
breast cancer cases diagnosed prior to year two excluded to avoid the possibility of
change in diet due to subclinical disease and to include only participants at risk of
developing breast cancer going forward. This approach was repeated until DII estimates
at all ten time points were used.172
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To determine how changes in patterns of the inflammatory potential of diet over
time affect breast cancer risk, we calculated the DII from baseline and year 3 FFQs
administered to 76,329 women in the OS and DMT. We categorized the DII at both time
points into quintiles (Q) and further categorized changes in the inflammatory potential of
diet based on quintile differences between baseline and year 3, as follows:
6. Anti-inflammatory stable: Q1 or Q2 at both time points or change from Q3 to Q2;
7. Anti-inflammatory change: changes ≤ -2Q;
8. Neutral inflammation stable: changes from Q2 to Q3, Q4 to Q3 or stable at Q3 at
both time points;
9. Pro-inflammatory change: changes ≥ 2Q;
10. Pro-inflammatory stable: Q4 or Q5 at both time points, or change from Q3 to Q4.
The names given to these categories of DII changes were meant to be qualitative.
Next, Cox regression PH models were used to estimate hazard ratios (HR) and 95% CI
for the incidence of invasive breast cancer including the molecular and histological
subtypes, by patterns of DII changes and with adjustment for multiple covariates. The
anti-inflammatory stable category, considered to be the healthiest category, was the
referent for all models.
All multivariable-adjusted models included the following covariates as potential
confounders based on ≥10% change in HR between age-adjusted models with and
without the potential confounder: age group (years) (50-59, 60-69, 70-79), race/ethnicity
(European American (EA), African American (AA), Hispanic (HP), Asian or Pacific
Islander (A/PI) and Other); educational levels (less than high school, some high school
/GED, at least some college/graduate education), smoking status (current, past, and
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never), body mass index [BMI= weight(kg)/height(m)2] (normal weight (<25kg/m2),
overweight (25-<30 kg/m2), and obese (≥30kg/m2)); physical activity (PA),categorized
based on public health recommendations,284 as meeting or not meeting PA
recommendations (≥150 minutes/week of moderate intensity PA or ≥75 minutes/week of
vigorous intensity PA versus<150 minutes/week of moderate intensity PA or <75
minutes/week of vigorous intensity PA, respectively); use of non-steroidal antiinflammatory drug (NSAID) (yes/no); category and duration of estrogen use and category
and duration of combined estrogen and progesterone use both categorized into five
groups (none, <5y, 5 to <10y, 10 to <15y, and ≥15y), total energy intake (Kcal/day).
Some covariates did not change HR of the association between age-adjusted DII and
breast cancer risk by ≥10% and were therefore not included in the final models. These
included study participation (OS/DMT), age at menarche, age at first birth, number of
live births, total duration of breastfeeding, mammography in the 2 years preceding study
enrollment, oophorectomy status, and first degree relative with breast cancer. Data on
potential confounders were collected by self-administered questionnaires on
demographics, medical history, and lifestyle factors.40
Each covariate in the final models of both the cumulative average DII and
patterns of DII change was tested for proportional hazards using cumulative sums of
Martingale-based residuals. Age group and combined use of estrogen and progesterone
violated the PH assumption and all models were therefore stratified by these two
covariates. To determine whether the association between both the cumulative average
DII and changes in the DII and breast cancer incidence differed by age, race/ethnicity,
education, BMI and combined use of estrogen and progesterone, we included interaction
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terms for these covariates in the models and assessed significant effect modification at p
<0.05. None of the interaction terms was significant. We evaluated 95% CIs to determine
statistical significance. Statistical analyses were conducted using SAS version 9.3 (SAS
Institute, Cary, NC), and all tests were two-sided.

6.4

Results
Table 6.1 presents the distribution of participants’ characteristics across quintiles

of the cumulative average DII between baseline and Year 3. Participants with higher
cumulative average DII scores (representing a more pro-inflammatory diet) consisted of a
higher proportion of women who were AA or HP, overweight or obese, current smokers,
not meeting physical activity guidelines, and with lower educational attainment. In
contrast, participants with a more anti-inflammatory diet consisted of a higher proportion
of women who were EA or A/PI, had a normal BMI, were highly educated, and adhered
to physical activity guidelines. Participants were followed for an average 11.7 years,
during which 4,242 cases of invasive breast cancer were identified.
Table 6.2 presents HR of the association between cumulative average DII and risk
of invasive breast cancer. There was an inverse association between cumulative DII and
invasive breast cancer comparing quintiles 2 and 1 in the first year of follow-up (HR,
0.81; 95%CI, 0.70, 0.93; Ptrend, 0.14), and in the second year of follow-up (HR, 0.84;
95%CI, 0.73, 0.98; Ptrend, 0.35), but the trends across quintiles of cumulative average DII
were not significant for these inverse associations. No other statistically significant
associations between averages of cumulative DII and risk of invasive breast cancer were
observed in the multiple adjusted models.
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Table 6.3 shows HR for the association between changes in DII between baseline
and Year 3, and risk of invasive breast cancer and its subtypes. Overall, there was no
substantial association between changes in DII over time and total breast cancer or any of
its subtypes. However, there was an inverse association between changes in DII and risk
of triple negative breast cancer (HR, 0.47; 95%CI, 0.28, 0.79), comparing participants in
the anti-inflammatory change category to those in the anti-inflammatory stable category
of changes in DII between baseline and Year 3. In participants with (HER2+, ER−, PR−)
subtype of breast cancer, HRs were indicative of a positive association, comparing
participants in the pro-inflammatory stable category to those in the anti-inflammatory
stable category of changes in DII, but did not attain statistical significance (HR, 1.60;
95%CI, 0.91, 2.80) (Table 6.3).

6.5

Discussion
In this large prospective study of the role of cumulative history, and changes in

the inflammatory potential of diet over time in breast cancer risk, we observed no
significant association between either 1) the cumulative history of dietary inflammatory
potential, or 2) changes in dietary inflammatory potential over time, and risk of invasive
breast cancer or subtypes of breast cancer in postmenopausal women, with the exception
of a reduced risk of triple negative breast cancer among women who moved toward a
more anti-inflammatory diet compared to those who consumed a more stable antiinflammatory diet from baseline to Year 3. To the best of our knowledge, this is the first
study to characterize the association between the cumulative history, or changes over
time in the inflammatory potential of diet, and risk of breast cancer. Given that FFQs
were administered to OS participants at baseline and Year 3 only; a cumulative average
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DII could be calculated for OS participants at Year 3 only and analyses at all other time
points included DMT participants. We selected these two time points for the analyses of
changes in the DII over time, to include the maximum number of participants with FFQs
(Figure 6.1).
Our results are generally similar to many previous prospective studies that did not
observe significant associations between dietary patterns and breast cancer risk,44,46,47
though these other studies assessed diet quality at only one point in time. Other previous
studies have described heterogeneity of the association between dietary patterns and
breast cancer by hormone receptor status.44,295,296 Cottet et al. found evidence of an
increased risk of ER+/PR+ tumors with a Western dietary pattern and reduced risk of
ER+/PR− tumors with a Mediterranean pattern in a French Cohort study.295 Fung et al
found that higher consumptions of fruits and vegetables was significantly associated with
decreased risk for ER- breast cancer in the Nurses Health Study,44 while Gaudet et al.,
found an inverse association between high fruit and vegetable intake and breast cancer
risk among postmenopausal women with ER+ tumors.296 We cannot rule out that chance
may account for our finding of an inverse association for invasive breast cancer
comparing quintile 2 with quintile 1 of cumulative average DII in the first two years of
follow-up in the DMT; and an inverse association in participants with triple negative
tumors; given the number of comparisons made in this study.
Two potential mechanisms by which diet may affect breast carcinogenesis include
hyperinsulinemia297-299 and inflammation.10,300 Generally, dietary patterns have been
shown to modulate inflammation,48-50 and inflammation exerts an important role in the
carcinogenesis process.10,300 However, our findings imply that inflammation may not be a
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primary mechanism through which diet substantially influences breast cancer risk.
Obesity, a state of low-grade chronic inflammation229,230 and a risk factor for breast
cancer in postmenopausal women,301 has been suggested to increase breast cancer risk
mainly through the hormonal pathway, with increased exposure to endogenous estrogen
from adipose tissue.302,303 Indeed, though concentrations of inflammatory markers have
been found to be higher in obese than normal weight women,304 a meta-analysis of
prospective studies did not find an association between inflammatory biomarkers and
breast cancer risk,305 further indicating that inflammation may not play an important role
in breast cancer development. Also, there was no data on inflammatory breast cancer in
the WHI, for an assessment of the association of the inflammatory potential of diet and
risk of this subtype of breast cancer.
While most of the evidence is consistent that chronic inflammation increases the
risk of breast cancer recurrence or survival,94-96 the evidence has been inconsistent for the
association between biomarkers of inflammation and breast cancer incidence. Studies of
the association between regular use of aspirin and other NSAIDS and risk of breast
cancer in postmenopausal women have found inconsistent results.300,306 However, two
meta-analyses showed that regular use of aspirin and other NSAIDs is associated with
reduced risk of breast cancer,307,308 though these findings were not supported by results
from randomized controlled trials.206,309
In contrast, hyperinsulinemia may play a more important role in breast
carcinogenesis. Hyperinsulinemia largely explained the association between obesity and
postmenopausal breast cancer in a case-cohort study,299 while glucose and insulin-like
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growth factors have been found to be positively associated with breast cancer
development in postmenopausal women.310
Strengths of the current study include accounting for changes in the inflammatory
potential of diet over time in a large, well-characterized population of more than 106,000
women, a long follow-up period, the inclusion of women of diverse race/ethnic groups,
and the central adjudication of breast cancer diagnosis. The use of a novel dietary index
to score diet quality based on inflammatory potential at multiple time points provides
evidence that inflammation may not be substantially linked to breast cancer risk.
Limitations include known measurement error in using an FFQ for the assessment of diet
and its inflammatory potential over time, and potential residual or unmeasured
confounding though we adjusted for many potential confounders in the models. We
assumed that the random 30% of DMT participants sampled from year 2 until study end
was representative of the entire DMT study population, a plausible assumption since
these random subsamples were used for intervention monitoring in the DMT, though the
sample size reduced substantially in the last two years of follow-up.

6.6

Conclusion
In this large prospective study, we did not observe a significant association

between a history of long-term pro-inflammatory diets as well as shorter-term changes in
the inflammatory potential of diets, and breast cancer risk in postmenopausal women.
Our findings imply that lowering the inflammatory potential of diet may not be a major
means for breast cancer prevention and that if there is a role for diet in breast cancer
prevention; it is likely through other mechanisms.
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6.7

Tables and figures

142,511 participants recruited into the WHI OS and DMT
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93,676 participants in the OS

48,835 participants in the DMT

72,247 included in final analyses (after
excluding 1,785 due to implausible total
energy values, 23 missing FFQs, 4,953
due to breast cancer at baseline, 121
missing breast cancer status at baseline,
266 due to breast removal at baseline,
1,280 due to extreme BMI values, and
13,001 due to single FFQ)

46,467 included in final analyses (after excluding 11 due to implausible
total energy values, 9 missing FFQs, 3 due to breast cancer at baseline,
1 missing breast cancer status at baseline, 11 due to breast removal at
baseline, 711 due to extreme BMI values and 1,622 due to single FFQ)

72,247
FFQs at
baseline

72,247
FFQs at
Year 3

43,118
FFQs at
Year 1
46,296
FFQs at
baseline

14,382
FFQs at
Year 2

7,844
FFQs at
Year 3

14,228
FFQs in
Year 5

12,392
FFQs at
Year 4

11,318
FFQs at
Year 7

17,171
FFQs at
Year 6

3,740
FFQs at
Year 9

6,821
FFQs at
Year 8

991
FFQs at
Year 10

Figure 6.1. Participant flow in the administration of food frequency questionnaires in the Women’s Health Initiative (WHI)
Observational Study (OS) and Dietary Modification Trial (DMT), 1993-2010

Table 6.1. Frequencies (%) of participant's characteristics across quintiles of cumulative average DII (Years 0-3); Women's Health
Initiative, 1993-2010

Characteristic
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Age groups (years)
<50-59
60-69
70-79
Race/ethnicity
Asian or Pacific Islander
African American
Hispanic/Latino
European American
Other
Educational level
< High school
Some high school/GED
Some years of college/graduate
Smoking status
Never
Former
Current
Body mass index (kg/m2)
Normal weight ( <25)

Q1 (-6.586, < 3.166)
(healthiest)

Q2 (-3.166,
< -2.085)

Q3 (-2.085, <
-0.710)

Q4 (< -0.710,
1.063)

Q5 (1.063,
5.255) (least
healthy)

6703 (30.8)
10346 (47.5)
4715 (21.7)

6541 (30.4)
10103 (46.9)
4890 (22.7)

6940 (32.6)
9775 (45.9)
4582 (21.5)

7344 (34.8)
9437 (44.7)
4325 (20.5)

7830 (37.4)
9195 (43.9)
3918 (18.7)

964 (4.4)
718 (3.3)
316 (1.5)
19473 (89.5)
293 (1.3)

518 (2.4)
1000 (4.6)
426 (2.0)
19303 (89.6)
2879 (1.4)

551 (2.6)
1380 (6.5)
636 (3.0)
18418 (86.5)
305 (1.4)

512 (2.4)
18796 (8.9)
823 (3.9)
17556 (83.2)
336 (1.6)

378 (1.8)
3052 (14.6)
1152 (5.5)
16007 (76.4)
354 (1.7)

83 (0.4)
4210 (19.3)

143 (0.7)
56482 (26.2)
157434
(73.1)

205 (1.0)
6193 (29.1)

257 (1.2)
6829 (32.4)

415 (2.0)
8123 (38.8)

14899 (69.9)

14020 (66.4)

12405 (59.2)

17471 (80.3)
10870 (49.9)
101481 (46.6)
746 (3.4)

11198 (52.0)
9308 (43.2)
1028 (4.8)

11102 (52.1)
9004 (42.3)
1191 (5.6)

10994 (52.1)
8724 (41.3)
1388 (6.6)

10757 (51.4)
8209 (39.2)
1977 (9.4)

9236 (42.4)

7897 (36.7)

7290 (34.2)

6731 (31.9)

6012 (28.7)

Overweight (25.0 - <30)
Obese (≥30)
Physical activity (PA),
minutes/week
Not meeting PA
recommendations
Meeting PA recommendations

7435 (34.2)
5093 (23.4)

9215 (42.3)
125497 (57.7)

7591 (35.2)
6046 (28.1)

114731
(53.3)
100611
(46.7)
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NSAIDs use
No
9135 (42.0)
8684 (40.3)
Yes
12629 (58.0)
12850 (59.7)
Duration of estrogen use by category
13342 (61.3)
12972 (60.2)
None
2682 (12.3)
2720 (12.6)
<5 Years
1746 (8.0)
1713 (8.0)
5 to <10 Years
1480 (6.8)
1412 (6.6)
10 to <15 Years
2514 (11.6)
2717 (12.6)
15+ Years
Duration of estrogen and progesterone use by category
14138 (65.0)
14636 (68.0)
None
3551 (16.3)
3228 (15.0)
<5 Years
2206 (10.1)
1906 (8.9)
5 to <10 Years
1308 (6.0)
1177 (5.4)
10 to <15 Years
561 (2.6)
587 (2.7)
15+ Years

7585 (35.6)
6422 (30.2)

7471 (35.4)
69047 (32.7)

7146 (34.1)
7785 (36.2)

12221 (57.4)

130938 (62.0)

14690 (70.1)

90769 (42.6)

8013 (38.0)

6253 (29.9)

8996 (42.2)
12301 (57.8)

9506 (45.0)
11600 (55.0)

10116 (48.3)
10827 (51.7)

13067 (61.4)
2768 (13.0)
1710 (8.0)
1319 (6.2)
2433 (11.4)

13178 (62.4)
2839 (13.5)
1523 (7.2)
1239 (5.9)
2327 (11.0)

13690 (65.4)
2745 (13.1)
1433 (6.8)
1102 (5.3)
1973 (9.4)

15036 (70.6)
3047 (14.3)
1763 (8.3)
973 (4.6)
478 (2.2)

15352 (72.7)
2916 (13.8)
1567 (7.4)
880 (4.2)
391 (1.9)

16067 (76.7)
2606 (12.5)
1300 (6.2)
657 (3.1)
313 (1.5)

Table 6.2. Risk of invasive breast cancer by quintiles of cumulative average dietary inflammatory index over a ten-year period of time;
Women's Health Initiative, 1993-2010

129

Quintile 1
(Healthiest)

Quintile 2

Quintile 3

Quintile 4

Quintile 5
(Least healthy)

Referent

HR (95%CI)a

HR (95%CI)

HR (95%CI)

HR (95%CI)

329/7231

353/7058

399/6995

365/6928

0.85 (0.74, 0.97)

0.89 (0.78, 1.01)

1.02 (0.89, 1.16)

0.96 (0.84, 1.09)

0.49

0.81 (0.70, 0.93)*

0.90 (0.78, 1.04)

1.04 (0.91, 1.20)

0.99 (0.86, 1.15)

0.14

317/7417

335/7245

364/7165

332/7128

0.86 (0.75, 0.99)

0.90 (0.78, 1.03)

0.99 (0.87, 1.13)

0.96 (0.84, 1.10)

0.70

0.84 (0.73, 0.98)*

0.93 (0.80, 1.07)

1.03 (0.89, 1.19)

0.98 (0.84, 1.15)

0.35

885/20649

832/20465

819/20287

797/20146

1.00 (0.92, 1.10)

0.97 (0.88, 1.06)

0.97 (0.88, 1.06)

0.98 (0.90, 1.08)

0.55

1.00 (0.91, 1.10)

0.98 (0.89, 1.07)

0.99 (0.90, 1.10)

1.02 (0.92, 1.14)

0.68

578/13121

537/13142

506/13102

476/13141

1.05 (0.94, 1.18)

0.99 (0.88, 1.11)

0.96 (0.85, 1.08)

0.93 (0.82, 1.05)

Baseline, year 1, DMT
Breast cancer
419/7257
n(cases/non cases)b
Age adjusted
1.00
Multivariable1.00
adjustedc
Baseline, years 1,2, DMT
Breast cancer
387/7431
n(cases/non cases)
Age adjusted
1.00
Multivariable1.00
adjusted
Baseline, years 1-3, OS and DMT
Breast cancer
909/20855
n(cases/non cases)
Age adjusted
1.00
Multivariable1.00
adjusted
Baseline, years 1-3: OS
Breast cancer
561/13155
n(cases/non cases)
Age adjusted
1.00
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Ptrend

0.08
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Multivariable1.00
adjusted
Baseline, years 1-3: DMT
Breast cancer
345/7523
n(cases/non cases)
Age adjusted
1.00
Multivariable1.00
adjusted
Baseline, years 1-4, DMT
Breast cancer
311/7625
n(cases/non cases)
Age adjusted
1.00
Multivariable1.00
adjusted
Baseline, years 1-5, DMT
Breast cancer
264/7732
n(cases/non cases)
Age adjusted
1.00
Multivariable1.00
adjusted
Baseline, years 1-6, DMT
Breast cancer
223/7821
n(cases/non cases)
Age adjusted
1.00
Multivariable1.00
adjusted
Baseline, years 1-7, DMT
Breast cancer
179/7833
n(cases/non cases)

1.05 (0.94, 1.19)

1.00 (0.89, 1.13)

0.98 (0.86, 1.11)

0.98 (0.86, 1.12)

305/7477

301/7321

329/7229

304/7191

0.93 (0.80, 1.08)

0.91 (0.78, 1.05)

1.03 (0.89, 1.18)

0.98 (0.85, 1.13)

0.67

0.91 (0.78, 1.07)

0.93 (0.80, 1.09)

1.05 (0.90, 1.23)

1.02 (0.86, 1.20)

0.35

280/7575

253/7483

308/7280

267/7294

0.95 (0.81, 1.11)

0.87 (0.74, 1.01)

1.07 (0.93, 1.25)

0.98 (0.84, 1.14)

0.64

0.93 (0.79, 1.09)

0.86 (0.73, 1.02)

1.09 (0.93, 1.28)

0.98 (0.82, 1.17)

0.48

263/7674

232/7564

246/7398

247/7356

1.04 (0.89, 1.23)

0.95 (0.81, 1.12)

1.01 (0.86, 1.19)

1.09 (0.93, 1.28)

0.38

1.03 (0.86, 1.22)

0.93 (0.78, 1.11)

1.02 (0.86, 1.22)

1.08 (0.89, 1.30)

0.44

216/7747

207/7629

210/7467

209/7421

1.03 (0.86, 1.22)

1.00 (0.84, 1.19)

1.02 (0.85, 1.22)

1.11 (0.93, 1.32)

0.27

1.00 (0.83, 1.21)

0.97 (0.80, 1.18)

1.03 (0.84, 1.25)

1.07 (0.88, 1.22)

0.43

172/7751

165/7680

176/7476

174/7452
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Age adjusted
1.00
Multivariable1.00
adjusted
Baseline, years 1-8, DMT
Breast cancer
149/7839
n(cases/non cases)
Age adjusted
1.00
Multivariable1.00
adjusted
Baseline, years 1-9, DMT
Breast cancer
114/7836
n(cases/non cases)
Age adjusted
1.00
Multivariable1.00
adjusted
Baseline, years 1-10, DMT
Breast cancer
78/7848
n(cases/non cases)
Age adjusted
1.00
Multivariable1.00
adjusted

0.99 (0.81, 1.20)

0.96 (0.79, 1.17)

1.04 (0.86, 1.26)

1.12 (0.93, 1.36)

0.16

1.00 (0.81, 1.23)

0.97 (0.78, 1.20)

1.09 (0.88, 1.36)

1.14 (0.91, 1.43)

0.15

145/7756

141/7685

160/7450

137/7506

1.03 (0.83, 1.27)

0.98 (0.79, 1.21)

1.13 (0.92, 1.39)

1.10 (0.89, 1.36)

0.21

1.02 (0.81, 1.29)

1.01 (0.80, 1.27)

1.22 (0.96, 1.53)

1.11 (0.86, 1.43)

0.18

112/7765

118/7653

121/7488

110/7519

0.99 (0.78, 1.26)

1.04 (0.82, 1.32)

1.10 (0.87, 1.39)

1.15 (0.97, 1.46)

0.15

1.03 (0.79, 1.34)

1.11 (0.85, 1.44)

1.20 (0.92, 1.56)

1.19 ( 0.89, 1.58)

0.14

80/7761

87/7625

92/7501

82/7526

1.04 (0.78, 1.38)

1.13 (0.86, 1.50)

1.19 (0.91, 1.57)

1.23 (0.93, 1.62)

0.09

1.09 (0.80, 1.49)

1.21 (0.88, 1.65)

1.34 (0.98, 1.83)

1.32 (0.94, 1.84)

0.05*

*Statistically significant multivariable-adjusted HR; aHR=hazard ratio, CI=confidence interval; bcases/non-cases in the multivariable models; call
models were adjusted for age, race/ethnicity, education, smoking status, physical activity, body mass index, NSAID use, category and duration of
estrogen use, category and duration of estrogen & progesterone use, and total energy intake.
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Table 6.3. Risk of breast cancer by subtype, across patterns of change in the dietary inflammatory index (DII) between baseline and
year 3; Women's Health Initiative, 1993-2010

Patterns of DII quintile changes

132

Invasive breast cancer
Breast cancer cases/noncasesb
Age adjusted model
Multivariable adjusted
modelc
Molecular subtypes of
breast cancer
Triple negative (HER2−,
ER−, PR−)
Breast cancer cases/noncases
Age adjusted model
Multivariable adjusted
model
HER2+/ER− subtype
(HER2+, ER−, PR−)
Breast cancer cases/non-

Antiinflammatory
stable

Antiinflammatory
change

Neutral
inflammation
stable

Proinflammatory
change

Proinflammatory
stable

Referent

HR (95%CI)a

HR (95%CI)

HR (95%CI)

HR (95%CI)

1293/21015

456/8542

897/17163

473/8743

835/16912

1.00

0.89 (0.81, 0.99)

0.88 (0.81, 0.95)

0.90 (0.81, 1.00)

0.86 (0.79, 0.93)

1.00

0.91 (0.81, 1.02)

0.91 (0.83, 0.99)*

0.98 (0.88, 1.10)

0.94 (0.85, 1.04)

90/21015

17/8542

64/17163

36/8743

67/16912

1.00

0.52 (0.32, 0.85)

0.88 (0.64, 1.21)

1.07 (0.74, 1.55)

1.02 (0.75, 1.38)

1.00

0.47 (0.28, 0.79)*

0.88 (0.63, 1.22)

1.02 (0.68, 1.52)

0.93 (0.66, 1.33)

25/21015

12/8542

28/17163

15/8743

33/16912
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cases
Age adjusted model
Multivariable adjusted
model
luminal A (ER+ and/or
PR+, HER2−)
Breast cancer cases/noncases
Age adjusted model
Multivariable adjusted
model
luminal B (ER+ and/or
PR+, HER2+)
Breast cancer cases/noncases
Age adjusted model
Multivariable adjusted
model
Histologic subtypes of
breast cancer
Ductal carcinoma
Breast cancer cases/noncases
Age adjusted model
Multivariable adjusted
model
Lobular carcinoma
Breast cancer cases/noncases
Age adjusted model

1.00

1.01 (0.54, 1.87)

1.14 (0.70, 1.85)

1.24 (0.69, 2.23)

1.47 (0.93, 2.32)

1.00

1.14 (0.57, 2.28)

1.38 (0.79, 2.39)

1.46 (0.79, 2.82)

1.60 (0.91, 2.80)

649/21015

238/8542

460/17163

257/8743

404/16912

1.00

0.94 (0.81, 1.08)

0.91 (0.81, 1.02)

0.98 (0.85, 1.13)

0.83 (0.73, 0.93)

1.00

0.94 (0.81, 1.10)

0.92 (0.81, 1.04)

1.03 (0.89, 1.19)

0.88 (0.77, 1.01)

106/21015

35/8542

63/17163

33/8743

70/16912

1.00

0.80 (0.55, 1.17)

0.78 (0.58, 1.07)

0.76 (0.52, 1.11)

0.86 (0.64, 1.16)

1.00

0.92 (0.62, 1.35)

0.84 (0.61, 1.15)

0.92 (0.61, 1.37)

1.11 (0.80, 1.54)

816/21005

282/8540

585/17154

303/8740

547/16906

1.00

0.89 (0.79, 1.01)

0.90 (0.82, 1.00)

0.92 (0.81, 1.05)

0.89 (0.80, 0.98)

1.00

0.89 (0.77, 1.02)

0.92 (0.82, 1.03)

0.96 (0.84, 1.10)

0.93 (0.83, 1.05)

122/21015

42/8542

92/17163

57/8743

81/16912

1.00

0.79 (0.57, 1.10)

0.89 (0.69, 1.14)

1.08 (0.81, 1.45)

0.81 (0.63, 1.05)
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Multivariable adjusted
model
Mixed ductal/lobular
carcinoma
Breast cancer cases/noncases
Age adjusted model
Multivariable adjusted
model

1.00

0.89 (0.62, 1.27)

0.95 (0.72, 1.25)

1.18 (0.85, 1.63)

0.95 (0.67, 1.23)

189/21015

68/8542

119/17163

54/8743

109/16912

1.00

0.88 (0.68, 1.15)

0.80 (0.64, 0.99)

0.71 (0.53, 0.95)

0.75 (0.60, 0.94)

1.00

0.95 (0.72, 1.25)

0.84 (0.66, 1.06)

0.78 (0.57, 1.06)

0.86 (0.67, 1.11)

*Statistically significant multivariable-adjusted HR; aHR=hazard ratio, CI=confidence interval; bcases/non-cases in the multivariable models call
models were adjusted for age, race/ethnicity, education, smoking status, physical activity, body mass index, NSAID use, category and duration of
estrogen use, category and duration of estrogen & progesterone use, and total energy intake.
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CHAPTER 7

LONGITUDINAL CHANGES IN DII AND RISK OF CANCER: A
DISCUSSION OF STUDY RESULTS
7.1

Summary of results
Our hypothesis for this dissertation was that the inflammatory potential of diet

changes over time and that long-term pro-inflammatory diets or shorter-term changes
towards pro-inflammatory diets increase risk of colorectal cancer and of breast cancer.
Using data from both the WHI OS and DMT, we first described changes over time in the
inflammatory potential of diet using the DII, and showed that the DII score in the OS
remained relatively stable from baseline to Year 3, while the DII decreased substantially
from baseline to Year 1 in the DMT intervention arm, achieving the lowest mean score in
Year 3, and then increasing gradually until study end while still remaining lower than
baseline throughout the study period. The longitudinal trend of changes in DII was
similar in both arms of the DMT; however, changes in the intervention arm were almost
double those observed in the control arm during the first five years of follow-up. In both
the OS and DMT, participants who experienced the largest DII decrease were more likely
to have a normal BMI, a high educational level, and were A/PI or EA, while those who
experienced the smallest decrease were more likely to be obese, had less than high school
education, and were HP or AA.
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Secondly, we demonstrated that: 1) a higher cumulative average score of the DII
is associated with an increased risk of colorectal cancer especially colon cancer, while 2)
a stable pro-inflammatory diet over a 3-year period increases the risk of rectal cancer. We
found no substantial association between either cumulative average DII or shorter-term
changes in DII and breast cancer, including molecular and histologic subtypes of breast
cancer. To the best of our knowledge, this is the first study to characterize longitudinal
changes in the inflammatory potential of diet and the association between the cumulative
history, and changes over time in the inflammatory potential of diet, and risk of colorectal
cancer or breast cancer.

7.2

Potential mechanisms of action
The link between inflammation and colorectal cancer is supported by findings

from several studies showing either a reduced risk of colorectal cancer with regular use of
NSAIDs,83,84 or a positive association between higher concentrations of inflammatory
biomarkers and colorectal cancer risk.89,113 Other potential mechanisms through which a
pro-inflammatory diet may increase risk of colorectal cancer include components of the
metabolic syndrome, especially insulin resistance or glucose intolerance,286-288 and the
microbiota. A high and sustained pro-inflammatory potential of the diet may compromise
the host-microbiota mutualism favoring the proliferation of toxic bacteria that have been
suggested to promote colon carcinogensis.289 For breast cancer, two potential
mechanisms through which diet may affect breast cancer risk include
hyperinsulinemia297-299 and inflammation.10,300 Generally, dietary patterns have been
shown to modulate inflammation,48-50 and inflammation exerts an important role in the
carcinogenesis process,10,300 but our findings imply that inflammation may not be a
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substantial mechanism through which diet may influence breast cancer risk. Obesity, a
state of low-grade chronic inflammation229,230 and a risk factor for breast cancer in
postmenopausal women,301 has been suggested to increase breast cancer risk mainly
through the hormonal pathway, with increased exposure to endogenous estrogen from
adipose tissue.302,303 Indeed, though concentrations of inflammatory markers have been
found to be higher in obese than normal weight women,304 a meta-analysis of prospective
studies did not find an association between inflammatory biomarkers and breast cancer
risk,305 further indicating that inflammation may not play an important role in breast
cancer development.

7.3

Strengths and limitations
Major strengths of this study are the use of a large, well-characterized cohort (the

WHI) with adequate number of outcomes providing ample power to detect significant
associations. The DMT had a relatively long follow-up duration with diet assessed
annually in random subsamples of the study population. Also, the use of a novel dietary
index to score diet quality based on inflammatory potential at multiple time points
provides evidence that inflammation may be substantially linked to colorectal cancer but
not to breast cancer risk. Other strengths include accounting for changes in the
inflammatory potential of diet over time, good regional and racial/ethnic representation,
and the central adjudication of colorectal cancer and breast cancer diagnoses.
Limitations to our study included the following: FFQ data were not available in
the OS after Year 3 and thus we were not able to compare dietary behavior change
between the OS and DMT beyond the first three years of follow up. The decrease in
dietary inflammatory potential over time may have been due to survey learning effects
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rather than a real improvement in diet quality. In our DMT sample, not every participant
had FFQ data at all 11 time points, which could have reduced the effect of survey
learning as participants did not complete the FFQs every year. We assumed that the
random 30% of DMT participants sampled from year 2 until study end was representative
of the entire DMT study population, a plausible assumption since these random
subsamples were used for intervention monitoring in the DMT. However, sample sizes
from Year 8 to 10 were very small and may not be representative of the entire DMT
population. WHI enrolled only postmenopausal women, so generalizability and
interpretation of our results is restricted to this population; however, average DII scores
in the WHI were comparable to other US populations that have been examined.39,282
Other limitations include known measurement error in using an FFQ for the assessment
of diet and its inflammatory potential over time, and potential residual or unmeasured
confounding, though we adjusted for many potential confounders in the models.

7.4

Public health implications
This dissertation addressed an important priority area of cancer research that

includes the role of dietary patterns in relation to risk of cancer. The study is highly
innovative in that this is the first time that repeated measures of the DII are being used to
evaluate the association between changes in the dietary inflammatory potential over time
and cancer endpoints. Our findings suggest lowering the inflammatory potential of diet as
a means for colon cancer, and potentially rectal cancer prevention in postmenopausal
women, but we did not find enough evidence that this potential prevention strategy may
apply to breast cancer. Nevertheless, striving towards a more anti-inflammatory diet may
have other potential health benefits beyond cancer prevention.
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Patients at risk of inflammation-related conditions such as osteoporosis, obesity,
cardiovascular disease, and diabetes, may also be at risk of cancer.51,52 Therefore a
reduction in the inflammatory potential of the diet among patients with these conditions
may improve overall health and reduce their cancer risk. We found that changes in the
DII over time in the DMT were significantly modified by BMI, education and
race/ethnicity, therefore interventions to reduce the inflammatory potential of diet need to
incorporate differences in these lifestyle and demographic variables, in their designs. The
diagnosis of most of these chronic diseases may be also a teachable moment during
which most patients undergo lifestyle changes including diet changes to improve their
survival experience,53,54 therefore health professionals armed with the knowledge of
changes in the inflammatory potential of diets may be able to impart sound nutritional
guidance that improves the overall health of patients with inflammation-related chronic
diseases.
Our finding of a relatively stable dietary inflammatory potential in an
observational setting could mean that diet assessment at any point in time in a ~10 year
observational study of postmenopausal women could be equally useful in determining
disease risk estimates. The same conclusion would not apply for dietary intervention
studies where we demonstrated that diet quality with respect to its inflammatory potential
improves significantly over time in women enrolled in a low-fat, high-fiber, highvegetable and fruit intervention. Therefore diet assessments at multiple time points in an
intervention study may be necessary for a more valid association between dietary
inflammatory potential and disease risk. Finally, our findings strengthen the evidence for
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a new tool assessing the long term overall quality of diet and providing support for its use
in other studies of diet and cancer.

7.5

Suggestions for future research
Future observational studies with multiple diet assessments beyond three years

will be needed to make more adequate comparisons in dietary behavior change in an
observational versus an interventional setting. Studies (both observational and
interventional) with multiple diet assessments in which every participant is surveyed at
all the time points of diet assessment may be expensive but necessary to avoid making
assumptions that random subsamples of participants are representative of the entire study
population. Finally, interventions to test reductions in the inflammatory potential of diet
as a means for both colon and rectal cancer prevention are now warranted given findings
in the current study.

7.6

Conclusion
In this large prospective study of postmenopausal women, the average DII was

relatively stable in the OS from baseline to Year 3, but decreased significantly over time
in a manner consistent with improved anti-inflammatory potential, achieving its lowest
mean value at Year 3 in DMT intervention participants and, to a smaller extent, among
control arm participants. In all three study groups, the extent of decrease was influenced
by BMI, education, and race/ethnicity.
A history of long-term pro-inflammatory diets as well as shorter-term stable proinflammatory diets; increase the risk of colon cancer and possibly rectal cancer, but was
not associated with breast cancer risk. Our findings suggest lowering the inflammatory
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potential of diet as a means for the primary prevention of colon cancer, and potentially
rectal cancer but not breast cancer or any of its subtypes in postmenopausal women.
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Investigators and Academic Centers: (Brigham and Women's Hospital, Harvard
Medical School, Boston, MA) JoAnn E. Manson; (MedStar Health Research
Institute/Howard University, Washington, DC) Barbara V. Howard; (Stanford
Prevention Research Center, Stanford, CA) Marcia L. Stefanick; (The Ohio State
University, Columbus, OH) Rebecca Jackson; (University of Arizona,
Tucson/Phoenix, AZ) Cynthia A. Thomson; (University at Buffalo, Buffalo, NY)
Jean Wactawski-Wende; (University of Florida, Gainesville/Jacksonville, FL) Marian
Limacher; (University of Iowa, Iowa City/Davenport, IA) Robert Wallace;
(University of Pittsburgh, Pittsburgh, PA) Lewis Kuller; (Wake Forest University
School of Medicine, Winston-Salem, NC) Sally Shumaker
Women’s Health Initiative Memory Study: (Wake Forest University School of
Medicine, Winston-Salem, NC) Sally Shumaker
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For a list of all the investigators who have contributed to WHI science, please visit:
https://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20In
vestigato r%20Long%20List.pdf
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